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TRAIL-R TNF-related apoptosis-inducing ligand-R 
TRAP Thyroid hormone receptor-associated protein 
Tregs Regulatory T cell 
TSC Tuberous sclerosis complex (TSC) tumor syndrome 
ULK UNC51-like kinase 
UPR Unfolded protein response 
UVRAG UV radiation resistance-associated gene protein 
VPS34 Phosphatidylinositol 3-kinase 





Acute lymphoblastic leukemia (ALL) is the most frequent cancer in children, and 
although highly treatable, challenges remain due to significant side effects of therapy and the 
poor outcome for some patients. Synthetic glucocorticoid, Dexamethasone (Dex), has been used 
to treat several haematological malignancies including ALL. To understand better how GC-
resistant leukemic cells respond to Dex treatment, combination treatment of Dexamethasone 
with Chloroquine (CLQ), Thapsigargin (TG), Rotenone (ROT) and Bortezomib (BTZ) were 
used to investigate the role of autophagy, endoplasmic reticulum stress (ER stress) and unfolded 
protein response (UPR) respectively, in acute lymphoblastic leukemia cell lines including 
CEM-C1-15, CEM-C7-14 and Molt4. 
The results showed that autophagy inhibition by CLQ increased cell death and 
combination treatment with Dex exerted cytotoxic effect in all cells. These findings suggest that 
autophagy may play the important role to protect the ALL cells from GC-induced cell 
apoptosis, especially in GC-resistant cells. Furthermore, ER stress inducer, TG, treatment in the 
absence and presence of dexamethasone resulted in increase of ER chaperone proteins GRP78 
and GRP94 in CEM-C7-14 cells. This is potentially related to increased cell death and may play 
a role in ER stress mediated cell apoptosis. Protein degradation inhibition by BTZ sensitised the 
ALL cells to the treatments and combination conditions had synergistic effect in all leukemic 
cells. Reactive oxygen species assay indicated that increased ROS levels correlate with the 
increase in CEM cells death in ROT only and combination treatment with Dex. Interestingly, 
ER chaperone proteins GRP78 and GRP94 increase in the protein but not mRNA expression 
levels in Dexamethasone treated glucocorticoid-sensitive cells. These results suggested that GR 
regulated chaperone protein levels by indirect mechanism. 
Taken together, these findings suggest that autophagy may be acting as pro survival 
process in glucocorticoid resistant leukemia. In GC sensitive leukemia, mitochondria and ER 
are important for GCs dependent cell death and GCs mediated increase in the GRPs protein 
levels that could lead to cell apoptosis. These results, if confirmed in clinical samples may have 




CHAPTER 1 INTRODUCTION 
Glucocorticoids (GCs) are the type of steroid hormones synthesized by the zona 
fasciculata layer of the adrenal gland. The secretion is controlled by adrenocorticotropic 
hormone (ACTH), which is produced in the brain (anterior pituitary gland) in response to stress 
signals. Glucocorticoid hormone found in the human blood stream is cortisol. The synthetic 
form of glucocorticoid, Dexamethasone, has been used to treat patients suffering from 
numerous diseases such as leukemia, inflammatory bowel disease (IBD), arthritis, asthma, 
allergies and other diseases because of their role in the regulation of cellular inflammatory 
responses, immunosuppression, cell cycle proliferation inhibition and cell apoptosis induction. 
Glucocorticoids bind to the glucocorticoid receptor (GR), which is member of the nuclear 
steroid receptor superfamily. This receptor plays the role as a ligand-dependent transcription 
factor to regulate the expression of glucocorticoid target genes and cellular response. Ligand-
bound GR regulates the genes expression in the way of positive or negative response depending 
on the glucocorticoid response element sequences (GREs) or alternatively, by binding to the 
DNA indirectly through other transcription factors. This binding is leading to altered production 
of several intracellular cytokines and other proteins involved in inflammation, metabolism and 
cell death. Several proteins that regulate apoptosis such as Bcl2 family members have been 
described to be the target of GR (Inaba & Pui, 2010). 
1.1 Overview of Glucocorticoid hormones function 
Glucocorticoids are steroid hormones produced by adrenal gland in response to stress that 
have anti-inflammatory, metabolic and immunosuppressive effects. The main function of GCs 
is to mediate response to stress and control of glucose metabolism such as maintaining of 
normal glucose level and concentration in the blood by increased glucose production in cells, 
stimulation of fat breakdown metabolism and inhibition of glucose and fat storage in cells. 
Regarding anti-inflammatory effects, glucocorticoids inhibit all stages of the inflammatory 
response. 
In the brain, glucocorticoids are controlled by the hypothalamic pituitary adrenal (HPA)-
axis that is the set of complex structures including hypothalamus, pituitary gland and adrenal 
cortex that communicate through several hormones including corticotropin-releasing hormone 
(CRH), adrenocorticotropic hormone (ACTH) and cortisol (Figure 1-1). CRH released from 
paraventricular nucleus of hypothalamus stimulates anterior lobe of pituitary gland to release 
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ACTH hormone to subsequently induce adrenal cortex to produce glucocorticoid hormones 
(mainly cortisol in humans). Over expression of Glucocorticoids will inhibit the production of 
CRH at hypothalamus and ACTH at pituitary gland that act as negative feedback loop of HPA-
axis response. 
 
Figure 1-1 Neuroendocrine regulation of adrenal GCs and their physiological 
roles 
Glucocorticoid hormones (GCs) are regulated by hypothalamus-pituitary-adrenal 
gland (HPA) axis that is an important neuroendocrine circuit system to control 
stress conditions by several hormones such as Corticotropin-releasing hormone 
(CRH), Arginine vasopressin (AVP) and Adrenocorticotropic hormone (ACTH). 
(adapted from (Chung et al., 2011)) 
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After cortisol is released in the blood stream, it is bound to the plasma transporter 
glycoprotein known as corticosteroid binding globulin (CBG) or transcortin. CBG plays an 
important role to regulate concentration plasma cortisol by binding to cortisol in a 1:1 ratio and 
maintaining the concentration of free cortisol (Ho et al., 2006). In human, CBG peptide chain 
consists of 383 amino acids (50-60 kDa) with six position for N-glycosylation. CBG belongs to 
a non-inhibitory member of serine protease (SERPIN) family and the main function is transport 
of steroids and thyroid hormones in the blood to the target cells (Hammond et al., 1987; Irving 
et al., 2000; Pemberton et al., 1988; Sumer-Bayraktar et al., 2011). 80-90% of cortisol is bound 
to CBG while the free active GCs are loosely circulated in the serum (Siiteri et al., 1982). The 
main source of CBG is the liver where the CBG is produced by hepatocytes (Khan et al., 1984) 
and the CBG concentration in plasma is between 175-365 nmol/L (Nenke et al., 2016) while the 
plasma cortisol levels are saturated at 400-500 nmol/L (Ballard, 1979). The cortisol binding 
affinity can be changed by external factors such as inflammation and fever. The conformational 
change of CBG structure from intact S form (high affinity native form) to cleaved R form (low 
affinity cleaved form) (Klieber et al., 2007; Zhou, A. et al., 2006), when exposed to 
inflammatory protease (neutrophil protease), leads to loss of binding affinity of CBG for 





Figure 1-2 Corticosteroid binding protein structure and its conformational 
change after cleavage 
The figure shows the cortisol binding region and the cleavage of reactive site of 
high affinity S from to low affinity R form of CBG that leads to cortisol release 




The cortisol is the active form of glucocorticoids and its concentration in tissues is 
regulated by 11β-hydroxysteroid dehydrogenase (11β-HSD) enzyme. This enzyme has two 
isoforms, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2), which regulate steroid hormones in the opposite way. Type 
1 converts cortisone, inactive form of glucocorticoid metabolite, to cortisol while the 
conversion of cortisol to cortisone is regulated by 11β-HSD2 enzyme (Diederich et al., 2002) 
(Figure 1-3). 11β-HSD1 is expressed widely in many tissues, mainly in the liver, to facilitate 
GC action whereas 11β-HSD2 has a major role to prevent excess function of mineralocorticoids 
(MCs) in water and mineral homeostasis. Therefore, type 2 enzyme is mainly expressed in 






Figure 1-3 Molecular mechanism of cortisol action 
The figure shows how cortisol is transported into the cell after dissociating from 
corticosteroid binding globulin (CBG). Most of GCs are bound by CBG in the 
blood, while the rest of GCs are in the free form. Unbound GCs are transported 
across the cell membrane and interact with the glucocorticoid receptor leading to 
GC-induced transcriptional regulation of target genes containing GREs regulatory 





Figure 1-4 Interconversion of cortisone and cortisol by 11β-HSD isoenzyme 
Type 1 11β-HSD (11β-HSD1) is NADPH-dependent reductase enzyme that 
converts inactive cortisone to active cortisol whereas type 2 11β-HSD (11β-HSD2), 
NAD-dependent dehydrogenase enzyme, regulates GC activity in the opposite way 





Corticosteroids are the steroid hormones that include glucocorticoid (GC) and / or 
mineralocorticoid. While mineralocorticoid effects are involved in electrolyte and water 
regulation, glucocorticoids predominantly affect carbohydrate, fat and protein metabolism, they 
have anti-inflammatory, immunosuppressive, and vasoconstrictive effects (Liu, D. et al., 
2013a). In clinical practice, synthetic glucocorticoids are often used as they retain many 
properties of natural hormones but are more potent of stable. They are used as 
immunosuppressive drugs in the patients suffering from immune disorder diseases and hyper 
inflammatory responses such as allergies and asthma as well as leukemia. Corticosteroids also 
are used to replace cortisol in adrenal insufficiency patients suffering from Addison’s disease, 
or after surgical removal of adrenal glands (Liu, D. et al., 2013a). 
Glucocorticoids are among most widely used drugs in medicine. They have been used for 
a long time to treat numerous pathological conditions including asthma, allergies, skim 
conditions, some autoimmune diseases and in haematological disorders (Table 1). Their use in 
clinic is mostly based on their effects in inflammatory processes as they modulate mediators of 
inflammation to yield anti-inflammatory effect; they also affect immune system leading to their 
anti-inflammatory effects; glucocorticoids have anti-proliferative effects and cause cell death in 




Table 1 Common clinical indications of glucocorticoids usage 
Corticosteroids have been used to treat various inflammatory and autoimmune 
disorders indicated in this table (adapted from Liu et al., 2013). 
Field of Medicine Clinical use 
Allery and Respiratory 
Asthma, Allergic rhinitis, Anaphylaxis, Nasal polyps, 
Interstitial lung disease 
Dermatology Pemphigus vulgaris, Acute or severe contact dermatitis 
Endocrine system Adrenal insufficiency, Congenital adrenal hyperplasia 
Gastroenterology Ulcerative colitis, Crohn's disease, Autoimmune hepatitis 
Hematology 
Lymphoma / Leukemia, Hemolytic anemia, Idiopathic 
thrombocytopenic purpura 
Rheumatology / Immunology 
Rheumatoid arthritis, Systemic lupus erythematous, 
Polymyalgia rheumatica 
Ophthalmology Uveitis, Keratoconjunctivitis 





Table 2 List of glucocorticoids (GCs) effects on cellular response 
The table shows the effects of glucocorticoids on cellular processes and mechanism 
of action of their effect. 
Application Mechanism of Action 
Anti-inflammatory 
Inhibit inflammation by blocking the action of 
inflammatory mediators (transrepression), or by inducing 
anti-inflammatory mediators (transactivation) 
Immunosuppressive 
Suppress delayed hypersensitivity reactions by directly 
affecting T-lymphocytes 
Anti-proliferative Inhibit of DNA synthesis and epidermal cell turnover 
Vasoconstrictive 
Inhibit the action of histamine and other vasoconstrictive 
mediators 
 
1.2 Molecular biology of glucocorticoids function 
In humans, GCs synthesis is induced by brain derived (hypothalamus) hormones. GCs 
play an important role for body metabolism by regulating a wide range of physiologic function 
and maintenance of basal and stress-related homeostasis (Chrousos et al., 2004). Around 20% 
of the genes that are expressed in human leukocytes are controlled by glucocorticoids in either 
positive or negative manner (Galon et al., 2002). The physiology and molecular cellular 
mechanisms involved with the effect of glucocorticoids are growth, nutrition metabolism, 
reproduction, immune system and inflammatory system (Clark et al., 1992; Galon et al., 2002). 
After release to blood stream and passing into cytoplasm of target cells, glucocorticoids exert 
their function by interacting with an intracellular protein, the glucocorticoid receptor (GR) 
(Chrousos et al., 2004; Galon et al., 2002; Zhou, J. & Cidlowski, 2005) which belongs to the 
steroid/thyroid/retinoic acid nuclear receptor superfamily of transcription factor proteins.  
In general, transcription factors are group of proteins that control the rate of transcription 
of specific DNA sequence to generate messenger RNA during gene expression. The major steps 
of gene transcription are initiation, promoter escape, elongation, and termination. Briefly, RNA 
polymerase II together with transcription factors binds to DNA sequences within, promoter 
region, subsequently separating double stranded DNA and starting synthesis of new RNA 
chain. TATA box is the highly non-coding conserved DNA sequence for TATA box binding 
protein (TBP) (general transcription factor). TATA box usually is 25-35 base pairs upstream of 
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transcription start site. General transcription factors have DNA-binding domains to interact with 
specific DNA sequences and they also facilitate RNA polymerase II binding to the transcription 
start site. Several transcription factors involved with RNA polymerase II are transcription factor 
IID (TFIID), transcription factor IIA (TFIIA), transcription factor IIB (TFIIB), transcription 
factor IIF (TFIIF), transcription factor IIE (TFIIE), and transcription factor IIH (TFIIH) 
(Orphanides et al., 1996) (Table 3). In addition, transcription complexes require distal DNA 
sequences such as enhancers, silencers, and insulators to regulate gene transcription.  
After first RNA bond is synthesized, RNA polymerase II moves away from promoter and 
drives RNA synthesis processes until approximately 10 nucleotides product is generated 
(Goldman et al., 2009). In the elongation step, RNA polymerase creates an RNA copy from 5ʹ 
to 3`using complementary base pairs except thymine that are replaced with uracil. Termination 
of RNA polymerase II transcription requires polyadenylation (poly-A) signal (within mRNA) to 
promote multi-component cleavage/polyadenylation complex including cleavage and 
polyadenylation factor (CPF), cleavage factors IA and IB (CFIA and CFIB). These complexes 




Table 3 General transcription factors families and their properties 
Several transcription factors have subunits compositions and are involved in 
transcription initiation step (adapted from (Orphanides et al., 1996)).  
 
In the absence of GCs, GR forms the complexes with chaperone proteins including 
heat-shock protein 90 (hsp90) and 70 (hsp70) and co-chaperone binding protein (FKBP52) to 
inactivate the nuclear translocation region on the GR. After binding of GCs, the GR dissociates 
from its hetero-complexes and exposes nuclear translocation region that leads to the GR 
translocation to the nucleus. The homodimer GR binds to the glucocorticoid response elements 
(GRE) to activate transcription of the target genes. The monomer GR interacts with 
transcription factor proteins such as activation protein-1 (AP-1) or NF-ĸB resulting in gene 





Figure 1-5 GR signalling pathway 
GCs enter into cytoplasm where inactive form of GR is bound with their 
heterocomplexes chaperone heat shock protein 90 (HSP90), 70 (HSP70) and co 
chaperone protein FKBP52. After hormone binding, GR dissociates from 
chaperone complexes, unmasking nuclear localizing domain, and leading to nuclear 
translocation. Both homodimers and monomeric forms of GR bind to 
glucocorticoid response elements (GREs) to activate gene transcription or to inhibit 
transcription factors such as activation protein1 (AP-1) and nuclear factor-ĸB (NF- 
ĸB) (adapted from (Inaba & Pui, 2010)). 
1.2.1 Glucocorticoid receptor gene and protein structure 
The human glucocorticoid receptor (hGR) cDNA was isolated by expression 
cloning technique (Hollenberg et al., 1985) and it has nine exons located on chromosome 5. The 
splicing process produces two homologous receptor isoforms, α and ß hGR, which are identical 
through 727 amino acids from N terminus. The hGRα has an additional 50 amino acids while 
the hGRß contains additional 15 amino acids (Figure 1-6). The molecular weights of these 
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receptor isoforms are 97 and 94 kDA, respectively. The human GR is a modular protein that 
contains unique regions; the amino-terminal A/B region or N-terminal domain which is an 
immunogenic region involved in transcriptional regulation; C, D and E regions are the DNA-
binding domain, the hinge region and ligand-binding domain, respectively (Nicolaides et al., 
2010). 
 
Figure 1-6 The human glucocorticoid receptor (hGR) gene.  
The figure shows the alternative splicing of the hGR gene that gives rise to the two 
mRNA and protein isoforms, hGRα and hGRβ where the NTD; N-terminal domain 
DBD, DNA-binding domain; HR; hinge region, and LBD; ligand-binding domain 
are located (adapted from Nicolaides et al., 2010). 
The hGRα N-terminal domain (NTD) consists of a major transactivation domain, 
referred as activation function (AF)-1 that is located from amino acids 77 to 262 of the human 
GR. The AF-1 domain has been reported to be involved in the interaction of the receptor with 
initiation of transcription factors, such as RNA-polymerase II, TATA binding protein (TBP) 
and numerous TBP-associated proteins (TAFIIs), co-activation factor and chromatin 
modulators (Chrousos et al., 2004; Duma et al., 2006; Zhou, J. & Cidlowski, 2005). 
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The DNA-binding domain (DBD) of the hGR is located between amino acids 420 
and 480, which contains two zinc finger motifs binding to DNA sequences glucocorticoid 
response elements (GREs) in the promoter regions of target genes. The DBD is the most highly 
conserved part of the steroid receptor family and it also includes sequences that are important 
for receptor dimerization and nuclear translocation (Chrousos et al., 2004; Duma et al., 2006; 
Zhu, 2005). 
The hinge region or D-region referred to as flexible region is located between the 
DNA binding domain and ligand binding domain. The amino terminus of hinge region shares 
the amino acid region with DBD and is involved in GR dimerization. The main function of D-
region is to provide flexibility to the GR structure by allowing a single receptor dimmer to 
interact with several GREs (Duma et al., 2006; Zhu, 2005). 
The hGR ligand-binding domain (LBD) is located between amino acids 481 and 
777, binds to glucocorticoids and plays an important role in hGR activation. The LBD also 
contains a second transcription regulatory domain, known as AF-2, which is important for 
receptor dimerization, nuclear translocation and heat shock protein binding (Duma et al., 2006; 
Zhu, 2005). 
1.2.2 Crystal structure of the ligand-binding domain of hGR 
The crystal structure of the GR ligand-binding domain (LBD) has 12 -helixes 
and 4 small -strands folding into a three-layer helical domain (Bledsoe et al., 2002). The 
structure has a space in the lower half of the ligand-binding domain, which is created by the 
arrangement of the helices 1 and 3 generating one side of a helical sandwich and helices 7 and 
10 form the other side. The top half include helices 4, 5, 8, and 9 (Tanenbaum et al., 1998). The 
binding of ligand to LBD of hGR can induce conformation changes of protein structure 
leading to a more compact structure and increases protein stability and electrophoretic mobility 
during non-denaturing conditions (Nicolaides et al., 2010). The helix (H) 12 has an important 
role to facilitate formation of the ligand-binding pocket and AF-2 surface interaction with 
coactivators after ligand binding and conformational changes have occurred (Lu & Cidlowski, 





Figure 1-7 Crystal structure shows the glucocorticoid receptor (GR) ligand 
binding domain area 
The figure presents helix 12 (H12) area that has a crucial role for ligand binding. 
After hormone binding, the conformational change of GR facilitates coactivator 
complexes to interact with at cofactor area in LBF resulting in increase in gene 
expression. (adapted from (Veleiro et al., 2010)). 
1.2.3 Transcriptional and translational regulation of hGR 
The hGR gene is expressed into two alternative mRNA forms containing either 
exon 9 and 9. The hGR mRNA expresses multiple isoforms with different alternative 
translation initiation sites (multiple start codons) (Lu & Cidlowski, 2005). The all hGR 
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isoforms have different transcriptional activity responding to GCs such as different distribution 
in the cytosol or nucleus in the absence of ligand, translocation into the nucleus in the presence 
of ligand, and unique transactivation or trans-repression patterns of the gene expression that 
was shown by microarray analysis (Lu & Cidlowski, 2005). The hGR gene contains three 
different promoter genes including A, B and C. Promoter A can be used with three untranslated 
exons, 1A1, 1A2 and 1A3, which have the specific unique promoter fragments (Breslin et al., 
2001). The hGR gene can produce the same hGR proteins from the five different promoters and 
hGR protein levels can vary in different tissues that come from 256 different combinations of 
homo-and hetero- dimers produced from different promoters and isoforms (Chrousos & Kino, 
2005). 
1.2.4 Mechanism of transcriptional regulation by hGR 
After ligand binding and unmasking nuclear localizing sequence, GR enters to the 
nucleus and binds to DNA sequences, glucocorticoid responsive elements (GREs), to regulate 
gene transcription. There are several proposed models with glucocorticoid receptor 
transcriptional modulation including classical GRE, composite GRE, tethering GRE, negative 






Figure 1-8 Glucocorticoid receptor mediated transcriptional activity models 
There are many GR transcriptional regulation models including: homodimers GR 
bind to GRE (A); binding of GR and second transcription factor on DNA region 
(B); interaction of GR with secondary transcription factor not requiring GR binding 
to GRE (C); homodimers GR binding to nGRE to repress the transcription (D); GR 
competitive binding to nGRE to prevent binding factors required for transcription 
(E); interaction of GR with second transcription factor resulting in transcription 
repression not requiring GR binding to GRE (F); and interaction of GR and second 
transcription factor on DNA region resulting in transcription repression requiring 
DNA binding of both factors (adapted from (Newton, 2000)). 
There are numerous genes known to be upregulated by GR (referred as 
transactivation) such as lipocortin I, p11/calpactin binding protein and β2-adrenoreceptors, 
secretory leucocyte protease inhibitor (SLIPI) which have an important role in inflammatory 
response (Abbinante-Nissen et al., 1995; Flower & Rothwell, 1994; Yao et al., 1999). The 
negative regulation by glucocorticoids (referred as transrepression) are descripted to involve 
nuclear factor-ĸB (NK- ĸB) and Activator protein 1 (AP-1) proteins (Barnes, 1999; Barnes & 
Karin, 1997). The hGR bound to GRE can stimulate the transcription of target genes and 
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activate the formation of the transcription initiation complex, such as the RNA-polymerase II 
via AF-1 and AF-2 domains (Beato & Sánchez-Pacheco, 1996). 
In early steps of transcription, hGR uses AF-1 and AF-2 domains to bind to 
nuclear receptor coactivators and chromatin-remodelling complexes. Many coactivators create 
the connection between the DNA-bound hGR and the transcription initiation complex, and 
promote the glucocorticoid signal transmission to the RNA-polymerase II. 
The transcription coactivator complexes comprise of p300 and homologous 
cAMP-responsive element-binding protein (CREB)-binding protein (CBP) that facilitate the 
core platforms of transcription process to receive signal for transcription from several 
transduction cascades such as nuclear receptors, CREB, AP-1, NF-ĸB, Ras-dependent growth 
factor, STATs and p53 (McKenna et al., 1999; McKenna & O'Malley, 2002). The p300/CBP-
associated factor (p/CAF) is the another complex that interacts with p300/CBP and the final 
complex is p160 family of coactivators that have been reported as the initial molecules to be 
attracted to the DNA-bound hGR and facilitate formation of other complexes such as 
p300/CBP and p/CAF proteins accumulation to the promoter region (Heck et al., 1994; Liu, J. 
& DeFranco, 2000; McKay & Cidlowski, 1999; Stocklin et al., 1996). The interaction occurs 
directly with both the AF-1 of human GR via their carboxyl-terminal domain and the AF-2 of 
human GR through multiple LXXLL motifs, which is located in the nuclear receptor-binding 
domain. Several other chromatin modulators can interact with human GR through its 





Figure 1-9 Proposed model of glucocorticoid receptor and coactivators 
interaction in the regulation of GR target genes transcription 
The figure demonstrates the interaction of coactivators and other chromatin 
modulators involved in GREs transcription regulation by GR. Glucocorticoid 
receptor attracts several coactivator complexes including HAT complexes, 
SWI/SNF complexes and DRIP/TRAP complexes to the GR promotor to turn on 
transcription of GR target genes and facilitate formation of transcription initiation 
complex (adapted from (Charmandari et al., 2004)). 
1.2.5 Post-translational modification of the GR 
There are several types of GR protein modification after its protein translation. 
These comprise of phosphorylation, ubiquitination, acetylation and sumoylation processes. 
Post-translational modifications (PTMs) have an important role in GR stability, subcellular 
localization, and interaction with other proteins. Several phosphorylation sites, such as S113, 
S141, S203, S211, S226 and S404 have been found in human GR, most of sites are in the AF-1 
domain of NTD (Ismaili & Garabedian, 2004; Krstic et al., 1997). In hGR, some 
phosphorylation is hormone dependent, and this mechanism may determine turnover, 
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subcellular trafficking, specificity of target promoter, cofactor interaction, duration and strength 
of receptor signalling, and receptor stability (Nicolaides et al., 2010). Moreover, 
phosphorylation can stabilize the protein receptor during the absence of ligand, and also 
facilitate transcriptional activation. Finally, phosphorylation is involved in the non-genomic 
activation of cytoplasmic signalling pathways controlled by GR. Therefore; it is a versatile 
mechanism for modulating and integrating multiple receptor functions (Ismaili & Garabedian, 
2004; Orti et al., 1993). Several protein kinases have been described to be involved in the 
phosphorylation of hGR including the yeast cyclin-dependent kinase p34 CDC28 (Wang, Z. et 
al., 2002), the p38 mitogen-activated protein kinase (MAPK) (Miller et al., 2005), CNS-specific 
cyclin-dependent kinase 5 (CDK5) (Kino et al., 2007), the glycogen synthase kinase 3 (GSK-
3) (Rogatsky et al., 1998) and the c-Jun N-terminal kinase (JNK) (Itoh et al., 2002).  Recent 
study indicated that S211 and S226 phosphorylation sites that were expressed differently in 
ALL cells have been involved in the regulation of GCs induced apoptosis in CEMs cells (Lynch 
et al., 2010).  
After ligand binding, the ubiquitin/proteasome pathway plays a critical role in GR 
stability by directing GR to the proteasome complex for degradation processes. Several 
transcription factors including p53, cjun, cMyc and E2F1 and also transcription intermediate 
factors such as nuclear receptor coactivators, chromatin-remodelling factors are ubiquitinated 
and are degraded by the proteasome complex. The ubiquitination and proteasome degradation 
leads to decrease in activity of GR transcription (Dennis & O'Malley, 2005; Kinyamu et al., 
2005). Ubiquitination also controls the GR motility in the nucleus (Deroo et al., 2002; Kino et 
al., 2004). 
Acetylation plays an important role in GR induced transcriptional activity. Several 
sites of acetylation occur by several acetyltransferase enzymes at lysine residues in hinge region 
of GR (amino acid motif, KXKK). Recent studies indicated that circadian locomotor output 
cycle kaput / brain-muscle-arnt-like protein1 (CLOCK/BMAL1) transcription factors, act as 
acetyltransferase enzymes and repress GR action in target tissues after acetylation at the 
multiple lysine sites such as K480, K492, K494 and K495 (Nader et al., 2009). CLOCK are the 
important transcription factors that play crucial role for diurnal oscillation rhythms formation in 
circadian CLOCK system (Takahashi et al., 2008). GRα acetylation inhibits the binding of GR 
to the GRE regions resulting in decrease of GR-induced transcription (Figure 1-10). However, 
some studies found that mutation of GR lysine residues at 494 and 495 that are target for 
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acetylation resulted in down regulation of GR-responsive gene SLP1 when cells were treated 
with glucocorticoids (Wang, C. et al., 2011b). 
 
Figure 1-10 Acetylation regulation on GR-induced transcription activity 
After CLOCK/BMAL1 acetylated GRα, the activity of GR binding to GREs was 
reduced resulting in down regulation of transcriptional activity on targeted genes 
(adapted from (Kino, 2000)). 
Sumoylation is the post translational modification of GR mediated by small 
ubiquitin like modifier (SUMO) proteins that target the glucocorticoid receptor at K277, K293 
(located in the NTD and are the major sites of modification) and K703 that is located in LBD 
region of GR (Figure 1-11). Sumoylation at K277 and K293 inhibits GR-induced 
transcriptional activity (Davies et al., 2008; Le Drean et al., 2002; Tian et al., 2002) while K703 





Figure 1-11 Post-translational sites of phosphorylation, acetylation, 
ubiquitination and SUMOylation 
The figure shows the amino acid residue sites of modification by phosphorylation 
(P, serine amino acid position S45, S203, S211, S226, S395), acetylation (A, lysine 
amino acid position K480, K492, K494, K495), ubiquitination (U, lysine amino 
acid position K419), and SUMOylation (S, lysine amino acid position K227, K293, 
K703) (adapted from (Kino, 2000)).  
1.2.6 Molecular mechanism of glucocorticoid resistance 
Glucocorticoid are used to treat several inflammatory diseases and auto-immune 
disorders. However, glucocorticoid resistance can have negative effects on health of the patient 
and lead to decrease in efficacy of glucocorticoid therapy used in clinic. Several mechanisms 
are linked to the resistance including ligand induced down regulation of the GR receptor, 
dominant negative inhibition by ß-isoform, inhibition by the NF-ĸB (Schaaf & Cidlowski, 
2002) (Figure 1-12) and alteration in other associated pathways such as alteration in apoptosis 
or autophagy. 
There are several studies that showed that some steroid hormone treatment 
decreased GR expression in tissues and cultured cell lines such as HeLa cell (Lacroix et al., 
1984), human lymphocytes (Schlechte et al., 1982), rat brain (Sapolsky et al., 1984), rat 
hepatoma cells and mouse fibroblasts (Dong, Y. et al., 1988). Some reports showed increase of 
GR expression after ligand binding to human leukemic T-cell (CEM-C7-14), human myeloma 
cell line OPM-2 and mouse thymoma cell line WEHI-7 (Antakly et al., 1989; Ashraf et al., 
1991; Eisen et al., 1988; Gomi et al., 1990; Gruol et al., 1989). The ligand induced repression of 
GR mechanism is still unclear. However, some evidence showed the reduction of GR promoter 
activity through the sequences in GR promoter (region between -2838 and -1476) which are the 
same as the nGREs ((Drouin et al., 1989). 
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The alternative splicing presented ß-isoform of GR is another repression mechanism 
of GR resistance. The hGRß form does not interact with the ligand. Several hypothesises were 
proposed about resistance mechanism such as competition of hGRß and hGRα for GRE 
binding, interaction of hGRß with coactivators and the forming of inactive heterodimers 
between hGRß and hGRα (Leung et al., 1997; Oakley et al., 1999; Strickland et al., 2001) . 
Crosstalk between GR and NF-ĸB is an important regulatory mechanism of 
glucocorticoid resistance in inflammatory diseases. Several studies indicated that certain GR 
target genes were inhibited by NF-ĸB subunit p65 and the activated form of NF-ĸB is required 
to repress hGRα (Schaaf & Cidlowski, 2002). 
Additional mechanisms contributing to GCs resistance in leukemia are discussed 





Figure 1-12 Proposed glucocorticoid resistance mechanism 
Three mainly mechanisms involved in GC-resistance are 1) reduction of GR level, 
2) hGRß isoform expression, and 3) repression of hGRα by transcription factor NF-
ĸB (adapted from (Schaaf & Cidlowski, 2002)). 
1.3 Leukemia 
1.3.1 Introduction to cancer 
Cancer is a group of diseases where normal process of cell proliferation is altered 
with potential to invade other parts of the body. There are more than 277 different types of 
disease and numerous gene mutations are involved in cancer pathogenesis. The alterations in 
oncogenes, tumor suppressor genes and genes involved in DNA repair play an important role in 
early stages of tumor formation (Imran et al., 2017). The process of normal cells becoming 
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malignant involves the sequential mutations that arise from genomic damaging. This can be the 
result of endogenous mechanism including inherited mutations but also numerous other 
processes such as errors in DNA replication, free radicals induced DNA instability, UV 
radiation and chemical carcinogens (Bertram, 2001). Microorganism infection such as viruses 
and bacteria are other carcinogenesis factors involving around 7% of all cancers (Parkin, 2006). 
In men, the highest prevalence of cancer occurs in the prostate gland, lung tissue 
and bronchus, colon and rectum, and urinary bladder while the breast tissue, lung and bronchus, 
colon and rectum, uterine corpus and thyroid are the most common types of cancer in women 
(Siegel et al., 2016). In children, the highest prevalence types of cancer are blood cancer, brain 
and lymph nodes, respectively (Yoo & Chin, 2003). The characteristic of cancers are 
summarised by six hallmarks including sustaining proliferative signalling, evading growth 
suppressors, activating invasion and metastasis, enabling replicative immortality, inducing 
angiogenesis and resisting cell death (Hanahan & Weinberg, 2011). 
1.3.2 Introduction to leukemia 
In UK, around 8000 people are diagnosed with leukemia each year has high 
mortally. Disease is white blood cells disorder or blood cancer affecting white blood cells and 
bone marrow and is characterised by abnormal leucocytes proliferation. Loss of white blood 
cell function effects the immune system and disrupt normal functions. Different types of 
leukemia are classified based on morphology and disease progression. There are four main 
types of leukemia including acute myeloid leukemia (AML) that presented myeloblast 
abnormality, chronic myeloid leukemia (CML) that presented myelocytes abnormality 
including neutrophils, eosinophils, and basophils, acute lymphoblastic leukemia (ALL) with 
lymphoblasts abnormality, and chronic lymphoblastic leukemia (CLL) with lymphocytes 
abnormality. In acute stage, the number of abnormal cells increases rapidly while chronic stage 
occurs slowly. T and B cells are derived from leucocytes while neutrophils, basophils, 
eosinophils, and monocytes are originated from myeloid cell (Grigoropoulos et al., 2013). Signs 
and symptoms of patients with leukemia are related to bone marrow failure, spontaneous 
bruising or abnormal bleeding and anemia.  
The most common cancer in children is ALL that has incidence rate at 3 to 100,000 
population and 75% of patients are under 6 years (Swerdlow et al., 2008). Although children 
ALL is curable leukemia with combination chemotherapy with 85% long term survival, adult 
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patients have a poor prognosis because of intensive chemotherapy intolerance and toxicity of 
the treatment can be considerable (Hann et al., 2000). 
Acute Lymphoblastic Leukemia (ALL) is the cancer of white blood cells that 
mainly affects children and teenagers. The ALL incident rate (around 1:100,000) in UK has 
been reported since the mid of the 1970s (Figure 1-13). Over 65% of ALL patients are young 
teenagers under 25 year old (Figure 1-14) and ALL is the frequent cause of death from cancer 
before 20 years of age (Smith, M. A. et al., 2010). Several genes mutation are linked to the risk 
factors of ALL while the hazardous environments are additional factors associated with ALL in 
children such as radiation and toxic chemical exposure. Combination chemotherapy reduced the 
clinical symptom and restored normal hematopoiesis activity in up to 90% of patients with ALL 
(Smith, M. A. et al., 2010). However, resistance to ALL Dexamethasone treated patients has 
been observed and the autophagy, endoplasmic reticulum stress and unfolded protein response 
may be involved in GC-induced ALL cell death (Bonapace et al., 2010) while the mechanism 





Figure 1-13 Acute Lymphoblastic Leukemia of European age-standardised 
incidence rates in Great Britain between 1993 and 2015  
The graph provides acute lymphoblastic leukemia incidence rates according to 





Figure 1-14 Acute Lymphoblastic Leukemia presented in average number of 
new cases per year and age-specific incidence rates, (CRUK, 2013 - 2015) 
ALL incidence is strongly related to the age, which has the highest rates in children, 
teenagers and young adults. There are similar rates between male and female except 
age between 15 and 19 that the incident rate in male higher than female (CRUK, 
2013 - 2015).  
1.3.3 Risk factors and causes of ALL 
Acute lymphoblastic leukemia is a malignant disorder of lymphatic stem cell, 
progenitor cell, in bone marrow. It affects not only children with the peak of prevalence 2 to 5 
year old but also occurs in adults (Pui et al., 2008). The causes of ALL are not completely 
understood but risk factors can be multi-factorial such as infection, chronic inflammation, 
oxidative stress, environmental exposure to chemicals and radiation and genetic disorders 
(Greaves, M., 2006; Greaves, M. F. & Wiemels, 2003). In some childhood ALL cases have 
gross chromosomal mutation that can disrupt several genes that regulate normal haematopoiesis 
and lymphoid development have been identified (Inaba et al., 2013) which are related 
significantly with the patient’s outcomes. Although the most patients with cancer have no 
recognized inherited factors, genomic studies have identified the polymorphism of several gene 
 
49 
that are associated with ALL including ARID5B, CEBPE, GATA3, and IKZF1 (Hunger & 
Mullighan, 2015a; Perez-Andreu et al., 2013; Trevino et al., 2009). Another rare germline 
mutation such as PAX5 and ETV6 have been found to be linked with familial ALL (Shah et al., 
2013; Zhang, M. Y. et al., 2015) while few environmental risk factors are linked with ALL in 
children (Hunger & Mullighan, 2015a) (Figure 1-15).  
There are several genetic alterations involved in ALL including change in 
chromosome number, chromosomal rearrangements (Philadelphia chromosome, Ph) resulting in 
gene expression inhibition or fusion proteins expression, DNA deletion, and mutation of DNA 
sequences (Harrison, 2009). The Philadelphia chromosome is the abnormal chromosome 22 
causes of reciprocal translocation of genetic material with chromosome 9 (gene ABL1 from 
chromosome 9 and BCR gene from chromosome 22). This genetic abnormality is found in 
chronic myeloid leukemia and acute lymphoblastic leukemia (Nowell & Hungerford, 1960; 





Figure 1-15 Genetic alterations resulting in the pathogenesis and relapse of 
ALL 
Both common variants and rare mutations in several genes lead to lymphoid 
progenitor self-renewal, increased proliferation rate and affect tumor suppressors 
genes, transcriptional signalling, transcriptional coactivators alterations (A). ALL 
relapse can be caused by remission-induction therapy by leaving subclones that 
contained specific genes mutations resulting in chemotherapy resistance (B) 
(adapted from (Hunger & Mullighan, 2015b)). 
1.3.4 ALL treatment 
ALL patients can present the symptoms including bruising or bleeding, 
thrombocytopenia, pallor and fatigue, anemia, neutropenia that lead to infection (Hunger & 
Mullighan, 2015a). There are several techniques to detect the ALL such as morphological 
identification of lymphoblasts, immunophenotypic determination and development stage, and 
chromosomal analysis (Inaba et al., 2013; Pui et al., 2008).  
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Combination chemotherapy has been used for a long time to cure leukemia. 
(George et al., 1968). The treatment of ALL comprises 3 steps taking around 2 years, 
remission-induction as the first step, following by intensification, and continuation (Pui et al., 
2008). The remission-induction phase is a period for 6 weeks treatment with chemotherapy 
agents such as glucocorticoids (prednisone or Dexamethasone), vincristine that inhibits 
microtubule formation in mitotic spindle resulting in cell cycle proliferation inhibition, and 
asparaginase, which is the hydrolase enzyme of endogenous L-asparagine resulting in inhibition 
of RNA and DNA synthesis. However, side effects can be found such as fever, nausea and 
vomiting, allergic reaction, and stomach cramping. 
With these drug agents, normal haematopoiesis can be restored in 69-99% of 
children and 78-92% of adult patients (Hunger et al., 2012; Stanulla & Schrappe, 2009). 
Prednisolone has been used in ALL treatment while Dexamethasone is increasingly considered 
(Inaba & Pui, 2010). Some adverse effects from glucocorticoid treatment can be identified such 
as infection, osteonecrosis, fractures, psychosis, and myopathy, which is higher with 
Dexamethasone than with prednisone (Pui et al., 2012). In the intensification phase, high-dose 
of methotrexate (MTX) is used with mercaptopurine to reduce leukemic activity. However, 
some residual leukemic cell can be observed in patients that have drug resistance (Seibel et al., 
2008). The final phase is continuation therapy that uses mercaptopurine (inhibits purine 
nucleotide synthesis) and methotrexate (inhibits Dihydrofolate reductase enzyme and also 
inhibits the binding of interleukin 1-beta to the cell surface receptor) weekly or without pulses 
of vincristine and Dexamethasone for 2 years (Inaba et al., 2013).  
1.4 Cell death 
Cell death normally occurs during cellular proliferation period to maintain and balance 
multi-cellular organisms. Disorders controlling cell death processes have pathological 
consequences and lead to embryogenesis disruption, neurodegenerative diseases, or 
development of cancer (Bröker et al., 2005). The cell has been considered dead according to 
molecular or morphological criteria when it has lost integrity of plasma membrane, the nucleus 
of cell has undergone fragmentation into apoptotic bodies and this cell fragments have been 
engulfed by adjacent cell (Kroemer et al., 2009).  
There are several cell death types such as apoptosis, autophagy, necrosis, necroptosis and 
others and are mostly classified according to cell morphological features. In apoptosis mode, 
cell morphologies were identified as rounding-up of the cell, retraction of pseudopods, 
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reduction of cellular and nuclear volume, called pyknosis, nuclear fragmentation, plasma 
membrane blebbing, and presenting of the engulfment by resident phagocytes. The 
characteristics of autophagy are described as lack of chromatin condensation, several large 
vacuolization in cytoplasm, and double-membraned vacuoles accumulation. The last mode of 
cell death is necrosis that includes cytoplasmic swelling, plasma membrane rupture, 






Figure 1-16 Major pathways of cell death 
Programmed cell death mechanism can be divided into different paths depending 
on stimuli factors. Apoptosis pathway (left panel) is represented with cellular 
shrinkage and apoptotic body formations. The cytoplasmic organelles swelling and 
rupture of plasma membrane are the characteristic of necrotic cell (middle panel). 
The autophagic cell death is represented with vacuoles appearance and formation of 




In 1972, term “Apoptosis” has been used to describe a morphological alterations 
leading to cell death. Light and electron microscopy have been used to identify the various 
morphological changes occurring in apoptosis (Häcker, 2000). Cell shrinkage was observed, the 
cells were smaller in size and condensation of cytoplasm and organelles was seen by light 
microscopy in early stage of apoptosis (Kerr et al., 1972). The apoptotic cells were smaller than 
normal cells, and were stained with eosin dye in cytoplasm while the nuclear chromatin 
fragments were stained with purple (haematoxylin) dye. 
1.4.1.1 Extrinsic apoptotic pathway 
The mechanisms of apoptosis are complex and involve an energy-dependent 
cascade of molecular events. There are two important pathways utilised by cells undergoing 
apoptosis, the extrinsic or death receptor pathway and the intrinsic or mitochondrial pathway, 
while several proteins between these pathways have been identified to link them and have 
influence on both pathways (Igney & Krammer, 2002). In the early process of extrinsic 
signalling pathway, transmembrane death receptors that are members of the tumour necrosis 
factor (TNF) receptor gene superfamily have been crucial for apoptotic process (Locksley et al., 
2001). TNF receptor family members share similar cysteine-rich extracellular domains that 
contains 80 amino acids located cytoplasmic domain, called “death domain” (Ashkenazi & 
Dixit, 1998). Briefly, tumor necrosis factor (TNF) is the molecule that binds to the receptors on 
cell membrane (tumor necrosis factor receptor, TNFR) resulting in gene activation, cell death 
and regulation of inflammatory processes. There are two main types of TNFR including death 
receptors that have intracellular region (death domain, DD) involved to induction of cell death, 
and TRAF domain which is involved in cell survival and inflammation (Cabal-Hierro & Lazo, 
2012; Dempsey et al., 2003). 
Death domain has an important role to transmit the death signal from the cell 
surface to the intracellular signalling processes that contain several ligands such as FasL/FasR, 
TRAIL-R1, TRAIL-R2, TNF-/TNFR1, Apo3L/DR3, Apo2L/DR4 and Apo2L/DR5 
(Ashkenazi & Dixit, 1998; Chicheportiche et al., 1997; Peter & Krammer, 1998; Rubio-
Moscardo et al., 2005; Suliman et al., 2001). Activation of these receptors subsequently 
activates intracellular death domain association molecules such as Fas associated death domain 
(FADD) and TNFR associated DD (TRADD). The activation of DD signalling triggers caspase 
cascade pathways directly or via mitochondria results in cell apoptosis (Figure 1-17) (Dempsey 
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et al., 2003). However, TNF-R1 receptor also triggers anti-apoptotic signalling pathway by 
interacting with TRADD molecule that can also recruit TRAF2, TRAF1 and receptor-
interacting protein (RIP) to induce inflammatory response and pro-apoptotic pathway such as 






Figure 1-17 Death receptor mediated regulation of cell apoptosis 
The figure shows death domain receptors and associated molecules involved in cell 
apoptosis regulation such as FADD, TRADD. Upon ligands binding, active FAS 
receptor interact with c-terminus DD of FADD molecule resulting in FADD 
activation. That triggers caspase-8 molecule to become active and subsequently 
activate downstream molecules including caspase-7, caspase-6, and caspase-3 
(adapted from (Dempsey et al., 2003)).  
In TRAFs pathway, there are several transmembrane receptors including TNF-R2, 
CD40, CD30, CD27, LTßR, Ox40, 4-IBB, BAFF-R, BCMA, etc. These receptors contain 
TRAF-interacting motifs (TIM) in cytoplasmic tails and activation of these molecules triggers 
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signal transduction pathway, nuclear factor ĸB (NF- ĸB), Jun N-terminal kinase (JNK), p38, 
extracellular signal-related kinase (ERK) and phosphoinositide 3-kinase (PI3K), for example, 
that are related in immune and inflammatory response (Dempsey et al., 2003). Tumor necrosis 
factor receptor associated factors (TRAFs) are the intracellular molecules (TRAF 1-6) that 
interact to several TNFR and IL-1/Toll-like receptor superfamily (Figure 1-18). All TRAFs 
have the conserved region at the c-terminus, TRAF domain, which contains 200 amino acid 
peptides and is divided into two sub-domains, TRAF-N and TRAF-C. TRAF domain is 
important part for interaction with its receptors or intracellular signalling molecules and it can 
produce homo-, hetero, or trimeric forms by association with TRAFs molecules such as TRAF1 
and TRAF2 or TRAF3 and TRAF5 or TRAF6 (Cao et al., 1996; Pullen et al., 1998; Rothe et 
al., 1994). Previous studies indicated that RING finger domain is important for NF- ĸB 
activation while zinc finger domains are crucial for the activation of JNK and NF- ĸB (Brink & 
Lodish, 1998; Dadgostar & Cheng, 1998; Rothe et al., 1995; Takeuchi et al., 1996).  
 
Figure 1-18 TRAFs interaction with transmembrane receptors 
The figure shows the interaction of TRAFs with death receptor domain of TNF-R1, 
TIM domains and TLR/IL-1R receptor. TRAFs contain TRAF-N and TRAF-C 
domains at C-terminus that play an important role in intracellular signalling 
molecules and receptors interaction (adapted from (Dempsey et al., 2003)).  
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1.4.1.2 Intrinsic apoptotic pathway 
Non-receptor-mediated apoptosis is the intrinsic signalling pathway that 
produces intracellular signals activating targets within the cell and mitochondria. The absence 
of growth hormone, factors, and cytokines is the negative signalling that can promote 
suppression of death programs dysfunction, thereby activating apoptosis. Several stimuli that 
have positive signalling regulation are ionising and UV radiation, toxic chemicals, hypoxia, 
hyperthermia, viral infections, and free radicals (Elmore, 2007) (Figure 1-19). 
These stimuli interrupt the inner mitochondrial membrane leading to the 
mitochondrial permeability transition (MPT) pore to lose the mitochondrial transmembrane 
potential between inner and outer parts. Mitochondrial transmembrane potential alteration leads 
to release of the pro / anti apoptotic proteins from intermembrane space into cytoplasm (Saelens 
et al., 2004) such as cytochrome c, Smac/DIABLO, serine protease HtrA2/Omi that activate the 
caspase-dependent mitochondrial pathway via Apaf-1 and procaspase-9, apoptosome 
(Chinnaiyan, 1999; Du et al., 2000; Hill et al., 2004) and AIF, endonuclease G and CAD, which 
are released at the late stage of cell death and translocate to the nucleus to induce DNA 
fragmentation (Enari et al., 1998; Joza et al., 2001; Li, L. Y. et al., 2001). 
The Mitochondrial electron transport chain produces the energy for cell 
metabolism and creates the mitochondrial membrane potential (MMP), which is the crucial 
parameter for mitochondrial functional evaluation (Chen, L. B., 1988; MITCHELL, 1961). The 
Mitochondrial membrane potential analysis is used to detect the alteration of the voltage 
between inner and outer membrane layers of mitochondria in cytoplasm. Changing of this 
voltage can cause the cell to become apoptotic or necrotic (Sakamuru et al., 2016). In healthy 






Figure 1-19 Proposed molecular function and regulation of Bcl-2 family 
members 
The BH3-only members play a crucial role in apoptotic signalling regulation. Noxa, 
Puma, Bad, and Bid inhibit the anti-apoptotic activity of Bcl-2 / BclXL while Bax / 
Bak interaction with Bim / Bid facilitates caspase-dependent or –independent 
apoptotic signalling pathways including cytC, AIF, Endo-G and Smac/Diablo 
mechanism (adapted from (Chan & Yu, 2004)). 
The regulation of mitochondrial-induced cell apoptosis is related with the Bcl-2 
family proteins that control mitochondrial membrane permeability. Bcl-2 family presents Bcl-2 
homology (BH) domains including BH1, BH2, BH3, and BH4. The anti-apoptotic members 
(Bcl-2, BclXL) consist of all BH domains, whereas pro-apoptotic members (Bax, Bak, and 
Bok) display BH1-3 domains (Chan & Yu, 2004) (Figure 1-20). In apoptotic signalling, BH3-
only members play and crucial role as sensor molecules and relay signals to the mitochondria 
during apoptosis. At mitochondria, BH3-only molecules interact with Bax and Bak to promote 
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apoptosis, while the interaction with Bcl-2 / BclXL results in inhibition of anti-apoptotic 
activities. Multidomain pro-apoptotic members act as apoptotic signalling molecules by 
facilitating permeability of mitochondrial outer membrane and by releasing apoptotic factors 
such as cytochrome c (CytC), endonuclease G (Endo-G), apoptosis-inducing factor (AIF), and 
Smac/Diablo. These factors subsequently trigger cell death via caspase-dependent or –
independent mechanism (Chan & Yu, 2004; Deng et al., 2003) (Figure 1-19).  
The both extrinsic and intrinsic apoptotic pathways lead to the execution phase, 
final pathway of apoptosis. In this phase, execution caspases are activated and lead to 
cytoplasmic endonuclease becoming active form, which degrades nuclear material, and 
proteases by degrading the nuclear and cytoskeletal proteins. Another apoptotic pathway that is 
related to lymphocyte, especially cytotoxic T lymphocyte (CTLs) is perforin/granzyme 
pathway. Briefly, CTLs are able to mediate the secretion of transmembrane pore-forming 
molecule perforin after the target cells are infected with virus or the cells become a tumor cell, 
which will activate two serine protease enzymes, granzyme A and granzyme B. The activated 
granzyme B will subsequently mediate procaspase-10, and then execution pathway is activated 
while granzyme A will cleave the SET complex resulting in blocking DNA maintenance and 





Figure 1-20 Bcl-2 family members 
The figure shows four Bcl-2 homology (BH) domains and its members. The most 
members, except Bid, Bad, Noxa, and Puma, contain carboxyl-terminal 
hydrophobic region (transmembrane domain, TM) to facilitate intracellular 






Figure 1-21 Diagram representations of apoptotic events 
The two main apoptotic pathways, extrinsic and intrinsic, require specific signals to 
activate an energy-dependent cascade of molecular events including caspases 8, 
caspases 9, and caspases 10, which activate execution caspases 3 resulting in cyto-
morphological features change (adapted form (Elmore, 2007)). 
In haematological malignancies, Bcl-2 has an important role in cell development, 
progression, and chemosensitivity (Cory, 1995; Smets & van den Berg, 1996). Bcl-2 protein is 
encoded by B-cell lymphoma/leukemia-2 gene that is involved in apoptosis. In GCs induced 
cell apoptosis, increasing of Bcl-2 level protects the cell from the death by several stimuli 
(Reed, 1994). There are several reports indicating that Bcl-2 enhanced prosurvival role against 
GC-mediated apoptosis using gene transfection, as discussed in more details below (Alnemri et 
al., 1992a; Alnemri et al., 1992b; Hartmann et al., 1999; Smets et al., 1999; Smets et al., 1994). 
The Bcl-2 exerts its anti-apoptotic effects through with inhibition of caspase-activation protein 
such as Apaf-1, the regulation of cytochrome c release and intracellular calcium concentration 
by preventing Bax and Ca2+ activation from cytochrome c release (Adams, J. M. & Cory, 1998; 




Autophagy is a highly conserved cellular degradation and recycling processes in 
mammalian cells. Three principal types of autophagy, microautophagy, macroautophagy, and 
chaperone-mediated autophagy (CMA), deliver the cargos to the lysosome for degradation and 
recycling (Figure 1-22). Autophagy is an important process to maintain normal cellular 
homeostasis by removing unfolded, excessive proteins. In cellular stress conditions, nutrient 
starvation, low oxygen concentration, DNA damage, pathogen infection, and ER stress have 
been reported to increase the expression of protein involving autophagic pathway (Jia & 
Sowers, 2015; Mei et al., 2015). There are several reports that impairment of autophagy 
processes is involved in pathological conditions such as cancer, neurodegeneration, 
autoimmunity, and inflammation disorders (Levine et al., 2011; Mizushima et al., 2008; 
Winslow & Rubinsztein, 2008; Yang, L. et al., 2015). 
While microautophagy is the processes of lysosome invagination of cytoplasmic 
contents, the chaperone-mediated autophagy engulfs both nonspecific and specific substrates to 
lysosome by recognizing KFERQ motif domain sequence of protein (Dice, 1990). Several 
targeted proteins such as glycolytic enzymes, transcription factors and inhibitors, calcium and 
lipid binding proteins, proteasome subunits, and vesicular trafficking proteins that contain 
KFERQ motif peptide sequence are unfolded by cytosolic chaperone (HSPA8) and are 
translocated to lysosomal membrane where they are degraded by lysosomal enzyme activities 
(Orenstein & Cuervo, 2010). At the lysosome membrane, lysosomal-associated membrane 
protein 2A (LAMP2A) receptor binds to protein substrate following targeted protein entering 
into lysosomal lumen (Cuervo & Dice, 1996). 
Macroautophagy is a complicated degradative mechanism of cytoplasmic 
components such as misfolded protein and dysfunctional organelles that are formed into 
double-membrane vesicles (autophagosome) (Ma, T. et al., 2013).  
In acute leukemia cells, macroautophagy has been reported to play an important 
role in promoting or suppressing acute leukemia cell proliferation or survival by activation and 
inhibition of autophagy (Evangelisti et al., 2014). Therefore, macroautophagy is referred to as 





Figure 1-22 Three types of mammalian autophagy 
The figure shows macroautophagy, microautophagy, and chaperone-mediated 
autophagy detected in mammalian cells. Macroautophagy forms double-membrane 
vesicles to transport cargo to the lysosome while chaperone-mediated autophagy 
targets individual targeted proteins with specific motif peptide sequence, KFERQ, 
by HSPA8 complex. Microautophagy is a directly uptake of cargo through 
lysosomal membrane invagination mechanism (adapted from (Parzych & Klionsky, 
2014)). 
1.4.2.1 Regulation of autophagy (macroautophagy) pathway 
In early studies, yeast, Saccharomyces cerevisiae, was used as model to identify 
major molecular machinery of autophagy, Autophagy-related (ATG) proteins (Table 4). These 
proteins are involved in autophagic process in each step of activation (Nakatogawa et al., 2009). 
Several different phases of autophagy are induction, nucleation of autophagosome, elongation 




Table 4 List of ATG proteins and their function 
The key autophagy proteins and function in macroautophagy activation complex 





The membrane induction and nucleation are the first events of autophagy that 
will form autophagosome, phagophore, for serving unfolded protein aggregates (Figure 1-23). 
Double membrane vacuole is formed by the nascent membrane that grows and fuses its edges 
during elongation phase. Then, the mature autophagosome subsequently fuses with the 
lysosomal membrane to form an autophago-lysosome. The luminal contents are degraded by 
acid hydrolase and are recycled through permeases inside autolysosome (Levine & Kroemer, 
2008; Yang, Z. & Klionsky, 2010). 
Two important regulators of induction autophagic phase are mammalian target of 
rapamycin complex1 (mTORC1) and AMP-activated protein kinase (AMPK) that were found 
in eukaryotic cells (Yang, Z. & Klionsky, 2010). It has been reported that mTORC1 is an 
important down-stream target protein of phosphoinositide 3-kinase (PI3K)/Akt pathway that 
were activated in haematological malignancies (Kelly et al., 2011; Martini et al., 2014; Polivka 
& Janku, 2014). The mTORC1 interacts with the UNC51-like kinase (ULK) multi-protein 
complex, which is the initial step for phagophore formation, resulting in inhibition of 
autophagy. Furthermore, inhibition of autophagy can occur via phosphorylation of ULK1 and 
ATG13 by mTORC1, therefore this modification leads to down regulation of autophagic 
activities (He & Klionsky, 2009). However, nutrient starvation or mTORC1 inhibition by 
rapamycin treatment have been reported to dissociate mTORC1 from ULK1/ULK2 complex, 
leading to inducing of down-stream complex and autophagic activities (He & Klionsky, 2009; 
Kroemer et al., 2010). 
AMPK plays a critical role in positive regulation of the autophagic process by 
directly phosphorylating ULK1 at multiple sites including Ser 317, Ser 467, Ser 556, Thr 575, 
Ser 638, Ser 777, thus increasing ULK1 activity (Dunlop & Tee, 2013) and it also inhibits 
indirectly mTORC1 activity (He & Klionsky, 2009). 
Autophagosome membrane formation during nucleation phase requires proteins 
and lipids to activate Beclin1 core complex. Complex is formed by Beclin1 and p150/hVps15 
(English et al., 2009) resulting in production of PI 3-phosphate, which promotes 
autophagosome membrane nucleation. It has been identified that Beclin1 can lead to either 
activation or inhibition of autophagy by direct interaction with numerous binding partners such 
as ATG14L, AMBRA1, Bcl-2, Bcl-xL (Abrahamsen et al., 2012; Pattingre et al., 2005). 
Vesicle elongation and autophagosome completion phases have two important 
ubiquitin-like conjugation systems. Both ATG7 and ATG3 proteins regulate the lipid 
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modification of Light Chain 3 (LC3) by conversion of cytosolic LC3 (LC3-I) into stable form, 
LC3-II, which conjugates with phosphatidylethanolamine (PE) (Tanida et al., 2004). Before 
conjugating with PE, LC3 is required to be cleaved initially by ATG4B protease. LC3 is 
involved in proteins and organelles-developing autophagosome. LC3 has been used as marker 
of autophagy when it is present in autophagosomes and in slow migration form, LC3-II, which 
is converted form of LC3-I (Denton et al., 2012). Another pathway contains ATG7 and ATG10 
that promotes LC3 lipidation by using ATG12-ATG5-ATG16L complex (Walczak & Martens, 
2013; Yang, Z. & Klionsky, 2010). 
Finally, autophagosomes fuse with lysosomes (Ravikumar et al., 2010b), 
forming autophago-lysosomes, to degrade the engulfed contents by resident enzymes (Yang, Z. 





Figure 1-23 The regulation of autophagic molecular machinery 
The figure represents the mTORC1 complex association and inhibition by ULK 
complex by the growth factors and amino acids by phosphorylating ATG13 and 
ULK1/2. To activate autophagy, stress stimuli or AMPK promote mTORC1 
dissociation form ULK1/2 complex, leading to the formation of the phagophore 
(adapted from (Evangelisti et al., 2014)).  
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1.4.3 Autophagy and stress conditions 
While ER plays an important role to facilitate protein folding and intracellular Ca2+ 
reservoir, exceeded folding capacity by ER stress stimuli leads to protein accumulation and 
induces ER stress and unfolded protein response activation. Several studies indicated that 
autophagy is induced by ER stress signalling pathway (Figure 1-24). The mechanisms of 
activation are dependent on specific stress condition and organism. In mammalian cells, GRP78 
inhibition decreases autophagosome formation during ER stress and starvation condition, 
however, the conversion of LC3 I to LC3 II is not affected. This finding indicated that GRP78 
in a crucial factor for autophagy in the phagophore expansion step (Li, J. et al., 2008). The c-
Jun N-terminal kinase (JNK), downstream target of IRE1 transmembrane receptor, is the 
essential molecule for lipid conjugation of LC3 during misfolded proteins induced autophagy in 
cancer cells (Ding et al., 2007; Ogata et al., 2006). Recent study indicated that IRE1-JNK and 
REPK-eIF2α pathways are required for LC3 conversion and autophagic degradation of mutant 
proteins in ER (Fujita et al., 2007; Kouroku et al., 2007). Hypoxia and oxidative stress also play 
and crucial role in regulating autophagy. These conditions can induce autophagy and several 
signalling molecules have been reported to be involved in the autophagy activation such as 
hypoxia-inducible factor-1 (HIF-1), BNIP3, NIX and reactive oxygen species level (Chen, Y. et 





Figure 1-24 Regulation of autophagy in stress conditions 
The figures show autophagy is induced by ER stress condition (A) via PERK-
eIF2α, IRE1-JNK1 and Ca2+ release pathways, and (B) by hypoxia, oxidative stress 
(ROS) stimuli. Several molecules are involved in this pathway such as HIF, E2F, 
JNK1 and BNIP3 (adapted from (He & Klionsky, 2009)). 
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1.5 Endoplasmic reticulum stress and unfolded protein response 
The endoplasmic reticulum (ER) is the cytoplasmic organelle that is involved in protein 
folding, translocation and post-translocation modifications. Impairment or imbalance in the ER 
environment occurs upon several stimuli including physiological and pathological causes such 
as nutrient deprivation, oxidative stress, glycosylation change, calcium depletion, damaging of 
DNA, and energy level alteration. This can lead to ER stress with subsequent accumulation of 
unfolded or misfolded proteins inside the ER organelle (Yadav et al., 2014). In case of 
unresolved ER stress conditions, cell can be lead to death via apoptosis (Tabas & Ron, 2011). 
ER stress causes an increase in Bcl2-like1 (BIM) transcription, p53-upregulated modulator of 
apoptosis (PUMA), NADPH oxidase activator (NOXA), and BH3-only proteins while 
imbalance between anti- and pro-apoptotic Bcl-2 family members occurs. 
ER stress has been found to restore homeostasis and to be involved in making the 
adjacent environment suitable for tumour survival and expansion (Martinon, 2012). During 
tumorigenesis, the high proliferation rates of cancer cells are required to increase ER activity or 
protein folding, assembly and transport that can induce physiological ER stress (Lee, A. S., 
2007). There are three ER stress signalling pathways including inositol-requiring enzyme 1 
(IRE1), activating transcription factor 6 (ATF6) and pancreatic ER kinase-like ER kinase 
(PERK) that are localized in the ER membrane and are involved with tumorigenesis (Yadav et 
al., 2014) (Figure 1-25). X-box binding protein (XBP1), down-stream signalling pathway, and 
IRE1 have been found to promote cancer progression (Koong et al., 2006). It has been 
reported that protein XBP1 is increased in several types of human cancer including breast 
cancer, hepatocellular carcinoma and pancreatic adenocarcinoma (Koong et al., 2006). Another 
ER stress pathway, PERK/eukaryotic initiation factor 2 (eIF2)/ATF4, also have an important 
role to contribute in the progression of cancer cell (Koumenis et al., 2002). For developing anti-
cancer drugs, ER stress has become a potential target mechanism to reduce adaptation to 
hypoxia, inflammatory response, and angiogenesis that causes drug resistance (Kraskiewicz & 
FitzGerald, 2012). 
ATF4, XBP1, and PERK regulation or inhibition has been reported to be involved in 
cancer therapies (Luo & Lee, 2013; Wang, Y. et al., 2012). ER chaperone and UPR component, 
glucose regulated protein 78 (GRP78), has been recently reported to be over-expressed in 
several tumour types such as breast cancer, lung tumor, liver cell, brain tumor, colon cancer, 
ovarian cancer, glioblastoma, and pancreatic cancers (Yadav et al., 2014). However, there are 
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several studies that have reported ER stress response is directly involved in pro-apoptotic 
mechanism in either UPR-dependent or –independent manners (Moenner et al., 2007). Agents 
that induced ER stress are also potential anticancer therapies (Rosati et al., 2010). The cytosolic 
domain of IRE1 connects with the Bax/Bak apoptotic pathway. This binding leads to IRE1 
becoming activated (Hetz et al., 2006). Induction of breast cancer-derived MCF-7 cell death 
occurring through the activation of ER stress-induced apoptosis and is mediated by Bim protein 
(Puthalakath et al., 2007). 
1.5.1 Regulation of unfolded protein response in ER stress 
Unfolded protein response (UPR) is cyto-protective mechanism of cell to balance 
the misfolded or unfolded proteins under ER stress. Tumour cells will undergo apoptosis when 
ER stress is prolonged and failure of UPR controlling ER homeostasis has been identified. 
During UPR process, cells maintain appropriate processes of protein folding in the ER by the 
dissociation of Grp78/binding immunoglobulin protein (Bip) from 3 membrane-bound ER 
stress protein sensors, including PERK, ATF6, and IRE1 (Szegezdi et al., 2006). Activation of 
these sensors occurs after Grp78/Bip protein is dissociated from sensing proteins and PERK is 
the first sensor protein to activate eIF2 by phosphorylation mechanism (Harding et al., 2000; 
Shi et al., 1998). These processes result in transcription factor NF-kB inhibition during cellular 
stress. ATF6 is cleaved in Golgi apparatus before it translocate in the nucleus to regulate gene 
expression (Schindler & Schekman, 2009). After IRE1 activation, the spliced XBP1 protein 
translocates into the nucleus and subsequently activates genes expression that are involved with 
chaperones proteins or folding enzymes involved in protein folding, secretion or ER-associated 





Figure 1-25 Mechanism of UPR during endoplasmic reticulum (ER) stress  
Dissociation of glucose-regulated protein 78/binding immunoglobulin protein (Bip) 
from membrane bound sensing protein activates inositol-requiring enzyme 1 
(IRE1), activating transcription factor 6 (ATF6), and pancreatic ER kinase-like 
ER kinase (PERK). Several proteins involved in transcription activation of desired 
gene are activated by active form of membrane sensing proteins resulting in UPR 
target genes transcription such as CCAAT/enhancer binding protein homologous 
protein (CHOP) and ER-associated protein degradation (ERAD) (adapted from 
(Yadav et al., 2014)). 
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1.6 Glucose regulated proteins (GRPs) 
The glucose regulated proteins (GRPs) are known as stress inducible chaperone proteins 
that mainly are located in the endoplasmic reticulum and the mitochondria. Recent studies 
indicated that GRPs play an important role in control of signalling, proliferation, invasion, 
apoptosis, inflammation and immune response and can be translocated to other locations such 
as cell surface membrane and vesicle membrane that are secreted outside the cell (Gonzalez-
Gronow et al., 2009; Gray & Vale, 2012; Ni et al., 2011; Sato et al., 2010). 
Glucose regulated proteins, GRP78 (Bip / HSPA5), GRP94 (gp96 / HSP90B1), GRP170 
(ORP150), and GRP75 (HSPA9) are stress- related chaperone heat shock protein (HSP) family 
(Figure 1-26). These GRPs play a crucial role in regulation of protein quality and metabolic 
balance by facilitating protein folding, assembly and export unfolded or misfolded proteins to 
degrade. Furthermore, GRPs also maintain ER and mitochondrial homeostasis in the 
physiological and pathological conditions (Lee, A. S., 2014). Previous studies reported that 
GRPs are overexpressed in cancer cell lines and are involved in cancer proliferation and 
metastasis process (Lee, A. S., 2007; Miao et al., 2013). While GRP78 regulates cancer cell 
viability and apoptosis (Wang, M. et al., 2009), GRP94 is involved in the process of 
tumorigenesis and implicated with insulin-like growth factor 1 (IGF-1), Toll-like receptors 
(TLRs) and integrins (Marzec et al., 2012). There are several studies that indicated that ER 
stress induced GRP78 cell surface expression that is involved in the regulation of PI3K-AKT 
oncogenic signalling pathway (Liu, R. et al., 2013b; Zhang, Y. et al., 2010; Zhang, Y. et al., 
2013). GRP94 and GRP170 expressed on cell surface play an important role in antigen 
presentation and they also have secreted form that can induce innate and adaptive immune 
response (Luo & Lee, 2013; Ni & Lee, 2007; Wang, X. Y. & Subjeck, 2013). GRP94 has an 
important role in immune system by inducing the maturation and activation involved in 
immune responses and by secreting pro-inflammatory cytokines leading to help antigen 
presenting cell (MHC class I) to promote the antigen (Luo & Lee, 2013). 
Glucose regulated proteins, GRP78, GRP94 are heat shock protein (HSP) family that are 
mainly found in the endoplasmic reticulum (ER) and in the mitochondria, which are the 
important organelles controlling protein quality and metabolic balance (Marzec et al., 2012; Ni 
& Lee, 2007; Wadhwa et al., 2002; Wang, X. Y. & Subjeck, 2013). In some cancers, cell 
surface GRP78 forms a complex with TGF-β to induce regulatory T cell (Tregs) that inhibit 
immune system and promote cancer progression by supressing immune response against the 
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tumor (Oida & Weiner, 2010). Some cancer cells secrete GRP78 into mature dendritic cells 
leading to Tregs cell production (Corrigall et al., 2009).  
 
Figure 1-26 Functional domains of glucose regulated proteins (GRPs) 
The figure shows several domains of GRPs including ATPase activity, substrate 
binding site, ER retention peptides (KDEL) and Ca2+ binding domain. All GRPs 
share ATPase and substrate binding domains while Ca2+ binding domain, 
dimerization domain and receptor binding domain are presented only in GRP94 
(adapted from (Lee, A. S., 2014)). 
1.6.1 ER stress and GRPs regulation 
GRPs are expressed constitutively at basal level and maintain homeostasis through 
different mechanism. During ER stress condition, the induction of GRPs is used as stress 
indicator and this overexpression has become the crucial issue to investigate intracellular 
signalling pathway due to ER stress; it can also be interconnected to the nucleus to activate 
transcription of unfolded protein response (UPR)-associated gene. In cancer cell, ER stress 
triggered by intrinsic and extrinsic stimuli such as metabolism alteration, aggressive 
proliferation, starvation, hypoxia, acidosis, viral infection, and genetic mutations, is related to 
GRPs expression and regulation that is yet to be elucidated (Luo & Lee, 2013; Ma, Y. & 
Hendershot, 2004). Several studies reported that GRP78 binds to all three ER stress 
transmembrane sensors including PRKR-like endoplasmic reticulum kinase (PERK), inositol-
requiring enzyme 1 (IRE1) and ATF6 under normal condition to regulate unfolded protein 
response (Luo & Lee, 2013; Wang, M. et al., 2009) (Figure 1-27). GRP activation also is 
involved in autophagy by upregulation ER chaperones during metabolic stress response 
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(Mathew et al., 2009). Under ER stress, alternative splicing of GRP78 is triggered to produce 
cytosolic isoform (GRP78va) that regulates PERK signalling sensor and facilitate leukemia cell 
survival (Ni et al., 2009). ER stress also regulates GRP78 localization to the mitochondria 
where mitochondrial-associated GRP78 can bind to RAF1 to regulate mitochondrial 
permeability and to protect the cell by ER stress induced apoptosis (Shu et al., 2008). GRP94 is 
linked to Ca2+ homeostasis pathway that can protect the cancer cells from apoptosis (Reddy, R. 
K. et al., 1999). 
In the immune response, there are several studies reported that GRPs are involved 
in the regulation of major histocompatibility complex (MHC) class I molecules to promote 
cancer cell survival by immune suppression activation or inhibition of cancer cell survival by 
pro-inflammatory activation. GRP78 interacts with MHC class I molecules on cell surface to 
regulate Gs-mediated cAMP production and the pro-inflammatory COX-2PGE-cAMP 
signalling cascade (Misra et al., 1993; Misra & Pizzo, 2013). In some cancers, GRP78 in T-cell 
interacts with cell surface TGF-ß to induce regulatory T cells (Tregs) that play an important 
role for immune suppression and promote cancer cell progression (Oida & Weiner, 2010). 
Secreted GRP78 also modulates human monocyte differentiation into dendritic cells 





Figure 1-27 Regulation of GRPs in ER stress and UPR conditions 
GRP78 located in ER lumen plays a crucial role in UPR signalling regulation by 
binding and maintaining to the ER stress sensors (PERK, ATF6 and IRE1) under 
un-stress condition. Upon ER stress, GRP78 dissociates from stress sensors and 
interacts with misfolded proteins subsequently triggering stress sensors activation 
and translocation to nucleus. ERSE is the target gene for unfolded protein response 
and several proteins such as pro-apoptotic transcription factor (CHOP) and ER 





Figure 1-28 GRPs regulation in Cell survival and immune response 
GRP78, GRP94 and GRP170 chaperone proteins are mostly found in ER lumen and 
mitochondria. GRP78 and GRP94 are translocated to cell surface and secreted 
outside cell upon ER stress or pathological stress. Cell surface GRPs affect growth, 




1.7 Reactive oxygen species (ROS) and leukemia 
Reactive Oxygen Species are the group of active molecules and free radicals (oxidants) 
including O2, H2O2, OH
-, NO and etc. that are derived from oxygen molecule. These molecules 
are produced during mitochondrial electron transport chain of aerobic respiration processes. In 
general, ROS are eliminated by host cell protecting mechanism (antioxidants molecules such as 
superoxide dismutase (SOD), glutathione (GSH), catalase (CAT) and Coenzyme Q10 (CoQ10) 
(Udensi & Tchounwou, 2014). Imbalance between ROS production and repairing active and 
free radical molecules can induce oxidative stress (OS) (Finkel, 2003). 
OS has been known to induce carcinogenesis but it also induces cancer cell apoptosis 
which has been used in cancer therapy (Kumar, S. et al., 2014). During cancer treatment, 
chemotherapeutic drugs and radiation creates ROS and induced OS. Chronic OS alters crucial 
cellular functions and triggers several types of cancer such as prostate cancer, melanoma, acute 
lymphoblastic leukemia (ALL), myeloid leukemia, and myelodysplastic syndrome (MDS) 
(Battisti et al., 2008; Farquhar & Bowen, 2003; Fried & Arbiser, 2008; Kumar, B. et al., 2008; 
Lau et al., 2008; Renschler, 2004; Weinberg & Chandel, 2009). However, ROS triggers 
tumorigenesis by anti-apoptosis mechanism, promoting cell survival, proliferation, migration 
metastasis and chemotherapeutic resistance (Arnold et al., 2007; Maraldi et al., 2009; Naughton 
et al., 2009; Trachootham et al., 2009; Wu et al., 2008). In leukemia, several observations 
indicated that activities of antioxidant enzymes are decreased in ALL patients such as SOD, 
CAT and GSH. The alterations in antioxidants activity disrupts free radical removal and 
interferes with biological protection mechanism (Flora, 2009). 
1.8 Mechanism of GC induced leukemic cell death 
GC-induced apoptosis is an important molecular response that has been used in lymphoid 
malignancies therapy (Gaynon & Carrel, 1999). There are several reports indicating that 
intrinsic apoptosis pathway is involved in GC-induced leukemia apoptosis. The extrinsic 
pathway inhibitor, crmA, had no substantial effect on GC-induced apoptosis in ALL (Geley et 
al., 1997; Smith, K. G. et al., 1996). Other molecules involved in GC-induced intrinsic pathway 
of apoptosis in thymocyts are APAF-1 (Cecconi et al., 1998; Yoshida, H. et al., 1998), Bax and 
Bak (Rathmell et al., 2002), Bim (Bouillet et al., 1999), Puma and Noxa (Villunger et al., 
2003). The knockout (KO) Bcl-2-/- mice showed the effect of GC induced lymphoid apoptosis 
indicated that anti-apoptotic proteins such as Bcl-2, Bcl-XL and Mcl-1 are the crucial factor to 
prevent GC-induced apoptosis (Veis et al., 1993). Further studies indicated that Bax and Bak 
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are an important proteins for GC-induced apoptosis; this was shown by using KO Bax-/- Bak-/- 
mice treated with GC and the result showed the thymocytes from KO mice were resistant to 
GC-induced apoptosis (Rathmell et al., 2002). 
Moreover, microarray-based expression profiling of cells in cells treated with GC-s 
identiified a number of genes were regulated by GR and these can be grouped into three classes 
1); death and survival regulation genes 2); cellular distress response genes and 3); non-death 
response genes (Ploner et al., 2005). There are several genes regulated by GCs in CEM cells 
apoptosis including NFĸB inhibitor α (IĸB- α), FK506 binding protein 5 (FKBP 51), BCL2-like 
11 (BIM), GILZ, HIF-1 responsive RTP801 (Dig-2), Glucocorticoid receptor α (GR- α), 
Interleukin 7 receptor, and TGF-β II receptor α, which increase gene expression levels, while 
the group of genes repressed by GC are Solute carrier family 16 (MCT-1), Tubulin β 
polypeptide, c-Myc, and Integrin α 4 (antigen CD49D) (Chauhan, D. et al., 2002; Chauhan, S. 
et al., 2003; Obexer et al., 2001; Tonko et al., 2001; Webb et al., 2003; Yoshida, N. L. et al., 
2002). 
In addition, mitochondria has been reported as the target organelle for GR translocation to 
be involved in GC-induced apoptosis. GR has been detected in the mitochondria in several cell 
types (Demonacos et al., 1995; Koufali et al., 2003; Psarra et al., 2005; Scheller et al., 2003; 
Scheller et al., 2000). Recent study in various T lymphoid cell lines indicated that only GC-
sensitive cells but not in GC-resistant cells were observed the mitochondrial translocation of 
GR while nuclear GR translocations were observed in both cell types (Sionov et al., 2006a). 
Further studies demonstrated that GR is located mainly to the inner mitochondrial membrane 
and mitochondrial GRE elements have been found in the mitochondrial genome which may 
involve in mitochondrial transcription and energy metabolism (Roussel et al., 2004; Scheller et 
al., 2003; Scheller et al., 2000; Tome et al., 2004). The binding of GR with mitochondrial 
membrane may regulate mitochondrial membrane potential and subsequently be involved in 
ROS generation and transient Ca+ mobilization that are crucial for the apoptotic response 
(Scheller et al., 2000; Sionov et al., 2006b; Zhang, L. et al., 2006) and the regulation between 
mitochondria and endoplasmic reticulum in apoptotic processes has been studied (Walter & 
Hajnoczky, 2005). 
Recently, autophagy has been reported to play an important role in drug resistant therapy 
including hepatocarcinoma cancer, lung cancer, and multiple myeloma (Guo et al., 2013; Lamy 
et al., 2013; Xi et al., 2011). In murine lymphoma cells, mTOR inhibitor, Dig-2, expression 
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level increased in Dex treated cells and subsequently activated autophagy processes. Further 
studies showed Dig-2 knockdown increased levels of dexamethasone induced cell death 
(Molitoris et al., 2011). Although inhibition of autophagy by chloroquine or 3-methyladenine 
(3-MA) increased amount of GC-resistant lymphoid cells to apoptosis, the mechanism of GC-
induced apoptosis and regulation of autophagy processes are still unclear (Jiang et al., 2015). 
1.9 Drugs used in this project 
1.9.1 Dexamethasone 
Dexamethasone is the synthetic steroid drug which is used in the treatment of anti-
inflammatory disorders, including rheumatism, skin diseases, severe allergies, asthma, brain 
swelling etc. (Figure 1-29). It also is used in the patients suffering with autoimmune diseases. In 
cancer treatment, Dexamethasone is used as chemotherapeutic agent especially in 
haematological malignancies such as multiple myeloma and acute lymphoblastic leukemia. The 
Dex chemotherapeutic effect is through binding to the receptor (GR receptor) to induce tumor 
cell death. In this study, 1 µM concentration of Dexamethasone is used to treat all cell lines 
with or without combination treatment with other drugs. 
Dexamethasone was purchased from Enzo Life Science Company. The molecular 
formula is C22H29FO5 with molecular weight at 392.5. The powder form can be prepared in 





Figure 1-29 The chemical structure of Dexamethasone 
(Adapted from Enzo Life Science product data sheet, BML-El126)  
1.9.2 Chloroquine 
Chloroquine is an antimalarial chemotherapy that belongs to the quinolone family 
(Figure 1-30). It was used as an antimalarial drug compound. The action of this drug inhibits 
parasite cell proliferation by binding to heme and forming toxic complex, which results in the 
cell and parasite becoming lysed. Chloroquine enters the cell to bind with lysosome and it will 
neutralize acidic property inside lysosome. The disruption of lysosomal pH inhibits the fusion 
of autophagosome with lysosome to form autophago-lysosome that is the end process of 




Figure 1-30 The chemical structure of Chloroquine 
The chemical structure composes of C18H26CIN3. This drug has 319.877 g/mol in 
molecular weight. It can be used as antimalarial drug and anti-inflammatory agent. 
The drug’s action inhibits enzyme heme polymerase leading to accumulate the 
toxic heme within the parasite (Xu et al., 2016). 
1.9.3 Thapsigargin 
Thapsigargin is used to inhibit sarco (endo)-plasmic reticulum Ca2+ ATPase 
(SERCA) pump, which is located on membrane of sarco (endo)-plasmic reticulum (Figure 1-
31). The SERCA pump controls Calcium concentration between cytoplasm of the cell and 
endoplasmic reticulum by pumps calcium ions from cytosol into ER lumen (Møller et al., 
2010). This inhibition raises intracellular calcium concentration that disrupts cellular 
homeostasis. Accumulation of cytoplasmic calcium can induce mitochondrial morphological 
change and cell apoptosis via ER stress induced cytochrome C release and caspases activation 
(Hom et al., 2007). 1 μM and 10 μM thapsigargin have been used in this study to treat ALL 
cells with or without Dexamethasone. 
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The drug was purchased from Sigma Company with the molecular formula 
C34H50O12 while the molecular weight is 650.75. Thapsigargin (TG) is extracted from the plant 
called Thapsiagarganica L. by HPLC technique.  
 
Figure 1-31 The molecular structure of Thapsigargin 
Carbon atoms on the structure interact with SERCA pump by hydrophobic bond 
while the oxygen atoms create hydrogen bonds with the backbone of SERCA 
pump. These interactions block Calcium homeostasis occurring between cytoplasm 
and ER lumen and leading to apoptosis activation by cascade pathways (adapted 
from Sigma (Doan et al., 2015)). 
1.9.4 Rotenone 
Rotenone (ROT) is a natural botanical compound extracted from Derris sp. Root 
(Figure 1-32). The drug is widely used as an insecticide and herbicide as it acts by inhibiting the 
electron transfer at the mitochondrial complex I, where is the major source of ATP production. 
Inhibition of this electron transport chain has been found to induce cell death and to increase 
mitochondrial ROS production (Li, N. et al., 2003). 1 μM and 10 μM concentration of rotenone 
has been used with or without Dexamethasone combination to treat cells. 
The molecular structure contains C23H22O6 while 394.4 is the molecular weight of 




Figure 1-32 The figure shows chemical structure of Rotenone 
The Rotenone structure contains 5 carbon rings and it is colourless crystal powder. 
The yellow colour could be visible when it is oxidized by the light (Gupta, 2012). 
1.9.5 Bortezomib 
The Proteasome is a cylindrically shaped multi-subunit structure that controls 
degradation of proteins involved in cell cycle regulation, cell differentiation, transcriptional 
regulation, and cell apoptosis (Figure 1-33). Ubiquitin-proteasome inhibitor, Bortezomib, 
inhibits 26S proteasome resulting in apoptosis in many malignant cell types (Horton et al., 
2006). Bortezomib has cytotoxic effect in T-ALL cells including Jurkat, Molt4 and CEM cells 
lines with the IC50 values 13.0±2.9, 4.5±0.24 and 3.5±0.24 nM respectively (Koyama et al., 
2014). Horton and colleagues demonstrated that T-ALL cell lines are very sensitive to single 
Bortezomib treatment after 48 hrs using MTT assay (Horton et al., 2006). In this study, 2 nM 
and 5 nM concentration of bortezomib have been used with or without Dexamethasone. 
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Bortezomib was purchased from Santa Cruz Company that contains C19H25BN4O4 
in molecular structure. The molecular weight is 384.24. 
 
Figure 1-33 The chemical structure of Bortezomib 
The figure represents chemical structure of Bortezomib that is a specific 
proteasome inhibitor. This drug has been approved for use in multiple myeloma and 




1.10 Project aims 
In this study we hypothesise that autophagy, ER stress and UPR play important role in 
GR function. Therefore the aim of this research is to elucidate the relationship between 
autophagy and glucocorticoids in human ALL cell lines, CEM-C1-15 and CEM-C7-14 and 
Molt4. Autophagic proteins such as LC3 I and II, Beclin1 will be analysed in the experiment. 
This study will also investigate the contribution of endoplasmic reticulum stress and unfolded 
protein response to the resistance in glucocorticoid therapy by observing ER stress related 
protein such as GRP78 and GRP 94, which play an important role as protein chaperones 
responding to unfolded protein accumulation. 
Several drugs have been used with Dexamethasone to investigate the autophagy and ER 
stress response relationship including chloroquine, that acts as autophagic inhibitor reagent, 
thapsigargin which induces ER stress by blocking calcium pump on ER membrane, rotenone 
that induces reactive oxygen species generation and bortezomib that induces the ER stress and 
unfolded protein response by inhibition of proteasome function. 
Cell viability assay such as MTS, cell cycle analysis and mitochondrial membrane 
potential assay will be used to test cytotoxicity of leukemia cells, cell cycle distribution and cell 
death, respectively. Western blotting technique will be used to investigate protein expression 
level while RT-qPCR will determine mRNA expression level. 
It is hoped that these findings will contribute to better understanding of glucocorticoid 
molecular mechanism of action, effects on white blood cells and glucocorticoid resistance 





CHAPTER 2 MATERIALS AND METHODS 
2.1 Chemicals 
Table 5 List of chemicals used in the project.  
This table also provides catalogue number and supplier names. 
Chemicals Company Catalog number 
Acrylamide (ProtoGel) Fisher, UK 12381469 
Ammonium per sulphate (APS) Sigma, UK 215589-500G 
Bovine serum albumin (BSA) Roche, UK 10711454001 
β-Glycerol phosphate (BGP) Sigma, UK 154804-51-0 
β-Mercaptoethanol (HSCH2CH2OH) Sigma, UK M6250-250ML 
Bromophenal blue Sigma, UK B8026-5G 
Chemiluminescent substrate (West 
FEMTO Max. Sensitivity substrate, 
SuperSignal) 
Fisher, UK 11859290 
Chemiluminescent substrate (West PICO 
Chemiluminescent Substrate, SuperSignal) 
Fisher, UK 10743105 
Dextran Coated Charcoal (DCC) stripped 
serum 
(Hyclone) SH30068.03 
Dimethylsulphoxide (DMSO) Fisher, UK D/4121/PB08 
Dithiothreitol (DTT) Sigma, UK 10708984001 
Ethylene-diamine-tetraacetatic acid 
(EDTA) 
Sigma, UK 60-00-4 
Fetal bovine serum (heat inactivated) 
(FBS) 
Fisher, UK 11550356 
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Chemicals Company Catalog number 
Fetal Bovine Serum charcoal stripped Fisher, UK 10706143 
HEPES Sigma, UK BP310-100 
IGEPAL CA-630 (NP-40) Sigma, UK 18896-100ML 
L-Glutamine SLS, UK LZBE17-605E 
Penicillin/Streptomycin Lonza, UK DE17-602E 
Phenylmethylsulphonylfluoride (PMSF) Sigma, UK 10837091001 
PBS (10X concentration) Fisher, UK BP399-20 
PBS tablets SLS, UK 79382-50TAB 
Propidium iodide solution (1 mg/ml) Sigma, UK P4864-10ML 
RG Developer 2 x 5l - ready to use Labtech international Ltd. RGDEV 
RG Fixer 2 x 5l - ready to use Labtech international Ltd. RGFIX 
Skimmed milk Marvel 3023034 
Sodium dodecyl sulphate (SDS) Fisher, UK S/5200/53 
Sodium ortho vandate (NaOV) Sigma, UK S6508-50G 
Sodium pyrophosphate (NaPPi) Sigma, UK 221368-100G 
Tetra methyl ethylene diamine (TEMED) Sigma-Aldrich, UK T9281-50 ml 
Trypan blue solution Fluka, UK 93595-50ML 
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Chemicals Company Catalog number 
X-ray film SUPER RX 100 NIF sheets 
18x24 
Fuji Films, UK 47410 19289 
X Ray Film 18x24cm Double Sided SLS UK MOL7016 
 
2.2 Protein marker, antibodies, and drugs 
Table 6 List of protein markers, antibodies and drugs used in the project 
This table also provides catalogue number and supplier names. 
Products Company Catalog number 
β-Actin rabbit polyclonal 
antibody 
Abcam, UK ab8227 
β-Actin mouse monoclonal 
antibody 
Invitrogen MA5-14739 
Beclin-1 rabbit monoclonal 
antibody 
Cell signalling, UK #3495 
Bortezomib Santa cruz biotechology sc-217785 
CellTiter 96 Aqueous MTS 
reagent powder 250 mg 
Promega, UK G1112 
Chloroquine diphosphate salt Sigma, UK C6628-25G 
DAPI staining (Solution-8) Chemometec, UK 910-3008 
DAPI staining (Solution-12) Chemometec, UK 910-3012 
Dexamethasone Enzo Life Science BML-El126 
ECL Anti-Rabbit IgG, 
Horseradish Peroxidase linked 
from donkey 
GE Healthcare,UK LNA934V 
ECL Anti-mouse IgG, 
Horseradish Peroxidase linked 
from sheep 
GE Healthcare,UK LNA931V 
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Products Company Catalog number 
GRP78 mouse monoclonal 
antibody 
Santa cruz biotechology sc-376768 
GRP 94 mouse monoclonal 
antibody 
Santa cruz biotechology sc-53929 
High Pure RNA Isolation kit Roche Diagnostics Ltd. 11828665001 
JC-1 staining (Solution-7) Chemometec, UK 910-3007 
LC3 rabbit polyclonal antibody Cell signalling,UK #4108 
Molecular Probe Carboxy-
H2DCFDA 25 mg 
Fisher Scientific UK 11500146 
PageRuler™ Prestained Protein 
Ladder 
Thermo Fischer Scientific, UK 26616 
Phenazine methyl sulfate (PMS) Scientific Laboratory Supplies P9625-500MG 
Reactive Oxygen Species (ROS) 
Assay kit 520 nm 
eBioscience, UK 88-5930 
Re-blot mild antibody stripping 
solution (10X) 
Millipore, UK 2502 
Ribonuclease A (RNase A) Sigma, UK R4875 
Rotenone Sigma, UK R8875-1G 
SensiFAST SYBR no-ROX Mix Bioline Reagent Ltd. BIO-98005 
TaqMan High Capacity RNA to 
cDNA kit 
Fisher Scientific UK 10704217 





2.3 Buffers and Reagents 
Table 7 List of buffers and reagents used in this project 
This table provided the buffers and reagents used in this thesis study 
Buffers and Reagents Composition 
High salt lysis buffer (HSLB) 
45mM HEPES pH 7.5, 400mM NaCl, 1mM EDTA 
pH 8.0, 10% Glycerol, 0.5% NP40 – IPEGAL, 1mM 
DTT, 1 mM PMSF, 2mM Sodium Orthovanadate 
(NaOV), 1X Protease inhibitors (PI) 1mg/ml 
(1000X), 20 mM ß-glycerol phosphate (BGP), 5 
mM Sodium Pyrophosphate (NaPPi) 
Radio-Immunoprecipitation Assay 
(RIPA) buffer (product code: R-
0278) 
20 mM Tris-HCl, pH 8.0, 150 mM sodium chloride 
1.0% Igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate 
3x SDS loading buffer 
187 mM Tris pH 6.95, 30% Glycerol, 6% SDS, 15% 
2-mercapto ethanol, 0.01% bromophenol blue 
10X western running buffer 250 mM Tris, 1.9 M glycine, 350 mM SDS 
10X western transfer buffer 220 mM Tris, 750 mM glycine 
Blocking buffer 5% skimmed milk in 1X PBS 
0.1% PBS tween 0.1% Tween in 1X PBS 
0.1% Sodium dodecyl sulfate (SDS) 0.1 g SDS was dissolved in 100 ml distilled water  
10% Sodium dodecyl sulfate 10 g SDS was dissolved in 100 ml distilled water  
0.2M EDTA pH 8.0 
18.61 g EDTA was dissolved in 100 ml distilled 
water and pH was adjusted to 8.00 with Sodium 
hydroxide (NaOH) before adding distilled water to 
the final volume. 
1M Tris pH 6.95 
12.14 g Tris was dissolved in 100 ml distilled water 
and pH was adjusted to 6.95 with concentration 
hydrochloric acid (HCl) before adding distilled 
water to the final volume. 
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Buffers and Reagents Composition 
1.5M Tris pH 8.95 
18.21 g Tris was dissolved in 100 ml distilled water 
and pH was adjusted to 8.95 with concentration 
hydrochloric acid (HCl) before adding distilled 
water to the final volume. 
200 mM Sodium pyrophosphate 
(NaPPi) 
8.92 g NaPPi in 100 ml distilled water 
10% Ammonium persulfate 
1 g ammonium persulfate was dissolved in distilled 
water and adjusted the final volume to 10 ml. 
1M Sodium Orthovanadate (NaOV) 
1.84 g NaOV was dissolved in 8 ml of distilled 
water and pH was adjusted to 10. 
1M HEPES pH 7.5 for 100 ml 
23.83 g of HEPES was dissolved in 80 ml distilled 
water then the solution was adjusted pH for 7.5 by 
NaOH. Distilled water was added to 100 ml. 
1M Dithiothreitol (DTT) 
1.5 g DTT was dissolved in 8 ml of distilled water 
and mixed it until the solution was mixed 
completely. Then adjusted the volume by adding 
distilled water to 10 ml. 
0.5 M EDTA pH 8.0 
93.05 g of EDTA was dissolved in 400 ml distilled 
water. Then adjusted pH with sodium hydroxide 
(NaOH) to 8.0 and filled up with distilled water to 
500 ml. 
100mM PMSF 
0.09 g of PMSF was dissolved in 5 ml of absolute 
ethanol. 
 
2.4 Primers used in Quantitative Reverse Transcription Polymerase Chain 
Reaction 
The primers used in the project were purchased from Eurofins Company. The details for 




Table 8 List of Primers used for RT-qPCR Assay 
All primers were ordered from Eurofins Company. 
Primer DNA Sequence (5`to 3`) Tm (°C) 
BECLIN1 forward TTGGCACAATCAATAACTTCAGGC 59.3 
BECLIN1 reverse CCGTAAGGAACAAGTCGGTATCTC 62.7 
LC3B forward TGTCCGACTTATTCGAGAGCAGCA 62.7 
LC3B reverse TGTGTCCGTTCACCAACAGGAAGA 62.7 
GRP78 forward TGCCGTTCAAGGTGGTTG 56.0 
GRP78 reverse CCAAATAAGCCTCAGCGG 56.0 
GRP94 forward CTGGGTCCAGCAGAAAAGAG 59.4 
GRP94 reverse CACTCCTTCCTTGGCAACAT 57.3 
RPL19 forward ATGTATCACAGCCTGTACCTG 57.9 
RPL19 reverse TTCTTGGTCTCTTCCTCCTTG 57.9 
 
2.5 Mammalian cell types 
There are three human haematological malignant cell lines that were used in the 
experimental research including ALL CEM-C1-15 and Molt4 which are resistant to 
glucocorticoids and CEM-C7-14 which is sensitive to glucocorticoid treatment. Molt4 cell line 
is derived from acute lymphoblastic leukemia patient that carried the mutated genes including 
CDKN2A, NOTCH1, NRAS, PIK3R1, PTEN and TP53 (ATCC No. TCP-1010). CEM cell 
lines were derived from lymphoblastic cells of acute lymphoblastic leukemia patient containing 
several gene mutations (Foley et al., 1965). CEM C1 and CEM C7 are clones isolated from the 
original CEM cell line and are glucocorticoid resistant and glucocorticoid sensitive, 
respectively (Medh et al., 2003). The sensitive clones of CEM cell have been identified after 
the cells were treated with 1 µM Dexamethasone for 4-5 days, when their proliferation was 
inhibited and they became pyknotic shape and lysed (Medh et al., 1998; Norman & Thompson, 
1977). The steroid resistant cells were isolated using semisolid agarose medium which 
contained 1µM Dexamethasone (Harmon & Thompson, 1981). These cells contained receptor 
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for glucocorticoids identical to CEM wild-type cells (Zawydiwski et al., 1983). However, CEM 
C1 (clone 15) was re-isolated in 1998 by Reem D. Medh to test the mechanism of 
Dexamethasone and forskolin synergism. In the genotypic alteration, CEM cell lines were 
found to have missense mutation of both alleles of the p53 genes that would inhibit normal 
function of cells (Cheng & Haas, 1990). The Molt4 cell line is another human acute T-
lymphoblastic leukemia and the karyotypic study has shown there were structural abnormalities 
of chromosomes that effected several genes (Ma, X. C. et al., 2014) 
2.6 Cell culture protocols 
2.6.1 Growth media 
Roswell park memorial institute-1640 (RPMI-1640) media purchased from Sigma, 
UK with catalogue number R1383 was used to maintain human cell line including CEM-C1-15, 
Molt4 and CEM-C7-14. Media was prepared by adding 10% of fetal bovine serum, 1% of 
penicillin/streptomycin and 1% L-glutamine making enrichment medium that was kept at 4° C. 
Dextran Coated Charcoal (DCC) or Fetal Bovine Serum Charcoal Stripped media 
were used before adding Dexamethasone in any experiments to decrease the levels of various 
hormones that can affect studies. To prepare the DCC containing media, RPMI-1640 media was 
supplemented with 10% fetal bovine serum charcoal stripped from Sigma, UK (catalogue 
number 6765-100ML), 1% of penicillin/streptomycin and 1% L-glutamine. The complete 
media can be kept in 4°C for a long term use. 
2.6.2 Maintenance of cell culture 
Cells were maintained in 25 cm2 tissue culture flasks (T25) or in 75 cm2 tissue 
culture flasks (T75) and sub-cultured every 2-3 days when they were 70-80% confluent. In this 
step, suspended cells were centrifuged in room temperature as 2,000 revolution per minute 
(RPM) for 3 minutes then the supernatant was discarded. The pellets were re-suspended in 2 ml 
of complete fresh medium and transferred into a new culture flask containing 8 ml of medium 
to maintain 1:5-10 dilutions ratio. For sterile environment, class II laminar flow microbiological 
safety cabinet (Walker Safety Cabinets Ltd. Serial number: 50000657) was used. During 
maintenance, cells were incubated in the incubator with 37°C and 5% carbon dioxide (CO2) 
concentration (Sanyo CO2 Incubator: MCO-17AIC, Serial number: 10908824). 
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2.6.3 Freezing and thawing of suspended cell 
In the first step, the fetal bovine serum was warmed in 37°C water bath. Once 
warmed, 2 ml DMSO was added into 8 ml FCS making 20% DMSO solution. Next, cells were 
pelleted by centrifugation at 2,000 rpm for 3 minutes at room temperature. Then, pellets were 
resuspended in 1 ml fresh FCS and 1 ml 20% DMSO solution. The DMSO prevents cells 
forming intracellular ice crystals. Finally, cells suspension was aliquoted into cryovial tubes 
and then transferred to -80°C respectively. 
For defrosting or thawing the cells, warmed RPMI-1460 media containing 
10%FCS, 1% L-glutamine and 1% penicillin/streptomycin was added to T25 flask and 
transferred the 1 ml cells directly into flask. The cells were incubated in the 37°C incubator 
with 5% CO2 for 24 hours and the media was changed with fresh completed RPMI-1460 
medium to avoid cytotoxic effect of the DMSO residue on the cells. Then the cells were 
maintained until 70-80% confluence in T25 flask. 
2.6.4 Cell counting using a haemocytometer 
Microscopic chamber slide with a small (3mm × 3mm) square etched onto surface 
was used to determine the number of cells before extracting the protein from cells. Cells were 
diluted in the first step with complete medium at the dilution ratio 1:12 (10 µl of cell 
suspension and 110 µl of fresh RPMI-1460 medium). The cell suspension was diluted with 
trypan blue dye with the ratio 1:2 by mixing 10 µl of cell suspension with 10 µl of dye and the 
cell suspension was loaded into the haemocytometer (C-Chip DHC-N01, from Digital Bio 
Company) and observed under 10X objective lens microscope (Figure 2-1). Generally, the total 
number of cells was counted in the four large corner squares and the cell concentration was 
calculated as 
Cell concentration (cells/ml) = average cell count from 4 corners × dilution factor × 10,000 
The cell counting was used to obtain the number of cells to optimize cell 
concentration for Dexamethasone treatment in any future experiments such as cell viability 





Figure 2-1 The figure shows outline of four corners in haemocytometer (C-
Chip) 
The outline is focusing on the grid with 10X magnification on objective lens. A, B, 






2.7 Cell viability assay using MTS dye 
To determine the effect of studied drugs on cell, cell-based assay using negatively 
charged compound, MTS, was applied in this study. MTS does not penetrate into cytoplasm of 
the living cell while the activity of alive cell will transfer electron from the cytoplasm or cell 
membrane to intermediate electron acceptor reagent such as Phenazine methyl sulfate (PMS) 
and Phenazine ethyl sulfate (PES) and then these reagents can convert tetrazolium compound in 
the culture medium to the soluble form of formazan reagent (Berridge et al., 2005). The soluble 
formazan will turn the medium to dark brown colour that is visible in the experiment plate. The 
MTS compound was purchased from Promega Company, CellTiter 96 Aqueous MTS reagent 
(Figure 2-2). It can be summarized that more alive cells were growing in the medium more dark 
brown colour was visible. 
2.7.1 Cell seeding into 96 wells plate 
After counting the cell using C-Chip, 50,000 cells were seeded into flat bottom 96 
wells plate containing 50 µl of DCC-RPMI medium. Then, the drug dilutions were prepared 
before loaded into 96 wells plate for 50 µl. Dexamethasone was prepared for maximal 
concentration at 20 µM and then the concentration was diluted in half 6 times. The 
Thapsigargin concentration started at 40 µM as same as Rotenone while the maximal 
concentration of Bortezomib was 20 µM. The untreated condition is set as row A and the 
maximal drug concentration was loaded in row H (the bottom of the 96 wells plate) while the 
rest of diluted condition were loaded from row Q to row B, respectively. Once the drugs have 






Figure 2-2 The principle of the MTS assay 
Figure shows that intermediate reagent accepts the electron from NADH in the 
cytoplasm of alive cell to activate soluble formazan from MTS dye. The figure was 
adapted from cell viability assay guideline (Terry L Riss, Published May 1, 2013; 




2.7.2 MTS dye incubation periods and optical density (OD) interpretation 
Once the incubation with drugs was completed, the 20 µl MTS working solution 
was added to the wells. The working MTS solution was prepared by mixing 2 ml of 2 mg/ml in 
PBS of MTS solution with 100 µl PMS solution at 0.92 mg/ml concentration in 1X PBS. This 
was performed in the dark as it is a light sensitive dye. The plate was incubated in the incubator 
at 37°C for 4 hours. Once the dye has converted the colour to dark brown, the MTS plate was 
read on the microplate reader (Multiskan Ascent Thermo Labsystems 354, SN: 354-01134), 
using Ascent software Multiskan. The absorbent values were set at 490 nm in wavelength to 
detect MTS dye and 690 nm for the 96 well plate background compensation absorbance. 
The OD values obtained by measurement at 690 nm (background) were subtracted 
from 490 nm (sample) reading. The experiment was carried out in triplicate to get the accurate 
value. Then the average of each treatment is divided by the average value for the control and 
multiplied by 100. The percentage of growth curve was plotted to observe the trend of cell 
proliferation and the concentration of the drug that inhibits cell growth. 
2.8 Cell Cycle Analysis 
2.8.1 Cell preparation for flow cytometry 
The cells were plated at 3×106 per well and the drug was added at desired 
concentration. Then cells were incubated at 37°C with 5% CO2 concentration for 48 hours. 
Once the incubation period was finished, the cells were transferred to new tubes and were 
centrifuged at 2,000 rpm for 3 minutes, and then supernatant was discarded. In the next step, 
the cells were re-suspended in 1 ml cold 1x PBS, transferred to new Eppendorf tube and 
centrifuged at 2,000 rpm for 3 minutes. Supernatant was discarded and the 500 l cold ethanol 
was added to cells before mixing by vortex for approximately 10 seconds. Then, the cells were 
incubated at 4°C for 30 minutes before the 50 l of a 100 g/ml solution of ribonuclease A 
(RNase A) was added, and then the cells were left at room temperature for 15 minutes. Before 
using the FACS machine, 300 l of 50 g/ml propidium iodide solution was added to the 
samples and incubated for 15 minutes. 
2.8.2 Cell cycle analysis using flow cytometry 
Cell cycle analysis by quantifying DNA content was one of the earliest applications 
of flow cytometry. This analysis is based on the ability to stain the cellular DNA that is directly 
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proportional to the amount of DNA within the cell. The most common DNA binding dye used 
to measure DNA is Propidium Iodide (PI), which binds to DNA groove and double stranded 
RNA. The 10,000 cells were collected and were analysed by flow cytometry. The forward 
scatter (FSC) and side scatter (SSC) were set to identify single cell. This can be performed by 
using pulse area and pulse width signals detection which can be set on FACS software. The 
DNA contents are converted into the signal using PE channel from the software. 
Cell division has 2 mainly processes including DNA replication and segregation 
into two cells. In the interphase, the cell is preparing for DNA synthesis, G1, and then the 
replication of DNA occurs in S phase followed by G2 phase, respectively (Vermeulen et al., 
2003). In this way, cells that are in S phase will present more DNA contents than cells in G1. 
The cell will absorb proportionally more dye and fluorescent intensity will be higher while the 
cells in G2 phase will be approximately twice as bright as cell in G1 phase. In healthy cell, 
SubG1 is not presented in the graph obtained from flow cytometry while in cell death 
condition, DNA fragments will be stained with PI and were shown in the area before G1 phase, 





Figure 2-3 Typical DNA content histogram obtained from PI staining method 
The figure represents DNA content distribution indicating cell cycle phases 




2.9 Mitochondrial Membrane Potential (MMP) Assay  
The principle of this method is based on the dye, JC-1, that has positive molecular charge 
and passes through the cell membrane and mitochondrial membrane into the matrix of 
mitochondria. The dye will bind to inner membrane and form aggregated JC-1 that can be 
detected as red fluorescence signal. In early apoptosis cells, the inner membrane will lose 
transmembrane potential (negative charge) that the dye will be presented in monomeric form 
and the green signal can be detected by fluorescence. 
2.9.1 Cell preparation for MMP Assay 
3 106 cells of CEM-C1-15, Molt4 and CEM-C7-14 were seeded in 6 well plates 
before the combination treatments were applied for 48 hrs. After that, cells were suspended in 1 
ml medium or PBS at approximately 1 106 cells/ml. 6.25 µl of solution 7 (JC-1 dye, Figure 2-
4) was added directly to each sample and incubated 20 minutes at 37°C. The stained cells were 
centrifuged at 400 g for 5 minutes at room temperature and supernatant was removed 
completely without disturbing cell pellet. Then, samples were washed twice with 1 ml 1X PBS 
by pipetting. After centrifuging the sample at 400 g for 5 minutes at room temperature, the 
pellets were resuspended in 250 µl of solution 8 (DAPI) by pipetting and the samples were 
analysed immediately by NucleoCounter NC-3000. 
2.9.2 MMP Measurement using NucleoCounter NC-3000 
8-chamber slide (NC-Slide A8) was used by loading 10 µl of each sample into the 
chamber of slide and then the loaded slide was placed on the tray of the NucleoCounter NC-
3000. Using image analysis, the NC-3000 software was used to analyse the different form of 
cationic JC-1 dye (5, 5, 6, 6-tetracholo-1, 1, 3, 3-tetraethylbenzimidazol-carbocyanine iodide) 
since this dye can be detected as green and red fluorescence intensity according to 
mitochondrial membrane potential voltage. The mitochondrial probe, JC-1, has a positive 
charge while the intact inner mitochondria contains negative charge. In case of disruption of 
mitochondrial membrane potential or loss of the mitochondrial membrane potential such as 
apoptosis, JC-1 localizes to the cytoplasm in its monomeric green fluorescence form that has an 
emission wavelength of 529 nm. In the case of healthy cell, the dye becomes aggregated red 
fluorescent form which can emit the fluorescence at 590 nm (Chazotte, 2011). The red/green 
fluorescence intensity ratio was determined by NC-3000 software where decreasing of 




Figure 2-4 Chemical structure of JC-1 dye using in MMP Assay 





Figure 2-5 Figure is the sample showing the ratio of red/green fluorescent 
intensity profiles and percent of cell death in chloroquine treated CEM-C1-15 
The figures showed the fluorescent signal of healthy cells in the upper right 
quadrant (QUR) and cell death in lower right quadrant (QLR) presenting in each 
condition including untreated, 1 μM Dex, 10, 20, 50 μM CLQ and combined Dex 
with 10, 20, 50 μM CLQ, respectively. 
2.10 Reactive Oxygen Species (ROS) Assay 
ROS production levels play an important role in the cell signalling pathways such as 
apoptosis, gene expression and cell signalling cascades activation (Hancock et al., 2001). In this 
study, Carboxy-H2DCADA (Invitrogen C400) probe was used to detect total reactive oxygen 
species generated in leukemic cells treated with various drugs (Figure 2-6). The probe 
containing 2ʹ, 7ʹ-dichlorofluorescein (DCF) and calcein is non-fluorescent compound until the 
acetate groups are removed by intracellular esterase and oxidation occurs inside the cell. This 
oxidation process can be detected by determination of the increase in fluorescent signal with 
flow cytometer using excitation sources and filters for FITC channel (excitation wavelength 




Figure 2-6 The structure of carboxy-H2DCFDA molecular probe 
The figure was adapted from Invitrogen Reactive Oxygen Species (ROS) Detection 
Reagents Kit Manual Protocol. (https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/mp36103.pdf) 
2.10.1 Cell preparation for ROS Assay 
3 106 cells of CEM-C1-15, Molt4 and CEM-C7-14 were seeded in 6 well plates 
before the combination treatments were applied using desired drug concentration and 24 hrs 
incubation time point. After the incubation periods, the cells were transferred into new 15 ml 
centrifuge tube to collect the cell suspension. The tubes were centrifuged at 2,000 RPM for 3 
minutes before supernatant was discarded. 1 ml cold 1X PBS was used to re-suspend cell 
pellets and then transferred all pellets into new Eppendorf tubes and centrifuged again at 2,000 
RPM for 3 minutes at 4°C for pellet collecting. Before adding 100 µl of working carboxy-
H2DCFDA dye to the pellets, 100 mM stock dye was diluted into 100 µM working dye by 
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adding 2 µl of stock dye into 2 ml 1X PBS. After re-suspending the pellets, the cells were 
incubated for 30 – 60 minutes at 37°C with 5% CO2 in the dark. Then, the dye was discarded by 
centrifuging the pellets at 2,000 RPM for 3 minutes. The cells were washed by cold PBS for 1 
ml and the pellets were collected before 1 ml cold PBS was used to resuspend the cells. The 
cells were then analysed by flow cytometry using FITC channel. 
2.10.2 ROS Assay analysis using flow cytometer 
This analysis is based on the intensity of the fluorescent signal emitted from the dye 
inside the cells containing ROS products. The 10,000 cells were collected and were analysed by 
flow cytometry. The forward scatter (FSC) and side scatter (SSC) were set to identify cell 
population. The appropriate filter FITC channel was selected to determine the fluorescent signal 
intensity. The FITC-A signal was collected by using geo-mean (the signal obtained at the peak 
of the intensity graph) and was analysed by Excel program to interpret the total ROS production 
in the cell during desired treated conditions comparing to untreated. 
2.11 Protein Expression Analysis 
2.11.1 Protein extracts preparation 
CEM-C1-15, Molt4 and CEM-C7-14 were counted by using haemocytometer and 
approximately 2 106 cells/ml were split into each 6 wells plate containing DCC-FCS RPMI 
medium. The cells were treated without/with combination treatment of 1M Dexamethasone 
and other drugs that related to inhibition of autophagolysosome formation (Chloroquine), ER 
stress inducer (Thapsigargin and Rotenone) and proteasome inhibitor (Bortezomib) in different 
concentration. Then, cells were incubated at 37°C with 5% CO2 for 48 hours to allow the drug 
taking their effects. Then the cells were transferred to new centrifuge tubes and spun at 2,000 
rpm for 3 minutes. Supernatants were discarded and re-suspended with 1 ml cold 1x PBS 
before transfer of the cells to new eppendorf tube and centrifuged to discard supernatant. Radio-
Immunoprecipitation Assay Buffer (RIPA buffer) was added into harvested cells for 100 l and 
re-suspended completely as the buffer solubilized wide range of proteins including cytoplasmic 
proteins, nuclear proteins and membrane bounded proteins (Ngoka, 2008). Then, lysates were 
incubated 20 minutes at 4°C on a rotating platform on ice, followed by centrifugation at 13,000 
rpm for 15 minutes at 4°C. Supernatant was transferred to a new Eppendorf tube without 
disturbing the cell lysate that placed on ice to preserve protein lysate. The protein concentration 
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was measured by using spectrophotometer at the wavelength absorbance 595 nm followed by 
Bradford assay. 
Bradford assay is a colorimetric assay measuring protein concentration using Bio-
Rad protein assay reagent. The working solution was prepared as 800 l distilled water and 200 
l Bradford reagent (Bio-Rad) and 2 l of protein extracted sample. The mixed solutions were 
added in a semi-micro cuvettes (VWR) and mixed gently by using parafilm to cover top of 
cuvette and inverted all cuvettes to avoid air bubbles. 2 l RIPA buffer was used as blank to 
calibrate the spectrophotometer. The protein samples were duplicated for each extract for a 
good practice and an average value used. Samples were incubated at room temperature for 5 
minutes and then the protein concentration was determined the absorbance at 595 nm 
wavelength. 
Following this step, each protein concentration was calculated following protein 
standard curve as protein concentration references and 3x SDS loading buffer was added as half 
volume of protein sample to denature secondary and tertiary protein structures. To making the 
protein standard curve, Bovine Serum Albumin (BSA) was dissolved in RIPA buffer to make 
various desired concentration tubes from 0.5 g/l to 5 g/. The absorbance at 595 nm 
wavelength in each tube was measured according and the regression equation was used to 
calculate protein concentration. 
2.11.2 Protein separation by SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique used to separate protein according to size in an electric field. SDS is an anionic 
detergent, which denatures the proteins by covering around the polypeptide backbone resulting 
in the protein becoming negatively charged and moving towards the positive electrode in an 
electric field according to the polypeptide mass. 10% resoling gel was prepared and the gel 
casting apparatus (Mini-Protean 3 Bio-Rad, UK) was set up according to manufacturer’s 
instruction. The gel was placed into electrophoresis tank (Bio-Rad) and then the tank was filled 
with 1x SDS running buffer. Before loading samples into the wells, the comb was removed and 
samples were boiled at 95°C for 5 minutes using hotplate. 5 l of Protein molecular weight 
marker (PageRuler™ Prestained Protein Ladder) and 40 g of total protein samples were 
loaded onto the well using a Hamilton microliter syringe or 2 µl pipette tip. The gel was run for 
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20 minutes at 80V then at 110V for 95 minutes or until the samples nearly reached the end of 
the gel. 
2.11.3 SDS-PAGE preparation 
Table 9 List of reagents used in 10% and 12% resolving gels preparation 
This table showes components for resolving part of SDS-PAGE preparation used in 
this study 
Reagents 10% Resolving gel 12% Resolving gel 
30% (w/v) Acrylamide-bisacylamide 9.33 ml 11.2 ml 
1.5M Tris-HCl (pH 8.95) 7 ml 7 ml 
10% SDS 0.28 ml 0.28 ml 
0.2M EDTA 0.28 ml 0.28 ml 
10% Ammonium persulfate 157 µl 157 µl 
Distilled water 10.74 ml 9.7 ml 
TEMED 17 µl 17 µl 
 
These solutions were mixed and loaded into a protein gel casting apparatus (Mini-
PROTEAN 3 Bio-Rad, UK) which was set up according to manufacturer’s instruction. The 
0.1%SDS solution was added on surface of gel protecting gel oxidation and was poured off 




Table 10 List of reagents used in stacking gel preparation 
This table provided the reagents used to prepare stacking part of SDS-PAGE 
Reagents Stacking gel 
30% (w/v) Acrylamide-bisacylamide 1.67 ml 
1M Tris-HCl (pH 6.95) 1.25 ml 
10% SDS 100 µl 
0.2M EDTA 100 µl 
10% Ammonium persulfate 157 µl 
Distilled water 6.73 ml 
TEMED 17 µl 
 
These solutions were mixed and poured on the surface of resolving gel and the 
10 wells comb was placed immediately. Gel was completely set after 30-45 minutes. 
2.11.4 Western blotting and detection of proteins 
Western blot is used to detect the specific protein in a mixture by adding specific 
antibodies against a desired protein. Basically, primary antibody binds to the target protein and 
secondary antibody, which is labelled with a fluorescent probe detected by light detection, 
which binds to the primary antibody. 
Before transferring protein from the gel to membrane, a sandwich of filter paper, 
gel, polyvinylidene difluoride (PVDF) membrane (Millipore, UK) and one more layer of filter 
paper were prepared in a cassette, which was placed between electrodes immersed in 1x SDS 
transfer buffer. The membrane was soaked in methanol for 30 seconds and the filter paper in 1x 
SDS-PAGE transfer buffer before placing in the cassette. The set of cassette and icebox were 
placed in the tank with 1x SDS-PAGE transfer buffer and stirrer bar was used to keep buffer 
and membrane cool. The transferring was set for 2 hour at 0.4 amps and ice was changed after 
an hour of running. Next, membrane was blocked with 5% skimmed milk in 1x PBS for an hour 
to prevent the nonspecific binding. After blocking, the nitrocellulose membrane was incubated 
with a primary antibody (dilution at 1:1,000 – 1:2,000) in 2.5% skimmed milk /1x PBS / 0.1% 
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Tween on a rocking platform overnight at 4°C. Next day, the membrane was washed 3 times 
with 1x PBS / Tween (0.1%) buffer for 10 minutes interval. Then, the membrane was incubated 
with Horse Radish Peroxidase (HRP) conjugated secondary antibody (antibody dilution 
1:5,000) dissolved in 10 ml of 2.5% skimmed milk /1x PBS / Tween (0.1%) and washed 3 
times again with 1x PBS / Tween (0.1%) buffer for 10 minutes interval. Protein bands were 
visualized by incubating PVDF membrane with Supersignal West Pico or West Femto 
Chemiluminescent substrates and the protein bands were captured on film using x-ray 
developer in the dark room. 
The intensity of protein bands was analysed using ImageJ software. Then the % of 
intensity was compared to the control condition to determine the effect of drugs on ALL cell 
lines. 
2.11.5 Membrane stripping 
The membrane can be re-probed multiple times before it is subjected to another 
desired antibody by stripping the membrane. This method unbinds of the first primary antibody 
and allows the other primary antibody to bind specific protein on the membrane. To strip the 
blot, 10 ml of 10% SDS solution was added into universal tube following 3.2 ml of 1M Tris pH 
6.95 and distilled water was added up to 50 ml. Under chemical hood, 2-mercaptoethanol was 
added and mixed by inverting the tube before placing the tube in the 50°C water bath for 30 
minutes. Solution was discarded under hood and PBS / 0.1% Tween was used to wash the 
membrane 3 times and the membrane blocking process was carried out as normal. 
Primary and secondary antibodies can be gently removed from PVDF membrane by 
using re-blot plus mild stripping buffer. Before stripping the blot, stripping solution was diluted 
by adding 18 ml distilled water into 2 ml of 10X re-blot solution (Merck Millipore, catalog 
number 2502). Then, membrane was placed into plastic tray with appropriate amount of 1X 
stripping solution. 15-20 minutes of incubation time of stripping processes was applied into 
membrane on the rotor machine. Normal blocking procedure using 5% skimmed milk in 1X 
PBS was done for 1 hour. After blocking, the blot was ready for reprobing with desired 
antibodies. 
2.12 Quantitative reverse transcription polymerase chain reaction (RT-qPCR) 
RT-qPCR is the method used to determine gene expression profiling starting with RNA. 
Real time PCR technique is a sensitive method for detection and quantification nucleic acids. 
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The fluorescent DNA binding dye, SYBR® Green I, was used in this study. Generally, SYBR® 
Green I dye will bind to double-strand DNA only and after binding has occurred, the dye will 
emit fluorescence signal and the intensity that correlates with amplified DNA will be detected 
by Rotor-Gene® Q. Three essential steps of this technique are total RNA isolation, conversion 
of total RNA to cDNA by reverse transcriptase enzyme and finally quantitative real time 
polymerase chain reaction (Peirson & Butler, 2007). The result obtained from experiment was 
analysed and compared using linear phase of exponential graph before it reached the plateau 
phase.  
2.12.1 Cell preparation for total RNA isolation 
CEM-C1-15, Molt4 and CEM-C7-14 were counted by using haemocytometer (C-
Chip) and approximately 2 106 cells/ ml were seeded into 6 wells plate containing 3 ml of 
DCC-FCS RPMI medium. The cells were treated without / with combination treatment of 1M 
Dexamethasone with other drugs using maximal dose including 10 µM thapsigargin, 5 nM 
bortezomib. Then, cells were incubated at 37°C with 5% CO2 for 24 hours to allow the drug 
taking their effects. 
2.12.2 Total RNA isolation and purification 
After the incubation periods, the cells were transferred to new sterile Eppendorf 
tubes and then pellets were harvested by centrifugation at 2,000 RPM for 3 minutes. Pellets 
were resuspended by adding 200 µl sterile 1X PBS followed by adding 400 µl Lysis/Binding 
Buffer and then the cells were vortexed for 15 seconds. The pellets were transferred to a high 
pure filter tubes (Roche® High Pure RNA Isolation Kit) and the cell lysates were collected by 
centrifuging the tube at 8,000 ×g for 15 seconds. After discarding the flowthrough, 100 µl 
DNase I mixed buffer (90 µl DNase I incubation buffer and 10 µl DNase I) was added on the 
each filter membrane and the membrane was incubated for 15 minutes at room temperature to 
allow the enzyme DNase to eliminate genomic DNA on the membrane. Once the incubation 
time has been finished, 500 µl Wash Buffer I was added to the filter tube and then the tube was 
centrifuged at 8,000 ×g for 15 seconds. After the flowthrough was discarded, 500 µl of Wash 
Buffer II was added to the filter tube before the flowthrough was discarded again by 
centrifuging the tube at 8,000 ×g for 15 seconds. Additionally, washing step was applied by 
adding 200 µl Wash Buffer II into the filter tube and centrifuged again at maximum speed 
(approx. 13,000 ×g) for 2 minutes to remove any residual washing buffer. Then, the filter tube 
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was inserted into clean, sterile 1.5 ml micro-centrifuge tube before 50 µl of Elution Buffer was 
added into the centre of filter membrane. The tube was centrifuged for 1 minute at 8,000 ×g to 
collect the purified total RNA that can be used directly in reverse transcription process (Roche 
Diagnostics GmbH, High Pure RNA Isolation Manual Leaflet). The concentration and purity of 
the total RNA were measured by using ThermoScientific NanoDrop™ machine.  
2.12.3 Total RNA conversion to cDNA by reverse transcription method 
Before adding 1 µg of total RNA into the reaction tube, total RNA stock solution 
was diluted to 1 µg by adding Nuclease-free water up to 10 µl of total volume. In this study, 
High-Capacity RNA-to-cDNA™ Kit was used to create cDNA strand. The RT mixture 
including 2X RT Buffer mix, 20X RT Enzyme mix and Nuclease-free H2O were prepared 
following product information sheet guideline. 9 µl of total RNA sample was added into RT 
master mixed reaction tube to fill up total volume 20 µl in each reaction tube the RT reaction 
tubes were kept on ice at all times until next step was performed. After sealing the tube with 
caps, the RT tube was briefly centrifuged to spin down the sample and to eliminate any air 
bubbles. The reaction tube was loaded to the PCR machine and sample tube was incubated at 
37°C for 60 minutes followed by heating the sample at 95°C for 5 minutes and holding the 
sample at 4°C until the RT tubes were collected. After finishing the cycle, the cDNA was ready 
for real time PCR application or long-term storage in the freezer (-20°C). 
2.12.4 Quantitative real time polymerase chain reaction assay 
Before the cDNA sample was added into the tube containing qPCR mixture, the 
primers used in this experiment were reconstituted by adding desired nuclease-free water to 
make 100 µM stock solution tube. The working primer sample was prepared by diluting the 
stock primer with nuclease-free water to make 10 µM. The SensiFAST SYBR® No-ROX Kit 
was used to determine the amount of cDNA template. The master mix qPCR tube was prepared 
by mixing 10 µl of 2X SensiFAST SYBR® with 0.8 µl forward primer, 0.8 µl reverse primer, 2 
µl cDNA template and 6.4 µl nuclease-free water to make 20 µl reaction tube. Then, the 
duplicated reactions were loaded into Qiagen Rotor-Gene Q Centrifuge machine. The qPCR 
thermal cycle parameters were set according to the company leaflet guideline (cycle 1: 95°C 2 
minutes, Cycles 2 – 40: 95°C 5 seconds for denaturation step, 60°C 15 seconds for annealing / 
extension steps). After the reaction reached completion, the melting curve analysis has been 
done before the threshold cycle was collected and was analysed. At the end of processes, 
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amplification plot where the x-axis represents the PCR cycle and y-axis is the fluorescence 
signal of the amplified cDNA was selected the appropriate fluorescence threshold. At this point, 
threshold cycle (Ct) was determined to further analysis. 
2.13 Computer programs 
2.13.1 Multiskan ascent software for ascent multiskan microplate reader 
Multiskan Ascent Software is the software to determine the colour intensity by 
using the filter to detect the optical density (OD) or an absorbent at 490 nm and 690 nm 
wavelength. The 96 well plate was used in this method and MTS dye was used to determine 
alive cell metabolism. 
2.13.2 ImageJ software 
ImageJ is the free analysis software, which can be downloaded from the website: 
http://imagej.nih.gov/ij/download.html. It can be used to measure and to compare the density of 
scanned picture or x-ray protein band from western blot technique. The suitable x-ray film for 
this software should be transparency film. ImageJ is the semi-quantitative tool and the selected 
area obtained from the experimental result can lead to different values so the average value of 
three independent choices of scanned area was calculated before a statistical test programs. 
2.13.3 BD FACSuite 
The BD FACSuite is the software which was used with flow cytometry machine 
(BD FACSVerseTM). This software has been used to analyse the cell cycle of CEM-C1-15, 
CEM-C7-14 cell lines and Molt4 cell after treating with drugs and it can also be applied to 
analyse autophagic cell activities, cell death and apoptosis events. 
2.13.4 NucleoView NC-3000 
The NucleoView NC-3000 is the software which was used to analyse mitochondrial 
membrane potential assay that detects the change of mitochondrial membrane voltage between 
inner and outer layers after drug treatment. Results obtained from this software can be applied 
to analyse early apoptosis and late apoptosis events. 
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2.13.5 Rotor-Gene Q series software 
To determine mRNA expression level, quantitative reverse transcription polymerase 
chain reaction (RT-qPCR) was used in this study. The software called Rotor-Gene® Q series 
which was installed in Rotor Gene Machine was used to determine the threshold cycle (Ct 
value). All results obtained from experiments were further analysed in excel. 
2.14 Statistical analysis 
Mean ± standard error of the mean (SEM) of the quantitative data from at least three 
independent experiments were calculated and displayed as error bars in bar charts. Statistical 
analysis was conducted by using Graph-Pad Prism Software. The difference in experimental 
data was analysed by student t.test when comparing to untreated group to obtain p-value. Less 




CHAPTER 3 CELL VIABILITY ASSAYS 
3.1 Introduction to cell viability assay 
The inhibition of lymphoid cells growth by steroid hormones, glucocorticoids, has been 
found to be important for treatment of haematological malignancies and lympho-proliferative 
diseases (Claman, 1972; Goldin et al., 1971). However, important problem of glucocorticoid 
usage is the occurrence of side effects and the drug resistance to the treatment. The 
combination treatment with other drug compounds is the potential way to increase the 
successful therapy in patients. 
The purpose of this set of experiments was to determine the optimal dose and duration 
for cytotoxic effect of glucocorticoid and other drugs including Chloroquine (inhibits 
autophagy), Thapsigargin (causes ER stress), Rotenone (increases ROS) and Bortezomib 
(inhibits proteasome and causes ER stress and unfolded protein response) treatments in order 
to maximize cytotoxic effects on leukemic cells (CEM-C1-15, CEM-C7-14 and Molt4). 
3.2 Determination cytotoxic effect of individual and combined drugs treatment 
on leukemia cells using MTS assay 
To determine the optimal dose and incubation time period of chemotherapeutic agents as 
mentioned above, MTS assay was performed after 24 hrs and 48 hrs treatment with 
glucocorticoid alone or in combination conditions. 
3.2.1 Cell viability of leukemia cells treated with Dexamethasone and 
Chloroquine 
The synthetic steroid compound, Dexamethasone (Dex), and anti-malarial drug, 
Chloroquine (CLQ), which also has the autophagic flux inhibition effect were tested to 
determine the concentration and incubation period needed to inhibit cell proliferation and to 
induce cell death. The most effective doses obtained from Dexamethasone treated alone, 
chloroquine treated alone and combination treated conditions were chosen to treat the cells 
throughout the study. 
CEM-C1-15, CEM-C7-14 and Molt4 cells were treated with Dexamethasone 
using wide range of concentrations between 0.15625 µM and 10 µM. The doses of 
Chloroquine (CLQ) used in this test were between 1.5625 µM and 100 µM (Ramakrishnan & 
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Houston, 1984; Verras et al., 2015). Cells were treated for 24 hrs and 48 hrs to determine 
optimal time to allow drugs taking their effects. The results obtained using 24 hrs treatment 
showed that Dex did not substantially inhibit cell proliferation in CEM-C1-15 cells with 
CEM-C7-14 and Molt4 showing greater Dex sensitivity respectively. However, no Dex 
concentration showed inhibition greater than 50% in all three cell lines tested (Figure 3-1 A-C, 
full black line). CLQ treated alone decreased cell proliferation in CEM-C1-15, CEM-C7-14 
and Molt4 cell lines (Figure 3-1, A-C, grey line). The concentrations that inhibited CEM-C1-
15 and CEM-C7-14 cell growths at 50% (IC50) were calculated for each cell line (38.5 µM 
and 37.7 µM, respectively) (Table 11). The IC50 was calculated using CompuSyn software 
which is the point where straight line passes through the y-axis at 50% cell viability and x-axis 
when the drug concentrations were represented as logarithm value. 
To analyse the effect of combination drug treatment, Combination index (CI) was 
considered, where CI<1, =1 and >1 indicates synergism, additive effect and antagonism, 
respectively (Zhang, N. et al., 2016). The combination treatment showed synergistic effect in 
CEM-C1-15 in all combinations of drugs concentration (Table 12 A), CEM-C7-14 in all 
combination treatments except the maximal dose of Dex and CLQ (Table 14 A), and in Molt4 
(Table 16 A) with Dex concentration greater than 1.25 µM and CLQ dose above 12.5 µM 
(Figure 3-1, A-C, black dashed line). 
At 48 hrs incubation time, Dexamethasone decreased the percent of cell death in 
CEM-C1-15 and Molt4 cells but the greater effect was observed in CEM-C7-14. CLQ alone 
inhibited the CEM-C1-15, CEM-C7-14 and Molt4 proliferations with IC50 at 22.0, 21.7 and 
35.1 µM, respectively. Cytotoxic effects increased when combination treatments were applied 
(Figure 3-1, D-F, black dashed line). In CEM-C1-15, the synergistic effects were observed in 
several combination treatments except in minimal dose treatment with 0.3125 µM of Dex and 
3.125 µM of CLQ (Table 13 A). Synergistic effect were also observed in CEM-C7-14 at all 
combined treatments excluding maximal doses (10 µM of Dex with 100 µM of CLQ) (Table 
15 A) while this effects in Molt4 were observed if Dex concentration was above 1.25 µM and 





Figure 3-1 Cytotoxicity curves of CEM-C1-15, CEM-C7-14 and Molt4 cells 
treated with Dexamethasone and Chloroquine 
Cells were treated with different concentrations of Dex alone (black line), CLQ 
alone (grey line) and combination (black dashed line) for 24 hrs (A to C) and 48 
hrs (D to F). Cell viability was determined using MTS assay and data expressed 
relative to untreated sample. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). Each sample was compared to untreated control. 
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3.2.2 Cell viability of leukemia cells treated with Dexamethasone and 
Thapsigargin 
CEM-C1-15, CEM-C7-14 and Molt4 cells were treated with Dexamethasone and 
thapsigargin to investigate the role of ER stress in glucocorticoid signalling. Dex was used at 
increasing concentrations from 0.15625 µM to 10 µM. The doses of Thapsigargin (TG) used 
in this test were between 0.3125 µM and 20 µM (Krysov et al., 2014; Rosati et al., 2010) and 
cells were treated for 24 hrs and 48 hrs. The results showed that 24 hrs treatment with 
Thapsigargin alone decreased the cell viability in all three cell lines in a dose dependent 
manner (cell viability was between 1% and 48%). However, no single drug treatment inhibited 
cell proliferation more than 50% when cells were treated for 24 hrs (Figure 3-2, A-C). The 
combination treatment with Dexamethasone and Thapsigargin exerted cytotoxic effect in 
CEM-C7-14 with CI value less than 1 in all combined conditions indicating synergistic effect 
(Table 14 B), while synergistic effects fluctuated in CEM-C1-15 and Molt4 cells (Tables 12 B 
and 16 B). 
After 48 hrs incubation time, Thapsigargin treatments significantly increased the 
cell proliferation inhibition in all cell lines. Dex also decreased cell viability in resistant cell 
and Molt4 while CEM-C7-14 were highly inhibited by Dex with minimal dose used. 
Additionally, combination treatments enhanced cytotoxicity effects in three cell 
lines when compared to the single drug treatment (Figure 3-2, D-F). IC50 which was 
calculated for Thapsigargin treatment in CEM-C1-15, CEM-C7-14 cells was 1.99 µM and 
4.27 µM respectively, while IC50 was very low calculated from Molt4 (0.06 nM). The 
combination index showed synergistic effects in CEM-C1-15 and CEM-C7-14 at all 
concentrations, while drug antagonism was observed in Molt4 if the Dex and TG 
concentration was more than 0.625 µM and 1.25 µM, respectively (CI>1) (Tables 13 B, 15 B 





Figure 3-2 Cytotoxicity curves of CEM-C1-15, CEM-C7-14 and Molt4 cells 
treated with Dexamethasone and Thapsigargin 
Cells were treated with different concentrations of Dex alone (black line), TG 
alone (grey line) and combination (black dashed line) for 24 hrs (A to C) and 48 
hrs (D to F). Cell viability was determined using MTS assay and data expressed 
relative to untreated sample. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). Each sample was compared to untreated control. 
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3.2.3 Cell viability of leukemia cells treated with Dexamethasone and 
Rotenone 
CEM-C1-15, CEM-C7-14 and Molt4 cells were treated with Dexamethasone with 
concentrations mentioned above and with Rotenone to analyse the role of ROS in 
glucocorticoid receptor function. The doses of Rotenone (ROT) used in this test were between 
0.3125 µM and 20 µM (Roedding et al., 2012; Velez et al., 2016) and the samples were 
analysed after 24 hrs and 48 hrs. The results showed that 24 hrs treatment with Rotenone 
alone did not substantially inhibit cell proliferation in Molt4 cell with CEM-C1-15 and CEM-
C7-14 showing greater Dex sensitivity respectively (Figure 3-3, A-C). However, IC50 for 
Rotenone was calculated in CEM-C7-14 at 16.61 µM (Table 11). The combination treatment 
showed synergistic effect observed in CEM-C1-15 and CEM-C7-14 at all concentrations 
(CI<1) (Tables 12 C and 14 C). 
In 48 hrs of incubation time, Rotenone treatment alone showed significant cell 
growth inhibition in all cell lines more than 50%, especially in CEM-C1-15 (Figure 3-3, D-F). 
The IC50 values for Rotenone in CEM-C1-15, CEM-C7-14 and Molt4 cells were 0.10 µM, 
0.47 µM and 0.68 µM, respectively. 
The combination treatments enhanced the cytotoxicity effects on three cell lines 
when compared to the single drug treatment. The synergistic effect has been indicated by the 
combination index calculated from CompuSyn software with CI<1 at all combined doses 





Figure 3-3 Cytotoxicity curves of CEM-C1-15, CEM-C7-14 and Molt4 cells 
treated with Dexamethasone and Rotenone 
Cells were treated with different concentrations of Dex alone (black line), ROT 
alone (grey line) and combination (black dashed line) for 24 hrs (A to C) and 48 
hrs (D to F). Cell viability was determined using MTS assay and data expressed 
relative to untreated sample. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). Each sample was compared to untreated control. 
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3.2.4 Cell viability of leukemia cells treated with Dexamethasone and 
Bortezomib 
CEM-C1-15, CEM-C7-14 and Molt4 cells were treated with Dexamethasone 
concentrations as above and Bortezomib to examine the role of proteasome and ER stress in 
GR signalling. The doses of Bortezomib (BTZ) used in this test were between 0.15625 nM 
and 10 nM (Dai et al., 2011; Wang, A. H. et al., 2011a) and cells were treated for 24 hrs and 
48 hrs. The results upon 24 hrs incubation time showed that Bortezomib inhibited CEM-C1-
15 proliferation more than 50% at 5 nM and 10 nM, while the combination treatment with 
Dex enhanced cytotoxic effect in all three cell lines (Figure 3-4, A-C). IC50 was calculated for 
only CEM-C1-15 cell line at 4.0 nM (Table 11). 
In 48 hrs incubation period, Bortezomib treatment led to a decrease of more than 
50% cell viability in CEM CEM-C1-15 and Molt4 with 5 nM and 10 nM, respectively. 
However, the drug did not have significant effect in glucocorticoid-sensitive cells at the 
maximal concentration (10 nM) (Figure 3-4 E, grey line). When drugs were combined, 
synergistic effects were observed in CEM-C1-15 at 2.5 µM of Dex and 2.5 nM BTZ, CEM-
C7-14 at all concentrations treated cells and Molt4 cells at all concentration except 1.25 µM of 





Figure 3-4 Cytotoxicity curves of CEM-C1-15, CEM-C7-14 and Molt4 cells 
treated with Dexamethasone and Bortezomib 
Cells were treated with different concentrations of Dex alone (black line), BTZ 
alone (grey line) and combination (black dashed line) for 24 hrs (A to C) and 48 
hrs (D to F). Cell viability was determined using MTS assay and data expressed 
relative to untreated sample. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 




All drugs including CLQ, TG, ROT and BTZ reached 50% of inhibition of ALL 
cells proliferation at different concentrations, while the combination treatment exerted their 
cytotoxic effects on ALL cells. IC50 values obtained from MTS assay vary according to type 
of cell lines and the duration of the incubation time (Table 11). TG and ROT treatments 
sensitized leukemic cells when cells were treated individually or in combination with studied 
compounds. BTZ induced apoptosis of CEM-C1-15 cells that was greater than Molt4 and 
CEM-C7-14 cells. Moreover, 48 hours of incubation time had higher cytotoxic effects than 24 
hours treatment. 
Drug doses including 1 µM Dexamethasone, 10, 20, and 50 µM Chloroquine, 1 
and 10 µM Thapsigargin, 1 and 10 µM Rotenone, 2 and 5 nM Bortezomib have been selected 




Table 11 IC50 obtained using MTS assay in CEM-C1-15, CEM-C7-14 and 
Molt4 cells 
The table shows IC50 after 24 hrs incubation time (A) and 48 hrs incubation time 
(B) with Dexamethasone, Chloroquine, Thapsigargin, Rotenone and Bortezomib 





Table 12 Combination index (CI) upon 24 hrs combination treatment of 
CEM-C1-15 cell 
The synergistic values in CEM-C1-15 combination treatments Dex (µM) and 
CLQ (µM) (A), Dex (µM) and TG (µM) (B), Dex (µM) and ROT (µM) (C) and 
Dex (µM) and BTZ (nM) (D) were considered by using combination index (CI) 






Table 13 Combination index (CI) after 48 hrs combination treatment of 
CEM-C1-15 cells 
The synergistic values in CEM-C1-15 combination treatments Dex (µM) and 
CLQ (µM) (A), Dex (µM) and TG (µM) (B), Dex (µM) and ROT (µM) (C) and 
Dex (µM) and BTZ (nM) (D) were considered by using combination index (CI) 






Table 14 Combination index (CI) after 24 hrs combination treatment of 
CEM-C7-14 cells 
The synergistic values in CEM-C7-14 combination treatments Dex (µM) and 
CLQ (µM) (A), Dex (µM) and TG (µM) (B), Dex (µM) and ROT (µM) (C) and 
Dex (µM) and BTZ (nM) (D) were considered by using combination index (CI) 






Table 15 Combination index (CI) after 48 hrs combination treatment of 
CEM-C7-14 cells 
The synergistic values in CEM-C7-14 combination treatments Dex (µM) and 
CLQ (µM) (A), Dex (µM) and TG (µM) (B), Dex (µM) and ROT (µM) (C) and 
Dex (µM) and BTZ (nM) (D) were considered by using combination index (CI) 






Table 16 Combination index (CI) after 24 hrs combination treatment of 
Molt4 cells 
The synergistic values in Molt4 combination treatments Dex (µM) and CLQ (µM) 
(A), Dex (µM) and TG (µM) (B), Dex (µM) and ROT (µM) (C) and Dex (µM) 
and BTZ (nM) (D) were considered by using combination index (CI) where CI<1, 





Table 17 Combination index (CI) after 48 hrs combination treatment of 
Molt4 cells 
The synergistic values in Molt4 combination treatments Dex (µM) and CLQ (µM) 
(A), Dex (µM) and TG (µM) (B), Dex (µM) and ROT (µM) (C) and Dex (µM) 
and BTZ (nM) (D) were considered by using combination index (CI) where CI<1, 





3.3 Determination of cell cycle phases of leukemia cells treated with individual 
and combined drugs using cell cycle progression analysis 
In order to determine effect of the studied compounds on ALL cell death and cell cycle 
progression, desired drugs concentrations were used to treat CEM-C1-15, CEM-C7-14 and 
Molt4 cells for 48 hrs. Cells then were stained with propidium iodide dye before flow 
cytometry was used to determine the percentage of cells in each cell cycle phase including 
subG1 (DNA fragmentation referred to cell death), G1, S and G2/M phases (Figure 3-5). 
 
Figure 3-5 The representative results obtained from flow cytometry to 
analyse the cell cycle distribution pattern in CEM-C1-15 cells treated with 
Chloroquine 
Graphs showed DNA content against cell numbers in SubG1, G1, S and G2/M 
phases in all treatments including untreated group (A), 10 μM (B), 20 μM (C) and 
50 μM (D), of Chloroquine, 1 μM Dexamethasone (E), combination treatments of 
Dex with 10 μM (F), 20 μM (G) and 50 μM (H) Chloroquine, respectively. 
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3.3.1 Determination of cell cycle profiles in Dexamethasone and 
Chloroquine treated leukemia cells 
To investigate the role of Autophagy in the glucocorticoid hormones mediated cell 
cycle progression control, Dex and CLQ were used individually and in combination to 
measure effect on ALL cell viability and cell cycle profile. After seeding the cells in 6-well 
plates, all treatments have been performed for 48 hrs. The PI-stained cells were loaded into 
flow cytometry and BD FACSuite software has been used to analyse all experiments. After 
gating, the percent of cells in each phase was compared to untreated sample and data were 
displayed using histogram charts. The results showed that Dex increased percentage of CEM-
C7-14 cells in SubG1 phase to a greater extent than in CEM-C1-15 and Molt4, respectively 
(Figure 3-6 A, compare lane 1 and 2). CLQ alone increased SubG1 phase in dose-dependent 
manner in CEM resistant and sensitive cells while Molt4 cell were not affected by CLQ 
(Figure 3-6 A, lanes 3 to 5 compare black, light grey and grey bars). The combination 
treatments caused substantial increase in fragmented DNA in CEM-C1-15 and CEM-C7-14 
while in Molt4 cells increase in SubG1 phase was not observed. Increase in G1 phase was 
observed in Dex treated Molt4 cells and marginal decrease in CEM-C1-15 and CEM-C7-14 
cells (Figure 3-6 B, lanes 2, 6 to 8 grey bars). S phase substantially decreased in the Dex 
treated Molt4 cells (Figure 3-6 C, lanes 2, and 6 to 8 light grey and grey bars). Furthermore, 
G2/M phase was decreased by Dex treatment alone in CEM-C7-14 and Molt4 while combined 
conditions with CLQ resulted in decrease of G2/M in CEM-C1-15 and CEM-C7-14 cells 




Figure 3-6 Cell cycle phase distribution in CEM-C1-15, CEM-C7-14 and 
Molt4 Chloroquine and Dex treated cells 
CEM-C1-15 (black bars), CEM-C7-14 (light grey bars) and Molt4 (dark grey 
bars) were treated with indicated concentration of Dex and CLQ for 48 hrs. Cells 
were either untreated (lane 1), or treated with 1 μM Dex (lane 2), 10, 20 and 50 
μM Chloroquine (lanes 3-5), and combination of 1 μM Dex with 10, 20 and 50 
μM Chloroquine (lanes 6-8). Cell cycle phases were gated and values for SubG1 
(A), G1 (B), S (C) and G2/M phases (D) across different treatments were 
expressed as a percentage of control group. The results are representative of 3 
independent experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, 
*** p < 0.001, student t.test). Each sample was compared to untreated control. 
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3.3.2 Determination of cell cycle phases in Dexamethasone and 
Thapsigargin treated leukemia cells 
In order to determine potential crosstalk of glucocorticoid hormones and ER 
stress, Dex and TG were used individually and in combination to measure effect on ALL cell 
viability and cell cycle progression. Dex and TG were added for 48 hrs (concentrations were 
mentioned above), and flow cytometry carried out as described above. Results indicated that 
TG increased SubG1 phase in C1-15 cells higher than in C7-14 and Molt4 cells. Moreover, 
the combination treatments increased SubG1 in all cell lines (Figure 3-7 A, lanes 5 and 6 
compare to lane 1). G1 phase significantly decreased when TG was used to treat CEM-C1-15 
cells (Figure 3-7 B, lanes 3 to 6 black bars) while the increase in G1 was observed in Molt4 
(Figure 3-7 B, lanes 2 to 6 grey bars). The percent of cells in G2/M phase decreased 
significantly in CEM-C1-15 and CEM-C7-14 with combination treatments (Figure 3-7 D, 





Figure 3-7 Cell cycle phase distribution in CEM-C1-15, CEM-C7-14 and 
Molt4 Thapsigargin and Dex treated cells 
CEM-C1-15 (black bar), CEM-C7-14 (light grey bar) and Molt4 (dark grey bar) 
were treated with Dex and TG in different conditions for 48 hrs. Cells were either 
untreated (lane 1), or treated with 1 μM Dex (lane 2), 1 and 10 μM Thapsigargin 
(lanes 3-4), and combination of 1 μM Dex with 1 and 10 μM Thapsigargin (lanes 
5-6). Cell cycle phases were gated and values for SubG1 (A), G1phase (B), S 
phase (C) and G2/M phase (D) across different treatments were expressed as a 
percentage of control group. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). Each sample was compared to untreated control. 
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3.3.3 Determination of cell cycle phases in Dexamethasone and Rotenone 
treated leukemia cells 
To investigate the role of oxidative stress in the function of glucocorticoid 
hormones, Dex and ROT were used individually and in combination to measure effect on 
ALL cell viability and cell cycle progression. Cells were treated with Dex and ROT for 48 hrs 
and analysed by flow cytometry. The results showed that SubG1 phase substantially increased 
in ROT treated CEM-C1-15 and CEM-C7-14 cells and the combination treatment led to 
further increase in SubG1 phase in CEM cells in a dose dependent manner (Figure 3-8 A, 
lanes 3 to 6 black and light grey bars compare to lane 1). G1 phase was decreased 
significantly in ROT and combined treatment with Dex in CEM-C1-15 and CEM-C7-14 cells 
(Figure 3-8 B, lanes 3 to 6 black and light grey bars). In addition, Dex increased G1 phase in 
Molt4 cells but this accumulation of cells in G1 phase was decreased when ROT was added 
(Figure 3-8 B, grey bars compare lane 2 and lanes 3 to 6). Dex had inhibitory effect on S 
phase in CEM-C7-14 and Molt4 cells. ROT alone increased G2/M phase in all cells with 
significant effects observed only in Molt-4, while inhibitory trend was observed in G2/M 





Figure 3-8 Cell cycle phase distribution in CEM-C1-15, CEM-C7-14 and 
Molt4 Rotenone and Dex treated cells 
CEM-C1-15 (black bar), CEM-C7-14 (light grey bar) and Molt4 (dark grey bar) 
were treated with Dex and ROT in different conditions for 48 hrs. Cells were 
either untreated (lane 1), or treated with 1 μM Dex (lane 2), 1 and 10 μM 
Rotenone (lanes 3-4), and combination of 1 μM Dex with 1 and 10 μM Rotenone 
(lanes 5-6). Cell cycle phases were gated and values for SubG1 (A), G1phase (B), 
S phase (C) and G2/M phase (D) across different treatments were expressed as a 
percentage of control group. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 




3.3.4 Determination of cell cycle phases in Dexamethasone and Bortezomib 
treated leukemia cells 
To investigate the role of ER stress and unfolded protein response in the function 
of glucocorticoid hormones, Dex and BTZ were used individually and in combination to 
measure effect on ALL cell viability and cell cycle progression. Dex and Bortezomib were 
incubated with cells for 48 hrs and flow cytometry used to obtain SubG1 and cell cycle 
phases. The results showed that SubG1 phase increased in CEM-C7-14 and Molt4 cells when 
BTZ was used alone (Figure 3-9 A, lanes 3 and 4 light grey and grey bars compare to lane 1) 
while increase in SubG1 was observed in CEM-C1-15 (Figure 3-9 A, lanes 4 and 5 black 
bars). The combination treatment with Dex substantially increased SubG1 in CEM cells 
(Figure 3-9 A, lanes 5 and 6 black and light grey bars). G1 phase substantially increased in 
Molt4 when Dex was added while decreasing of S phase was observed in CEM-C7-14 and 
Molt4 (Figure 3-9 B and C). In CEM-C1-15 and CEM-C7-14, decrease of G1 phase was 
observed in combined treatment of Dex and BTZ (Figure 3-9 B, lanes 5 and 6 black and light 
grey bars). G2/M phase decreased in CEM-C7-14 when treated with Dex alone and combined 





Figure 3-9 Cell cycle phase distribution in CEM-C1-15, CEM-C7-14 and 
Molt4 Bortezomib and Dex treated cells 
CEM-C1-15 (black bar), CEM-C7-14 (light grey bar) and Molt4 (dark grey bar) 
were treated with Dex and BTZ in different conditions for 48 hrs. Cells were 
either untreated (lane 1), or treated with 1 μM Dex (lane 2), 2 and 5 nM 
Bortezomib (lanes 3-4), and combination of 1 μM Dex with 2 and 5 nM 
Bortezomib (lanes 5-6). Cell cycle phases were gated and values for SubG1 (A), 
G1phase (B), S phase (C) and G2/M phase (D) across different treatments were 
expressed as a percentage of control group. The results are representative of 3 
independent experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, 





Dexamethasone mediated increase in SubG1 was higher in CEM-C7-14 than in 
CEM-C1-15 and Molt4, whereas stronger effects were observed in combination treatments 
with Chloroquine, Thapsigargin, Rotenone and Bortezomib. Dex also increased G1 phase in 
Molt4 while lower number of CEM-C1-15 and CEM-C7-14 cells were observed in G1 phase. 
Dex significantly decreased S and G2/M phases in CEM-C7-14 and Molt7 cells. Increase in 
SubG1 in a dose dependent manner was observed in CLQ and ROT treated cells, however cell 
death did not increase when BTZ was used in CEM-C7-14 and Molt4 cells. Finally, ROT 




3.4 Determination of mitochondrial membrane potential alteration in leukemia 
cells treated with individual and combined drugs 
Mitochondria is the crucial organelle involved in cellular physiology and is the source of 
intracellular energy (ATP). It produces the ATP through oxidative phosphorylation processes 
during electron transport chain (Chance & Williams, 1956). During the ATP synthesis, series 
of redox reactions generate the gradient of electrochemical voltage that also creates the 
mitochondrial membrane potential (MMP), which becomes the important parameter to detect 
and to determine mitochondrial function (Chen, L. B., 1988; MITCHELL, 1961). The 
alteration of mitochondrial membrane potential is linked to cell apoptosis. Several cell 
membrane permeable fluorescent dyes such as 3, 3ʹ-dihexyloxacarbocyanine iodide, 
rhodamine-123, and JC-1 have been used to detect the change of MMP that were associated 
with various disorders (Lemasters et al., 2002; Sakamuru et al., 2012). 
3.4.1 MMP alteration in Dexamethasone and Chloroquine treated 
leukemia cells 
To investigate the role of Autophagy in the role of glucocorticoid hormones in 
mitochondrial mediated processes, Dex and CLQ were used individually and in combination 
to measure the disruption of mitochondrial membrane potential on ALL cells. After seeding 
the cells in 6-well plates, cells were treated with indicated drugs concentrations for 48 hrs, 
stained with JC-1 and loaded into A8 slide. Cells were analysed using NucleoCounter. The 
percent of cell death presenting in lower right quadrant (QLR) in each condition was noted 
and normalised to control group. Results showed that Dexamethasone alone substantially 
changes the mitochondrial membrane potential in CEM-C7-14 cells (Figure 3-10 B lane 2), 
while slight increase was observed in CEM-C1-15 cells. However, the mitochondrial 
membrane voltage was not affected by Dex in Molt4 cells. Only 50 μM Chloroquine alone 
significantly increased MMP alteration in all cell lines (Figure 3-10 A-C lane 5) and further 
increase was observed when CLQ was combined with Dex in CEM-C1-15 and CEM-C7-14 
(Figure 3-10 A and B lanes 7-8). In Molt4, the combination conditions did not increase the 




Figure 3-10 Mitochondrial membrane alterations observed in CEM-C1-15, 
CEM-C7-14 and Molt4 Dexamethasone and Chloroquine treated cells 
The figures show the relative MMP alterations in CEM-C1-15 (A), CEM-C7-14 
(B) and Molt4 (C) cells in different conditions including untreated group (lane 1), 
1 μM Dex (lane 2), 10, 20 and 50 μM Chloroquine (lanes 3-5), and combination 
treatment of 1 μM Dex with 10, 20 and 50 μM Chloroquine (lanes 6-8). The 
results are representative of 3 independent experiments. Error bars represent ± 
SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). Each sample was 
compared to untreated control. 
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3.4.2 MMP analysis in Dexamethasone and Thapsigargin treated cells 
To investigate the role of ER stress and unfolded protein response in the role of 
glucocorticoid hormones in mitochondrial functions, Dex and TG were used individually and 
in combination to measure the mitochondrial membrane potential alteration on ALL cells. 
Cells were treated as mentioned above 48 hrs. The results showed that in CEM-C1-15 cells 
increase in MMP was caused by 10 μM TG treatment (Figure 3-11 A lane 4), in CEM-C7-14 
cells this increase was more substantial than in CEM-C1-15 and Molt4 cells when cells were 
treated with Dex and TG individually (Figure 3-11 B). The combination treatments increased 





Figure 3-11 Mitochondrial membrane alterations observed in CEM-C1-15, 
CEM-C7-14 and Molt4 Dexamethasone and Thapsigargin treated cells 
The figures show the relative MMP alterations in CEM-C1-15 (A), CEM-C7-14 
(B) and Molt4 (C) cells in different conditions including untreated group (lane 1), 
1 μM Dex (lane 2), 1 and 10 μM Thapsigargin (lanes 3-4), and combination 
treatment of 1 μM Dex with 1 and 10 μM Thapsigargin (lanes 5-6). The results are 
representative of 3 independent experiments. Error bars represent ± SEM (* p < 




3.4.3 MMP analysis in Dexamethasone and Rotenone treated cells 
To investigate the role of oxidative stress and glucocorticoid hormones in 
mitochondrial functions, Dex and ROT were used individually and in combination to measure 
the alteration of mitochondrial membrane voltage on ALL cells. After treating the cells with 
studied drugs for 48 hrs, Nucleocounter was used to determine MMP as described above. The 
results showed that Rotenone alone substantially increased MMP in CEM-C1-15 and CEM-
C7-14 cells (Figure 3-12 A and B lanes 3-4), while marginal increase was observed in Molt4. 
The combination conditions increased the percent of MMP alterations to a greater extent in 
CEM cell lines (Figure 3-12 A and B lanes 5-6), while the Molt4 cells were not affected by 





Figure 3-12 Mitochondrial membrane alterations observed in CEM-C1-15, 
CEM-C7-14 and Molt4 Dexamethasone and Rotenone treated cells 
The figures show the relative MMP alterations in CEM-C1-15 (A), CEM-C7-14 
(B) and Molt4 (C) cells in different conditions including untreated group (lane 1), 
1 μM Dex (lane 2), 1 and 10 μM Rotenone (lanes 3-4), and combination treatment 
of 1 μM Dex with 1 and 10 μM Rotenone (lanes 5-6). The results are 
representative of 3 independent experiments. Error bars represent ± SEM (* p < 





3.4.4 MMP analysis in Dexamethasone and Bortezomib treated cells 
To investigate the role of ER stress and unfolded protein response in the function 
of glucocorticoid hormones and in mitochondrial processes, Dex and BTZ were used to treat 
cells for 48 hrs individually and in combination, and the mitochondrial membrane alterations 
on ALL cells measured as described above. The results indicated that 5 nM Bortezomib 
increased MMP alterations in CEM-C1-15, CEM-C7-14 cells and Molt4 cells but only in 
CEM-C1-15 significant values were observed (Figure 3-13 A). Combination treatment 
significantly increased MMP alterations only in CEM-C1-15 and CEM-C7-14 cells (Figure 3-





Figure 3-13 Mitochondrial membrane alterations observed in CEM-C1-15, 
CEM-C7-14 and Molt4 Dexamethasone and Bortezomib treated cells 
The figures show the relative MMP alterations in CEM-C1-15 (A), CEM-C7-14 
(B) and Molt4 (C) cells in different conditions including untreated group (lane 1), 
1 μM Dex (lane 2), 2 and 5 nM Bortezomib (lanes 3-4), and combination 
treatment of 1 μM Dex with 2 and 5 nM Bortezomib (lanes 5-6). The results are 
representative of 3 independent experiments. Error bars represent ± SEM (* p < 






Dexamethasone substantially increased the mitochondrial membrane potential 
alterations in glucocorticoid-sensitive cells while the marginal changes of mitochondrial 
membrane voltage were observed in CEM-C1-15 cells. However, Dex did not change MMP in 
Molt4 cells. Chloroquine interrupted mitochondrial membrane voltage when used at high dose 
in all three cell lines while combined drugs with Dex have stronger effects in CEM-C7-14 and 
CEM-C1-15. CEM-C1-15 and CEM-C7-14 MMP alterations were affected by Thapsigargin 
and Rotenone alone treatments in a dose dependent manner. Combination treatments of Dex 




CHAPTER 4 REACTIVE OXYGEN SPECIES PRODUCTION IN LEUKEMIA 
4.1 Overview of reactive oxygen species generation in leukemia 
In redox homeostasis, Reactive Oxygen Species (ROS) level plays an important role in 
cell proliferation, survival and genomic mutation in leukemic cell. The increased ROS levels 
disrupt oxidative pathway leading to genomic instability and leukemogenesis (Irwin et al., 
2013). The major source and target of ROS in leukemic cells are in the mitochondrial electron 
transport chain (ETC) and the variety of genomic and mitochondria mutations play the critical 
role to increase ROS levels in leukemic cells (Carew et al., 2003; Quillet-Mary et al., 1997; 
Silva et al., 2011). In order to determine ROS generation in ALL cells treated with studied 
compounds indicated drugs concentrations were used to treat CEM-C1-15, CEM-C7-14 and 
Molt4 cells for 24 hrs. Cells were then stained with carboxy-H2DCFDA dye to determine the 
total reactive oxygen species generation by flow cytometry. The percent of total ROS signal 
intensity was normalized to control group. 
4.2 Determination of reactive oxygen species levels in Dexamethasone and 
Chloroquine treated leukemia cells 
In order to investigate the role of autophagy and ROS generation in glucocorticoid 
treatment, Dex and CLQ were used individually and in combination to measure ROS levels in 
ALL cells. After seeding the cells in 6-well plates, Dex and CLQ were added for 24 hrs and 
stained cells analysed using flow cytometry. The results showed that Dex significantly 
decreased the total ROS levels in CEM-C7-14 cells, caused marginal reduction in Molt4 cells, 
whereas in CEM-C1-15 cells there was no change in ROS levels (Figure 4-1 A to C, lane 2). 
CLQ alone at 20 and 50 µM decreased ROS level only in CEM-C1-15 cells (Figure 4-1 A 
lane 4-5). The combination with Dex decreased ROS generation in CEM-C1-15 and CEM-C7-
14 cells at all combined drug treatments except 50 µM CLQ in CEM-C7-14 cells (Figure 4-1 





Figure 4-1 Reactive oxygen species generation in CEM-C1-15, CEM-C7-14 
and Molt4 cells treated with Chloroquine and Dexamethasone 
The figures show the relative ROS generation intensity in CEM-C1-15 (A), CEM-
C7-14 (B) and Molt4 (C) cells in different conditions including untreated group 
(lane 1), 1 μM Dex (lane 2), 10, 20 and 50 μM Chloroquine (lanes 3-5), and 
combination treatment of 1 μM Dex with 10, 20 and 50 μM Chloroquine (lanes 6-
8). The results are representative of 3 independent experiments. Error bars 
represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). Each 




4.3 Reactive oxygen species generation in Dexamethasone and Thapsigargin 
treated leukemia cells 
In order to investigate the role of ER stress and glucocorticoid treatment in ROS 
signalling, Dex and TG were used individually and in combination to measure ROS level in 
ALL cells. Cells were treated with Dex and TG for 24 hrs and analysed using flow cytometry. 
The results indicated that TG alone significantly decreased ROS generation in all cells (Figure 
4-2 lane 3 and 4) and the combination with Dex also decreased ROS level in three cell lines 





Figure 4-2 Reactive oxygen species generation in CEM-C1-15, CEM-C7-14 
and Molt4 cells treated with Thapsigargin and Dexamethasone 
The figures show the relative ROS generation intensity in CEM-C1-15 (A), CEM-
C7-14 (B) and Molt4 (C) cells in different conditions including untreated group 
(lane 1), 1 μM Dex (lane 2), 1 and 10 μM Thapsigargin (lanes 3-4), and 
combination treatment of 1 μM Dex with 1 and 10 μM Thapsigargin (lanes 5-6). 
The results are representative of 3 independent experiments. Error bars represent 
± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). Each sample was 
compared to untreated control. 
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4.4 Reactive oxygen species generation in Dexamethasone and Rotenone treated 
leukemia cells 
In order to determine the role of oxidative stress and ROS generation in glucocorticoid 
treatment, Dex and ROT were used individually and in combination to measure ROS level in 
ALL cells. Dex and ROT were added for 24 hrs to leukemia cells and flow cytometer used for 
analysis. The results showed that ROT alone substantially increased ROS production in CEM-
C1-15 and CEM-C7-14 cells in dose dependent manner (Figure 4-3 A and B, lane 3 and 4) 
and the combination treatment with Dex significantly increased ROS level in CEM-C1-15 and 
CEM-C7-14 cells (Figure 4-3 A and B, lane 5 and 6). However, decreased ROS production in 
Dex and 1 μM ROT CEM-C7-14 treated cells when compared to ROT alone has been 
observed (Figure 4-3 B lane 3 and 5). Molt4 cells did not change ROS levels when treated 





Figure 4-3 Reactive oxygen species generation in CEM-C1-15, CEM-C7-14 
and Molt4 cells treated with Rotenone and Dexamethasone 
The figures show the relative ROS generation intensity in CEM-C1-15 (A), CEM-
C7-14 (B) and Molt4 (C) cells in different conditions including untreated group 
(lane 1), 1 μM Dex (lane 2), 1 and 10 μM Rotenone (lanes 3-4), and combination 
treatment of 1 μM Dex with 1 and 10 μM Rotenone (lanes 5-6). The results are 
representative of 3 independent experiments. Error bars represent ± SEM (* p < 




4.5 Reactive oxygen species generation in Dexamethasone and Bortezomib 
treated leukemia cells 
In order to determine the role of unfolded protein response and ROS generation in 
glucocorticoid treatment, Dex and BTZ were used individually and in combination to measure 
ROS level in ALL cells. Dex and BTZ were added for 24 hrs to leukemia cells and results 
obtained using flow cytometer. The results showed that ROS production decreased 
significantly in BTZ alone treatment in CEM-C1-15 cells at 2 nM BTZ and CEM-C7-14 cells 
at 2 and 5 nM (Figure 4-4 A and B, lane 3 and 4) while BTZ did not change ROS level in 
Molt4 cells. The combination treatment with Dex significantly decreased ROS generation in 
CEM cells in dose dependent manner (Figure 4-4 A and B, lane 5 and 6) but not in Molt4 





Figure 4-4 Reactive oxygen species generation in CEM-C1-15, CEM-C7-14 
and Molt4 cells treated with Bortezomib and Dexamethasone 
The figures show the relative ROS generation intensity in CEM-C1-15 (A), CEM-
C7-14 (B) and Molt4 (C) cells in different conditions including untreated group 
(lane 1), 1 μM Dex (lane 2), 2 and 5 nM Bortezomib (lanes 3-4), and combination 
treatment of 1 μM Dex with 2 and 5 nM Bortezomib (lanes 5-6). The results are 
representative of 3 independent experiments. Error bars represent ± SEM (* p < 






Dexamethasone treatment significantly decreased reactive oxygen species (ROS) levels 
in GC-sensitive cells and Molt4 after 24 hrs. However, there was no alteration of ROS level in 
CEM-C1-15 cells treated with Dex. Chloroquine decreased ROS production only in CEM-C1-
15 cells when the single treatment was performed whereas the combination treatment 
decreased ROS in CEM cells. Thapsigargin caused decrease in ROS levels in all cell lines 
when used alone and in combination with Dex. Rotenone substantially increased ROS 
generation in CEM cells in dose dependent manner in both individual and combination 




CHAPTER 5 AUTOPHAGY, ER STRESS AND UNFOLDED PROTEIN 
RESPONSE IN LEUKEMIA CELLS 
5.1 Analysis of individual and combined drugs treatments on protein expression 
levels in leukemia cells 
To investigate the effect of drugs on endogenous protein expression alteration, the 
immunoblotting technique was used. Cell lysates were collected for protein extraction after 48 
hrs of incubation with studied drugs and western blots were performed to detect ER stress 
related chaperone protein levels including GRP94 and GRP78 or autophagic protein levels 
such as Beclin1 and LC3. Protein intensities quantification was carried out using ImageJ 
software and statistical analysis carried out using GraphPad prism software. 
5.1.1 Protein expression levels in Dexamethasone and Chloroquine treated 
leukemia cells 
In order to determine effect of steroids and autophagy inhibition on endogenous 
protein levels, Dexamethasone 1 µM and Chloroquine 10, 20 and 50 µM individual and in 
combination were used to treat CEM-C1-15, Molt4 and CEM-C7-14 cells. Endogenous 
protein intensities of GRP94, GRP78, Beclin1, LC3 I and II were analysed using actin as 
loading control (Figure 5-1). The results indicated that Dex alone significantly increased 
GRP94 protein expression level in CEM-C7-14 cells, there were no changes in CEM-C1-15 
and Molt4 cells (Figure 5-2 A, lane 2 compare to lane 1). GRP94 protein levels were not 
changed in CLQ alone treatment except in CEM-C1-15 cells, which significantly increased 
GRP94 expressions, but increasing trends of GRP94 level were observed in CEM-C7-14 when 
combined with Dex (Figure 5-2 A, lanes 6 to 8 grey bars). In addition, GRP78 level 
significantly increased in Dex alone treated GC-sensitive cells (Figure 5-2 B, lane 2 grey bar) 
and the increasing trend of GRP78 protein was observed in CEM-C7-14 when CLQ was used 
with combination conditions (Figure 5-2 B, lanes 6 to 8 grey bars). 
Beclin1 levels were not changed by Dex treatment in all cells (Figure 5-2 C, lane 
2). LC3 II / LC3 I ratio, which can be used to analyse the autophagy process, significantly 
increased in Molt4 cells but decreased in CEM-C7-14 cells treated by Dex alone (Figure 5-2 
D, lane 2 light grey bar and grey bar). There were increasing trends of LC3 II / LC3 I ratio in 
CLQ alone treated cells and in combination conditions with Dex in all cells (Figure 5-2 D, 




Figure 5-1 Protein levels in CEM-C1-15, CEM-C7-14 and Molt4 cells treated 
with Chloroquine and Dexamethasone 
The figures show representative protein intensities of GRP94, GRP78, Beclin1, 
LC3 and Actin as loading control protein in CEM-C1-15 (A), Molt4 (B) and 
CEM-C7-14 (C) cells in different conditions including untreated group (lane 1), 1 
μM Dex (lane 2), 10, 20 and 50 μM of Chloroquine (lanes 3-5), and combination 






Figure 5-2 Protein expression levels in CEM-C1-15, Molt4 and CEM-C7-14 
Chloroquine and Dex treated cells. 
The figures show the relative protein intensities of GRP94 (A), GRP78 (B), 
Beclin1 (C) and LC3 II / I (D) in CEM-C1-15 (black bars), Molt4 (light grey bars) 
and CEM-C7-14 (grey bars) cells in different conditions including untreated 
group (lane 1), 1 μM Dex (lane 2), 10, 20 and 50 μM Chloroquine (lanes 3-5), and 
combination treatment of 1 μM Dex with 10, 20 and 50 μM Chloroquine (lanes 6-
8). The results are representative of 3 independent experiments. Error bars 
represent ± SEM. (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). The 
values were normalised to the corresponding actin loading control and each 




5.1.2 Protein expression levels in Dexamethasone and Thapsigargin 
treated leukemia cells 
In order to determine effect of glucocorticoid and ER stress conditions on 
endogenous levels of proteins that mark ER stress and autophagy processes, Dexamethasone 1 
µM and Thapsigargin 1 and 10 µM were used to treat individually and in combination 
leukemia cells as described above (Figure 5-3).  
The results indicate that GRP94 and GRP78 proteins expression levels were 
increased substantially by TG and Dex in combination treatment of GC-sensitive cells (Figure 
5-4 A and B, lanes 5 and 6 grey bars compare to lane 1). In TG alone treated Molt4 cells, 
GRP94 levels were increased (Figure 5-4 A, lanes 3 and 4 light grey bars). Beclin1 protein 
levels increased in TG alone and combination treated CEM-C7-14 cells while decreasing 
trend was observed in CEM-C1-15 and Molt4 cells (Figure 5-4 C, lanes 3 to 6). TG alone and 
combined with Dex increased LC3 II / I ratio in GC-resistant cells (Figure 5-4 D, lanes 3 to 6 
black bars and light grey bars) while TG alone increased LC3 II / I ratio in GC-sensitive cells 
(Figure 5-4 D, lanes 3 and 4 grey bars). Finally, Dex decreased LC3 expression in GC-






Figure 5-3 Protein levels in CEM-C1-15, CEM-C7-14 and Molt4 cells treated 
with Thapsigargin and Dexamethasone 
The figures show representative protein intensities of GRP94, GRP78, Beclin1, 
LC3 and Actin as loading control protein in CEM-C1-15 (A), Molt4 (B) and 
CEM-C7-14 (C) cells in different conditions including untreated group (lane 1), 1 
μM Dex (lane 2), 1 and 10 μM of Thapsigargin (lanes 3-4), and combination 





Figure 5-4 Protein expression levels in CEM-C1-15, Molt4 and CEM-C7-14 
Thapsigargin and Dex treated cells 
The figures show the relative protein intensities of GRP94 (A), GRP78 (B), 
Beclin1 (C) and LC3 II / I (D) in CEM-C1-15 (black bars), Molt4 (light grey bars) 
and CEM-C7-14 (grey bars) cells in different conditions including untreated 
group (lane 1), 1 μM Dex (lane 2), 1 and 10 μM Thapsigargin (lanes 3-4), and 
combination treatment of 1 μM Dex with 1 and 10 μM Thapsigargin (lanes 5-6). 
The results are representative of 3 independent experiments. Error bars represent 
± SEM. (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). The values were 
normalised to the corresponding actin loading control and each sample was 




5.1.3 Protein expression levels in Dexamethasone and Rotenone treated 
leukemia cells 
To investigate effect of glucocorticoid and reactive oxygen species production on 
endogenous levels of proteins that mark ER stress and autophagy processes, Dexamethasone 1 
µM and Rotenone 1 and 10 µM were used to treat individually and in combination leukemia 
cells and follow protein levels as described above. (Figure 5-5). 
The results indicate that GRP94 expression levels were increased by ROT alone 
and combination treatment in CEM cells (Figure 5-6 A, lanes 3 to 6 black bars and grey bars 
compare to lane 1). The opposite trends were observed in Molt4 cells treated with ROT alone 
and in combination conditions (Figure 5-6 A, lanes 3 to 6 light grey bars). GRP78 levels were 
increased in CEM-C7-14 cells treated with ROT alone and in combination conditions while no 
significant changes were observed in Molt4 cells (Figure 5-6 B, lanes 3 to 6 light grey bars 
and grey bars). Beclin1 levels had increased trends in Molt4 cells while increased trends of 
Beclin1 levels were observed in CEM-C1-15 cells treated with ROT alone and in combination 
treatments (Figure 5-6 C, lanes 3 to 6 light grey bars and black bars). There were no changes 
of Beclin1 expression levels in Dex and ROT treated CEM-C7-14 cells. The LC3 expression 
ratios did not change significantly in ROT alone and combination conditions treated cells 





Figure 5-5 Protein levels in CEM-C1-15, CEM-C7-14 and Molt4 cells treated 
with Rotenone and Dexamethasone 
The figures show representative protein intensities of GRP94, GRP78, Beclin1, 
LC3 and Actin as loading control protein in CEM-C1-15 (A), Molt4 (B) and 
CEM-C7-14 (C) cells in different conditions including untreated group (lane 1), 1 
μM Dex (lane 2), 1 and 10 μM of Rotenone (lanes 3-4), and combination 





Figure 5-6 Protein expression levels in CEM-C1-15, Molt4 and CEM-C7-14 
Rotenone and Dex treated cells 
The figures show the relative protein intensities of GRP94 (A), GRP78 (B), 
Beclin1 (C) and LC3 II / I (D) in CEM-C1-15 (black bars), Molt4 (light grey bars) 
and CEM-C7-14 (grey bars) cells in different conditions including untreated 
group (lane 1), 1 μM Dex (lane 2), 1 and 10 μM Rotenone (lanes 3-4), and 
combination treatment of 1 μM Dex with 1 and 10 μM Rotenone (lanes 5-6). The 
results are representative of 3 independent experiments. Error bars represent ± 
SEM. (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). The values were 
normalised to the corresponding actin loading control and each sample was 




5.1.4 Protein expression levels in Dexamethasone and Bortezomib treated 
leukemia cells 
In order to determine effect of glucocorticoid, ER stress and unfolded protein 
response on endogenous levels of proteins that mark ER stress and autophagy processes, 
Dexamethasone 1 µM and Bortezomib 2 and 5 nM were used to treat individually and in 
combination leukemia cells as described previously (Figure 5-7). 
The results show that GRP chaperone proteins were increased in CEM-C1-15 cells 
treated with 5 nM BTZ alone and in combination with Dex (Figure 5-8 A and B, lanes 4 and 5 
black bars). Decreased protein expression level of Beclin1 were observed in BTZ alone and 
combination treated CEM-C1-15 cells, while there was no change in expression levels in 
Molt4 and CEM-C7-14 cells (Figure 5-8 C, lanes 3 to 6). LC3 II / I ratios were not changed by 
BTZ alone and combination with Dex treatment in Molt4 and CEM-C7-14 cells (Figure 5-8 





Figure 5-7 Protein levels in CEM-C1-15, CEM-C7-14 and Molt4 cells treated 
with Bortezomib and Dexamethasone 
The figures show representative protein intensities of GRP94, GRP78, Beclin1, 
LC3 and Actin as loading control protein in CEM-C1-15 (A), Molt4 (B) and 
CEM-C7-14 (C) cells in different conditions including untreated group (lane 1), 1 
μM Dex (lane 2), 2 and 5 nM of Bortezomib (lanes 3-4), and combination 





Figure 5-8 Protein expression levels in CEM-C1-15, Molt4 and CEM-C7-14 
Bortezomib and Dex treated cells 
The figures show the relative protein intensities of GRP94 (A), GRP78 (B), 
Beclin1 (C) and LC3 II / I (D) in CEM-C1-15 (black bars), Molt4 (light grey bars) 
and CEM-C7-14 (grey bars) cells in different conditions including untreated 
group (lane 1), 1 μM Dex (lane 2), 2 and 5 nM Bortezomib (lanes 3-4), and 
combination treatment of 1 μM Dex with 2 and 5 nM Bortezomib (lanes 5-6). The 
results are representative of 3 independent experiments. Error bars represent ± 
SEM. (* p < 0.05, ** p < 0.01, *** p < 0.001, student t.test). The values were 
normalised to the corresponding actin loading control and each sample was 





In summary, Dexamethasone significantly increased chaperone proteins in GC-
sensitive cells while Beclin1 expression levels were not changed. LC3 II / I ratio increased in 
Molt4 cells treated with Dexamethasone and Chloroquine. GRPs expression levels were 
increased in combination treatment of Thapsigargin and Dexamethasone in GC-sensitive cells. 
Rotenone increased GRP94 in CEMs cells while GRP78 levels were increased in GC-
sensitive cells. CLQ and BTZ increased chaperones proteins expression levels in CEM-C1-15 
cells. 
5.2 Determination of individual and combined drugs treatments on mRNA 
expression levels in leukemia cells 
To determine levels of gene expression of above studied proteins, mRNA levels were 
measured. After 24 hours of incubation time, RNA was isolated from cellular extract and 
cDNA synthesised. The quantitative polymerase chain reaction was performed to quantify 
mRNA expression level in desired drugs treatments. The mRNA level quantification was 
analysed using Rotor Gene Q Series software and statistical analysis done using GraphPad 
prism software. 
5.2.1 The mRNA expression levels in Dexamethasone, Thapsigargin and 
Bortezomib treated leukemia cells 
In order to determine the role of ER stress and unfolded protein response in 
glucocorticoid mediated transcriptional regulation, Dex, BTZ (5 nM) and TG (10 µM) were 
used individually and in combination to measure mRNA expression level of GRP94, GRP78 
which are markers of ER stress condition and Beclin1 and LC3 which are related to autophagy 
in ALL cells. After seeding the cells in 6-well plates, Dex, BTZ and TG were added for 24 
hrs. 
The result showed that GRP94 levels increased in TG treated alone and in 
combination with Dex CEM-C1-15, Molt4 and CEM-C7-14 cells, when compared to 
untreated condition (Figure 5-9, lane 4 and 6 compare with lane 1). GRP94 level was not 
changed by Dex treatment in CEM cells while decrease of GRP94 was observed in Molt4 
cells (Figure 5-9 B, lane 2). BTZ affected GPR94 mRNA level in GC-sensitive cells when 




Figure 5-9 mRNA expression levels of GRP94 in Dex, BTZ and TG treated 
leukemia cells  
Bar charts show relative GRP94 mRNA expression levels upon 24 hrs incubation 
time with 1 µM Dex (lane 2), 5 nM BTZ (lane 3), 10 µM TG (lane 4), 
combination treatment of Dex with BTZ (lane 5) and TG (lane 6) in CEM-C1-15 
(A), Molt4 (B) and CEM-C7-14 (C) cells. The results are representative of 3 
independent experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, 
*** p < 0.001, student t.test). The values were normalised to the corresponding 




GRP78 mRNA expression levels substantially increased by TG alone treatment 
and in combination with Dex in all cells after 24 hrs (Figure 5-10, lane 4 and 6 compare to 
lane 1). GRP78 mRNA levels in GC-sensitive cell decreased when BTZ alone and in 
combination with Dex was used (Figure 5-10 C, lane 3 and 5) while GRP78 was not changed 
in CEM-C1-15 and Molt4 cells. 
To determine the level of Beclin1 and LC3 gene expression upon glucocorticoid 
and ER stress conditions mRNA expression levels were determined. The result showed that 
Beclin1 mRNA expression levels increased in Dex treated GC-sensitive cell while increase of 
Beclin1 has been observed in Molt4 cells. Dex had no significant effect on Beclin1 level in 
CEM-C1-15 cells (Figure 5-11, lane 2 compare to lane 1). BTZ had no effect on the level of 
Beclin1 mRNA except in CEM-C1-15 cells when Dex and BTZ were used in combination. 
TG alone and combination treatment significantly increased Beclin1 mRNA level in all cells 
(Figure 5-11, lane 4 and 6 compare to lane 1). 
BTZ alone and combination treatment increased LC3 mRNA expression levels in 
GC-resistant cells (Figure 5-12 A and B, lane 3 and 5) while only combined treatment with 
Dex increased LC3 level in CEM-C7-14 cells (Figure 5-12 C, lane 5). LC3 mRNA level 
substantially increased in TG alone and combination treatment in all cells and the Molt4 cells 
were more sensitive to TG than CEMs by expressing LC3 levels higher than 10 times when 






Figure 5-10 mRNA expression levels of GRP78 in Dex, BTZ and TG treated 
leukemia cells  
Bar charts show relative GRP78 mRNA expression levels in 24 hrs incubation 
time of 1 µM Dex (lane 2), 5 nM BTZ (lane 3), 10 µM TG (lane 4), combination 
treatment of Dex with BTZ (lane 5) and TG (lane 6) in CEM-C1-15 (A), Molt4 
(B) and CEM-C7-14 (C) cells. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). The values were normalised to the corresponding RPL19 internal 





Figure 5-11 mRNA expression levels of Beclin1 in Dex, BTZ and TG treated 
leukemia cells  
Bar charts show relative Beclin1 mRNA expression levels in 24 hrs incubation 
time of 1 µM Dex (lane 2), 5 nM BTZ (lane 3), 10 µM TG (lane 4), combination 
treatment of Dex with BTZ (lane 5) and TG (lane 6) in CEM-C1-15 (A), Molt4 
(B) and CEM-C7-14 (C) cells. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). The values were normalised to the corresponding RPL19 internal 





Figure 5-12 mRNA expression levels of LC3 in Dex, BTZ and TG treated 
leukemia cells  
Bar charts show relative LC3 mRNA expression levels in 24 hrs incubation time 
of 1 µM Dex (lane 2), 5 nM BTZ (lane 3), 10 µM TG (lane 4), combination 
treatment of Dex with BTZ (lane 5) and TG (lane 6) in CEM-C1-15 (A), Molt4 
(B) and CEM-C7-14 (C) cells. The results are representative of 3 independent 
experiments. Error bars represent ± SEM (* p < 0.05, ** p < 0.01, *** p < 0.001, 
student t.test). The values were normalised to the corresponding RPL19 internal 





In summary, Thapsigargin significantly increased GRP94, GRP78, Beclin1 and 
LC3 mRNA levels when used alone and in combination with Dex to treat CEM-C1-15, Molt4 
and CEM-C7-14 cells. Dexamethasone affected CEM-C1-15 and Molt4 cells by decreasing 
GRP94 and LC3 mRNA expression levels but increasing Beclin1 and LC3 mRNA levels in 
CEM-C7-14 and Molt4 cells, respectively. Bortezomib decreased GRP94 and GRP78 mRNA 
levels in GC-sensitive cells, while LC3 levels increased in Molt4 and CEM-C1-15 treated 
with BTZ. 
When comparing effects of studied drugs on mRNA and protein levels of 
autophagy and ER stress markers, it was observed that Dexamethasone increased Beclin1 
protein levels in CEM-C1-15 cells while increase in Beclin1 mRNA level was observed in 
CEM-C7-14 cells. Dex increased LC3 protein (LC3 II / I ratio) and mRNA levels in Molt4, 
but the decrease of mRNA and protein expression levels were observed in CEM-C1-15 and 
CEM-C7-14 cells, respectively. In GC-resistant cells, GRP94 protein levels decreased in Dex 
treated CEM-C1-15 cells while the mRNA levels were affected in Motl4 cells. Interestingly, 
Dex increased GRP94 and GRP78 protein levels only in GC-sensitive cells. 
Chloroquine alone and in combination with Dex increased LC3 II / I ration in all 
cells but there were no statistic significant value observed. However, mRNA levels have not 
been analysed to detect autophagy and ER stress markers. Thapsigargin treatment individually 
and combined with Dex lead to increased mRNA expression levels of Beclin1, LC3, GRP94, 
and GRP78 in all cells. However, increased trend but not significant of LC3 protein 
expression levels were observed in GC-resistant cells while increase of GRP94 and GRP78 
protein levels was found in only CEM-C7-14 cells. In rotenone treated cells trend of increase 
in protein expression levels of GRP94 in CEM-C1-15 and CEM-C7-14 cells was observed and 
increased GRP78 protein levels in CEM-C7-14 cells was detected. However, no statistically 
significant values were observed in ROT individual and combination treatments. Bortezomib 
increased mRNA expression of LC3 in GC-resistant cells and GC-sensitive cells in 
combination treatment with Dex. GRP94 and GRP78 mRNA levels decreased in only 
Bortezomib treated CEM-C7-14 cells, but in combined treatment with Dex only GRP78 




CHAPTER 6 DISCUSSION 
ALL is the most frequent cancer in children. Although the treatment of this disease can be 
considered as highly successful, compared to other types of cancer, toxicity of therapies and 
drug resistance still pose substantial problem. In this thesis focus of study is molecular 
mechanism of action of glucocorticoids that have been used as part of ALL therapy towards 
developing better understanding how these drugs function, and what could be cause of 
resistance. 
There are several proposed resistance mechanisms observed in different tissues. These 
include; 
1) Down-regulation of GR at both mRNA and protein levels by its own hormone ligand 
glucocorticoid (Schaaf & Cidlowski, 2002). Post translational modification 
mechanism are also involved to decrease expression level of GR protein (Dong, Y. et 
al., 1988). Hormone treatment has been shown to decrease GR protein stability 
resulting in reduced GR half-life by 50% (Mcintyre & Samuels, 1985) 
2) The human GRβ-isoform that is a result of alternative splicing of hGR pre-mRNA and 
can inhibit hGRα as observed in vitro studies (Bamberger et al., 1995; Oakley et al., 
1996; Oakley et al., 1999) 
3) Transrepression by NF-ĸB. Under basal condition, NF-ĸB heterodimer locates in the 
cytosol and is inactivated by association with an inhibitory protein IĸB α or β. Studies 
have shown that IĸB is affected by inflammatory signals such as tumor necrosis 
factor- α (TNF- α) and lipopolysaccharide (LPS) resulting in dissociation of the 
complex of NF-ĸB and IĸB and leading to NF-ĸB nuclear translocation (Baeuerle & 
Henkel, 1994; Brown et al., 1995; DiDonato et al., 1997; Krappmann et al., 1996). 
One mechanism of NF-ĸB to GR repression is competition binding of p65 subunit and 
hGRα on GRE site (Caldenhoven et al., 1995; McKay & Cidlowski, 1998; Ray & 
Prefontaine, 1994). 
4) Microenvironment and stem cell niche have been proposed to affect response to drugs 
(Bakker et al., 2016). 
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5) Several factors that modulate GR function and its ability to induce apoptosis in 
leukemia cells and include posttranslational modifications and crosstalk with other 
less well studied pathways such as autophagy and necroptosis. 
In leukemia cells, mechanisms of GR-induced apoptosis are linked with several intrinsic 
apoptotic molecules such as APAF-1, Bax, Bak, Bim, Puma, and Noxa (Bouillet et al., 1999; 
Cecconi et al., 1998; Rathmell et al., 2002; Villunger et al., 2003; Yoshida, H. et al., 1998). 
These regulations subsequently activate downstream apoptosis processes. GR also increases 
expression of several genes that are involved in GR activities and apoptosis pathway such as 
FKBP 51, IĸB-α, BIM and Dig-2. 
Over the past decade, several studies linked the autophagy (macroautophagy) to the 
cancer therapy as this pathway plays an important role in proteins and organelles degradation 
and recycling (Mizushima, 2007; Ravikumar et al., 2010a) and many chemotherapeutic agents 
affect autophagy in both tumor and normal cells. In addition, the role of cellular stress such as 
ER stress and UPR in modulating GR function has not been described in detail. This topic is 
not well understood and needs to be investigated further towards future development of 
beneficial anti-cancer treatment. 
In this study, we used several drugs including Dexamethasone, Chloroquine, 
Thapsigargin, Rotenone and Bortezomib treated in GC-resistant cells (CEM-C1-15 and Molt4) 
and GC-sensitive cells (CEM-C7-14) to investigate the role of autophagy processes, ER stress, 
unfolded protein response, and ROS expression levels on the mechanisms of GC-induced 
leukemia apoptosis. We found that autophagy, mitochondrial and endoplasmic reticulum play 
an important role in GC-resistant mechanisms. Several drug combination conditions showed 
increase cell death that may be used in chemotherapy with the aim of minimising side effects 
from high dose single treatment. 
6.1 The role of macroautophagy in glucocorticoid induced ALL cells death 
Autophagy plays an important role in maintaining normal cellular homeostasis by 
removing misfolded protein and neutralising hazardous stimuli. Autophagy has been reported to 
promote or supress acute lymphoblastic cell proliferation (Evangelisti et al., 2014). To 
investigate how ALL cells respond to glucocorticoid hormones when autophagy is inhibited, 
chloroquine individually or combined with Dexamethasone was used to inhibit autophagy with 
the mechanism of autophago-lysosome formation blockage. 
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Recent studies showed that autophagy is involved in ALL chemotherapeutic treatment. 
Both pro-survival and pro-death roles of autophagy in ALL cells have been found and it is still 
unclear how autophagy process determines cell fate (Evangelisti et al., 2014). It has been 
reported that autophagy is induced by ER stress, unfolded protein response and reactive oxygen 
species (He & Klionsky, 2009). However, the mechanisms linking ER stress and autophagy are 
dependent on the stress stimuli and type of organism. In myeloid leukemia cells, combination 
treatment of Chloroquine and other therapeutic agents such as Imatinib mesylate (IM), 
HDACi/SAHA, HDACi/ valproic acid increased cytotoxic effect on cancer cells (Bellodi et al., 
2009; Carew et al., 2007; Torgersen et al., 2013). IM inhibits BCR/ABL tyrosine kinase and 
subsequently triggers apoptosis. While IM induces autophagy, suppression of autophagy 
enhanced cell death during IM treatment in CML cells (Bellodi et al., 2009). Suberoylanilide 
hydroxamic acid (SAHA) is a well-tolerated pan-HDAC inhibitor used as anticancer agent. 
SAHA’s effects have been linked to ROS generation and increase of autophagy (Shao et al., 
2004). Disruption of autophagy enhanced the anticancer activity of SAHA in CML (Carew et 
al., 2007). 
Our results indicated that Dex alone induced early stage of autophagy, as measured by 
increase in Beclin1 protein levels, in CEM-C1-15 and induced late stage of autophagy (as 
suggested by the increase in the ratio of LC3 II / I protein levels) in Molt4, while the opposite 
effect was observed in GC-sensitive cell (decrease of LC3 II / I) (Figure 5-2, C and D lane 2). 
These findings suggest that macroautophagy may be involved in the mechanism of GR induced 
cell death by facilitating pro-survival mechanism in GC-resistant cells. However, Dex induced 
autophagy is different between leukemic cell types. The preliminary studies in multiple 
myeloma (MM) cells indicated that Dex induced autophagy and increased percent of cells 
undergoing apoptosis. The inhibition of autophagy by Beclin1 protein silencing and type III 
Ptdlns3K inhibitor during Dex treatment resulted in apoptosis inhibition in MM cells (Grander 
et al., 2009). 
We used combination treatment with CLQ, autophagy inhibitor, in ALL cells and found 
increase in the percent of cell death based on cell viability assays (Chapter 3, sections 3.1-3.3) 
is increased by dose-dependent manner. Our results suggest that autophagy is involved in the 
regulation of GC-induced ALL cells apoptosis. These finding have been supported with the 
report indicating that inhibition of autophagy induces cell apoptosis in glucocorticoid resistant 
ALL cell lines (Jiang et al., 2015). Recent study indicated that chloroquine can induce 
lymphoma cell apoptosis and activated ER stress pathway including GRP78 up-regulation, as 
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well as IRE6α and ATF6 activation (Masud Alam et al., 2016). However, our results show 
CLQ did not affect ER stress chaperone protein markers, GRP78 and GRP94, in ALL cells. It is 
possible that different pathways may be activated in CLQ induced ALL death, depending on 
cell type, experimental or other conditions. 
During ER stress, GC-resistant cells respond to stress by increasing autophagic protein 
marker to a greater extent than GC-sensitive cell (Figure 5-4 D, lanes 3 and 4). After 
combination with Dex, only CEM-C7-14 cells showed decrease in autophagy (Figure 5-4 D, 
lanes 5 and 6). This finding suggests that autophagy plays an important role in the ALL cells 
apoptosis and resistance to Dex treatment. In clinical trials, CLQ has been used with other anti-
cancer agents to sensitise solid tumors such as malignant neoplasm, breast cancer, glioblastoma, 
and multiple myeloma. Phase II multiple myeloma trial indicated that combination treatments 
of Bortezomib and Chloroquine may induce cancer cells to become more sensitised to the drugs 
(ClinicalTrials.gov, 2018). 
6.2 Role of GRPs chaperone proteins in glucocorticoid induced ALL cells death 
Leukemia is characterized by abnormal proliferation and maturation of leukocytes and 
precursors cells in blood and bone marrow. Although there are several indications that unfolded 
protein response (UPR) is involved in solid tumor pathogenesis, the role of the UPR in 
leukemogenesis remains unclear (Schardt et al., 2011).  
Early studies showed that XBP1s and GRP78 were up-regulated in Ph+ leukemia cell 
lines and this subsequently activated CCAAT/enhancer-binding protein homologous protein 
(CHOP), inducer of UPR-related apoptosis (Dengler et al., 2011; Tanimura et al., 2009). In our 
studies, Dexamethasone treatment in GC-sensitive cells but not GC-resistant cells led to 
increase chaperone proteins levels, especially GRP78 and GRP94 (described in Chapter 5) that 
is a novel finding in ALL cells. Furthermore, Dex also induced GC-sensitive cell death, as 
determined by increasing of subG1 phase in cell cycle analysis (Chapter 3, section 3.2), and 
disrupted the mitochondrial membrane voltage, suggesting effects in early apoptosis (Chapter 3, 
section 3.3). 
GRPs over expression has been reported widely in several cancer cell lines such as breast 
carcinoma, prostate adenocarcinoma, liver cancer, colorectal cancer, multiple myeloma, and 
leukemia (Chen, W. T. et al., 2014a; Chen, W. T. et al., 2014b; Dong, D. et al., 2008; Fu et al., 
2008; Hua et al., 2013; Morales et al., 2014; Wey et al., 2012). These increases of GRP 
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expression are associated with cancer cell aggressive and metastasis properties (Lee, A. S., 
2007; Miao et al., 2013). While cell surface GRP78 triggers ERK and AKT activation and 
increase in DNA and protein synthesis in prostate cancer (Misra & Pizzo, 2012) GRP94 binds 
to IGF-1 or IGF-2 and controls IGFs maturation and secretion leading to PI3K-AKT activation 
(Wanderling et al., 2007). 
GRPs act as apoptosis suppressor proteins (Luo & Lee, 2013). GRP78 binds to caspase-7 
and inhibits apoptosis induced by etoposide (Rao et al., 2002; Reddy, R. K. et al., 2003). 
Recently, it has been reported that interaction of GRP78, BIK and Bcl-2 is associated with the 
regulation of ER Ca2+ and cytochrome c release which initiates apoptosis pathway. 
Overexpression of GRP78 inhibits the suppressing of Bcl-2 by BIK and releases anti-apoptosis 
properties of Bcl-2 in breast cancer cells (Fu et al., 2007; Zhou, H. et al., 2011). GRP94 also 
has a role to protect cancer cells from apoptosis by maintaining ER Ca2+ homeostasis (Reddy, 
R. K. et al., 1999). Under ER stress conditions, GRP78 and GRP94 translocate to cell surface 
for growth and apoptotic signaling regulation and interact with MHC class I molecule to 
mediate antigen presentation (Lee, A. S., 2014; Luo & Lee, 2013; Triantafilou et al., 2001). 
However, it is possible that increase of GRP protein levels, detected by western blotting 
technique in GC-sensitive CEM cells may be involved in another pathway during Dex mediated 
apoptotic mechanism. 
Out results showed that mRNA expression levels were not altered by Dex as measured by 
RT-qPCR technique. This finding indicated that post transcriptional mechanism including 
protein stability, posttranslational modification and others may be involved in GR mediated 
control of GRP levels in GC-sensitive cell. GR may also induce transcription of other genes 
that can affect GRPs protein levels. However, some reported showed high expression level of 
GRP94 is associated with clinical outcome in multiple myeloma (MM) patients. They found 
that higher expression level of GRP94 is associated with malignant stage of MM patients 
(International Staging System (ISS) stage III MM patients is higher than those in ISS stage I/II 
MM patients) (Chhabra et al., 2015). 
Several studies have reported that loss of mitochondrial membrane voltage induced cell 
apoptosis by releasing pro-apoptotic proteins and Cyto c to the cytosol (Chang et al., 2010; Ott 
et al., 2007; Zhang, R. et al., 2008b). Mitochondria are another target organelle of GRP 
proteins, the disruption of mitochondria also induces GRPs translocation to the cell surface and 
secretion outside the cell to control apoptosis, cell growth and immune system (Lee, A. S., 
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2014). We found that GR-induced cell apoptosis in ALL sensitive cell is correlated with the 
increase in mitochondrial membrane voltage disruption (Figure 3-10, A to C, lanes 2). This 
finding suggests that Dexamethasone induced ALL apoptosis may be triggered via 
mitochondrial pathway. There are several studies that indicated that mitochondria is the target 
organelle for GC-induced apoptosis and these are in agreement with our findings. 
Dexamethasone disrupts mitochondrial membrane potential in Nalm-6 and Reh ALL cells, 
releases cytochrome c and increases caspase-3 activities in Dex-induced ALL apoptosis 
(Abdoul-Azize et al., 2017), In MM cells, Dexamethasone triggers the release of SMAC, a 
second mitochondria-derived activator of caspases, into cytoplasm and subsequently stimulates 
cytochrome c and Apaf-1 pathway resulting in cell apoptosis precesses activation (Chauhan, D. 
et al., 2001; Chauhan, D. et al., 1997a; Chauhan, D. et al., 1997b). Eberhart and colleagues 
demonstrated that Dexamethasone alters the mitochondrial membrane properties and represses 
mitochondrial respiratory activity resulting in GC-sensitive ALL cells apoptosis (Eberhart et al., 
2011; Eberhart et al., 2009). 
In addition, ER stress inducer such as Thapsigargin was used to test the role of GR and 
glucose-regulated proteins 78 and 94 on the cell survival regulation. We found that increasing 
of GRP proteins in GC-sensitive cells is correlated with increasing of apoptotic cell death in 
Dex and TG combination treatments (based on MTS, SubG1 detection, and mitochondrial 
membrane potential assays). The mRNA and protein expression levels of GRP78 and GRP94 
were increased by TG treatment alone and combination treatment with Dex in all cells (Figures 
5-9 and 5-10, lanes 4 and 6). These findings were supported by Li and colleagues in 1993 and 
Lee in 2001 who reported that TG was a strong ER stress inducer and activated GRP 
transcription through decreasing Ca2+ concentration in ER (Lee, A. S., 2001; Li, W. W. et al., 
1993). Our results also showed the combination treatment, with Dex, enhanced cytotoxic 
effects observed in CEM-C1-15, Molt4, and CEM-C7-14 cells after 48 hrs treatment. These 
results could mean that unfolded protein response in GC-resistant cells play a critical role in the 
regulation of GR induced cell death and could be used as a target for drug development and 
future clinical use in both sensitive and resistant leukemia. In medicine, the first clinical trials 
of thapsigargin started in 2008 under the generic name Mipsagargin (G-202) (Andersen et al., 
2015). Several trial studies reported that Thapsigargin has been used to induce glioblastoma 
(GBM), cancer of nervous system, renal cell carcinoma, prostate cancer, and hepatocellular 
carcinoma (HCC) apoptosis. G-202 is activated by prostate specific membrane antigen 
(PSMA), which is expressed in most solid tumor vessels (NIH, 2018). 
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However, the link between ER stress and Autophagy in ALL cells remains unclear. The 
results showed that TG activated autophagy by increasing protein levels of LC3 II / I ratio and 
mRNA levels of Beclin1 and LC3 in all cells (Figure 5-11, A to C lanes 4, Figure 5-12, A to C 
lanes 4). The decrease of LC3 protein expression levels was observed in only GC-sensitive cell 
when Dex and TG were applied. 
6.3 Role of reactive oxygen species in glucocorticoid induced ALL cells death 
Under normal condition, intracellular ROS levels are stable and are maintained by non- 
enzymatic molecules including glutathione, flavonoids, vitamins A, C and E to prevent ROS 
induced cellular damage. In cancer cells, high metabolic activity, mitochondrial dysfunction, 
and peroxisome over expression elevate the level of reactive oxygen species. These can lead to 
increased cellular receptor signalling, activity of oncogenes and oxidative activity (Babior, 
1999; Storz, 2005; Szatrowski & Nathan, 1991). Mitochondria are the source of reactive 
oxygen species such as superoxide radicals that generate during electron transport chain 
activation and they release into mitochondrial matrix or cytoplasm via mitochondrial 
permeability transition pores (MPTP) (Liou & Storz, 2010). The elevated basal level of ROS 
promotes development and progression of tumor cells, whereas the cells also express high level 
of antioxidant proteins to neutralize high level of ROS. Several signalling pathways have been 
found that were regulated by ROS in cancer cell such as mitogen-activated protein (MAP) 
kinase/Erk cascade, phosphoinositide-3-kinase (PI3K)/Akt-regulated signalling cascades, and 
NF-ĸB-activating pathways (Irani et al., 1997; Khavari & Rinn, 2007; Reddy, K. B. & Glaros, 
2007; Roberts & Der, 2007). Increased ROS levels by chemotherapeutic agents can also induce 
cell cycle arrest and promote tumor cell death (Liou & Storz, 2010). Our studies showed that 
high levels of ROS (ROT treatment) increased accumulation of cells in G2/M phase (Figure 3-8 
D lanes 3 and 4), interrupted mitochondrial membrane integrity and induced cell death.  
The results obtained from MMPA indicated that Rotenone increased the proportion of 
cells that altered mitochondrial membrane potential in CEM-C7-14, CEM-C1-15 and Molt4 
cells (Figure 3-12, A to C lanes 3 and 4) and these alterations mostly supported results obtained 
using MTS assay that determined cell survival (Figure 3-3 D to F). The combination with Dex 
increased MMP disruption and enhanced cytotoxic effect as indicated by viability assays in 
CEMs cell, whereas effects in Molt4 cells were marginal. High ROS levels in CEM cells is 
correlated with the increase in cell death (Figure 4-3, A and B lanes 3-4 and Figure 3-3, A, B, 
D, and E), suggesting that reactive oxygen species can induce apoptosis pathway in CEM cells. 
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Moreover, the synergistic effects observed in combination treatment with Dex treated CEM 
cells indicated that high ROS levels may be beneficial in GC-induced CEM cells death. 
However, the sensitivity to ROS levels depend on leukemia cell type and incubation time. 
Molt4 cells did not respond to ROT treatment in 24 hrs but marginal effect can be observed in 
48 hrs. 
Previous studies showed that rotenone induced ER stress and increased ROS production 
in rat retinal cells (Han et al., 2014). Rotenone also induced human promyelocytic leukemia cell 
line (HL-60) apoptosis through ROS production (Li et al., 2003). 
The ROS levels in glucocorticoid treated cells are different across the cell lines. CEM-
C7-14 and Molt4 cells have the low level of ROS during Dex treatment while the ROS level is 
not changed in CEM-C1-15 cells and the mechanisms of ROS production on response to 
glucocorticoid treatment are unclear. Some studies indicated that Dexamethasone induced ROS 
production in Nalm-6 and Reh leukemia cell lines (Abdoul-Azize et al., 2017). However, the 
combined treatment between ROS modulator and ROS generating agents may lead to increase 
apoptosis of cancer cells and enhance cytotoxic effect in resistant cells that do not respond to 
ROS generating drug alone (Lau et al., 2008). 
6.4 Role of protein degradation inhibition in glucocorticoid induced ALL cells 
death 
Protein degradation is the main pathway for maintenance of protein homeostasis in the 
intracellular proteins. The multi-complexed structure, proteasome, regulates protein clearance 
of misfolded and /or unfolded and cytotoxic proteins (Adams, J., 2004). Proteasome inhibitor, 
bortezomib, blocks protein degradation processes by inhibiting 26S proteasome complex 
resulting in induction of ER stress response. Bortezomib has been used to treat multiple 
myeloma (MM) and mantle cell lymphoma while the mechanism of anticancer action is still 
unclear (Du and Chen, 2013). 
Our results indicate that CEM-C1-15 and Molt4 cells are highly sensitive to Bortezomib, 
which enhances the cytotoxic effects of Dexamethasone as observed in MTS assay (Figure 3-4 
D and F) and this finding suggest that UPR to restore protein folding in GC-resistant cells may 
be altered subsequently to trigger ER stress induced cell apoptosis. The previous study was 
performed by Horton and colleague in 2006 and they found that several leukemic cell lines are 
sensitive to bortezomib, especially CEM, which was sensitive to Bortezomib with IC50 at 2 nM 
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(Horton et al., 2006). However, GC-sensitive cells were not affected by Bortezomib at the 
maximal dose of 10 nM, while Our western blot results indicated that 5 nM bortezomib 
treatment increased the GRP94 and GRP78 chaperone proteins in CEM-C1-15 cell more than in 
CEM-C7-14 (Figure 5-8 A and B, lanes 4 and 6). The LC3 mRNA levels increased in CEM-
C1-15 and Molt4 cells but not in CEM-C7-14 (Figure 5-12 A to C, lane 3). These findings 
suggested that CEM-C1-15 and Molt4 cells are sensitive to ER stress and unfolded protein 
response when the protein degradation mechanism is disrupted while GC-sensitive cells may 
use alternative pathways to restore misfolded proteins. Pre-clinical studies in AML have 
indicated that proteasome inhibition disrupts pathways in cell proliferation, enhances cytotoxic 
effects of other anti-cancer agents, and induces autophagy. Bortezomib inhibits the degradation 
of NFĸB inhibitor (IĸBα) leading to decrease in the expression of NFĸB target genes involved 
in pro-survival and expression of proliferative pathways resulting in apoptosis (Csizmar et al., 
2016). 
In clinical trials, Bortezomib is used to achieve complete remission (CR) in relapsed 
ALL. Bortezomib was used with other chemotherapy agents including Dexamethasone, 
Doxorubicin, Vincristine and PEGylated asparaginase in 30 and 7 children with B-cell 
precursor (BCP) and T-cell ALL, respectively. The results of the trial indicated that more than 




6.5 Overall conclusions 
GC-induced ALL cells apoptosis is the beneficial process for anti-leukemia therapy. 
Several pathways are linked and involved in the GC-induced apoptosis mechanisms. This study 
demonstrated that chaperone proteins, GRP78 and GRP94 are stimulated by dexamethasone in 
GC-sensitive cells but no change of mRNA expression levels was detected suggesting that the 
regulation of GRPs by GC is not by direct effect on GRPs mRNA but occurs via other 
pathways 
Autophagy is an important process to consider in studies of GC resistance. We found that 
autophagy marker, LC3 II / I ratio, is activated in Dex treated Molt4 cells and Beclin1 
expression levels is increased in Dex treated CEM-C1-15 cells. These autophagic responses are 
related with increase in cell death in GC-resistant cells after autophagy is inhibited, which 
indicated that autophagy may be a pro-survival mechanism in GC-resistant cells (Figure 6-1 A).  
Mitochondria may be the target organelle involved in GC-induced cell apoptosis and this 
phenomenon is observed by MMP assay in Dex treated CEM-C7-14 cells. This mitochondrial 
membrane disruption may trigger several apoptotic molecules release and subsequently induces 
leukemia cellapoptosis (Figure 6-1 B). 
Combination between Dex and the drugs that regulate ER stress showed enhanced 
cytotoxic effects in all cells. TG increased mRNA levels of autophagy markers, Beclin1 and 
LC3 and ER stress markers chaperone proteins, GRP78 and GRP94, in all cell lines. These 
findings indicated that distruption of ER hoeostasis during Dex treatment has potential to 
inhibit ALL cell proliferation. However, autophagy is also activated during ER stress and that 
could be pro-death or prosurvival mechanisms.  
Increase of ROS levels exerted cytotoxic effects and induced cell death in CEM cells 
higher than Molt4 cells. And high ROS levels can activate autophagy in only Molt4 cells. The 
sensitivity to ROS levels depends on leukemia cell type and incubation time.  
Finaly, numerous pathways are linked and important for ALL cells apoptosis and this 
could be usedd to improve the anti-cancer therapy and alleviate side effects from high dose of 




Figure 6-1 Proposed model in GCs induced ALL apoptosis 
The figures show autophagy may have a role as anti-apoptotic process in CEM-C1-
15 / Molt4 (A) while in CEM-C7-14, mitochondria and ER are the important 
organelles in GCs induced cell death (B). GRPs activation may regulate ER stress 
mediated cell apoptosis and mitochondrial membrane potential alteration may be 




6.6 Limitations of the study 
One limitation of this study is the specificity of drugs used in different leukemia cell 
types (CEMs and Molt4 cells). It is possible that drugs used to study effects on one process (for 
example ER stress) could affect other processes as well. In addition, the sensitivity of leukemia 
cells to drug treatment varies and the minimum doses used to approach the maximum effects 
are different across leukemia cells.  
There are some limitations of laboratory techniques and the systems used in this study. 
Cells growing in suspension (such as leukemia cells) are difficulty to transfect and carry out 
immunofluorescence and immunohistochemistry studies. However, the availability of GC-
sensitive and GC-resitant cell lines provides certain advantage for analysis of resistant 
phenotype, given that mouse models of ALL are difficult to obtain and study. 
Some other technical difficulties include potential false positive results when using RT-
qPCR, SYBR Green system, although this possibility was minimised by exon-exon junction 
primer design and by melting curve analysis. 
In vitro assays are limited when predicting and extrapolating the in vivo responses. 
Therefore, 3D systems, experiments in mice as well as clinical triels will be needed to confirm 
data obtained in this project as well as to explore in clinical use of these findings. 
6.7 Future Directions 
Although Dexamethasone and several compounds have been used to explore the 
relationship between autophagy, ER stress and unfolded protein response, the mechanism of 
glucocorticoid-resistant ALL cells remains unclear. These issues have become interesting study 
topics for the potential improvement of ALL treatment. The role of GR induced cell death and 
the novel mechanism we found here of increasing chaperone proteins GRP78 and GRP94 in 
GC-sensitive cell lacks mechanistic details. Novel approaches to analyse these at molecular 
levels are needed including analysis of promoter region of GRPs and modulation of potential 
transcription factors involved in their regulation. The mechanism of protein stability of GRPs 
could also lead to finding out the link with glucocorticoid effects. 
Our results suggested that GRP78 and GRP94 may have an important role in GR 
function, while chloroquine induced glucocorticoid sensitive and resistant ALL cells death and 
increased ER stress protein levels. The further studies such as detection of secreted form and 
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cell surface expression of GRP proteins in cell lines and patient’s samples will be needed to 
elucidate these mechanisms. We are currently developing flow cytometry based assay to detect 
intracellular and membrane based GRPs in cells treated as above. Complete picture of GRPs 
distribution could be obtained if extracellular levels of GRPs are also determined using ELISA 
method. Future experiments can also address GRP's role in antigen presentation and potentially 
link their expression to immunotherapy of ALL. 
Finally, in order for these findings to be translated into clinical practice expression of 
GRPs needs to be detected in patient’s samples. This can potentially be carried out in Thailand 
and results correlated with clinical parameters including stage and grade of the cancer, 
resistance and type to therapy, weight, age and gender of patients. Ultimately, these results may 
find application in clinical practice by combining Dexamethasone treatment with other drugs 
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